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Abstract 
The new δ-lactam (N-methyl-2Ɛ,4Ɛ-dihydroxypentano-5-lactam, AT.1) and six known 
dammarane triterpenoids, (20S,24R)-epoxydammarane-3,25-diol (AT.2), (20S,24S)-
epoxydammarane-3,25-diol (AT.3), 25-hydroxy-(20S,24R)-epoxydammaran-3-one (AT.4), 
25-hydroxy-(20S,24S)-epoxydammaran-3-one (AT.5), 3-acetoxy-(20S,24R)-epoxydammaran-
25-ol (AT.6), 3-acetoxy-(20S,24S)-epoxydammaran-25-ol (AT.7) were isolated from the 
twigs of Aglaia argentea, together with a mixtures of sitosterol (AT.8) and stigmasterol 
(AT.9).  Acetylated derivative AT.1a was synthesized for confirming the structure of AT.1.  
Compounds AT.2, AT.4, AT.5 and AT.7 have been isolated from this genus before.
1-3
 
 
 
 
 
 
 
 
 
 
 
 
Figure 0.1 Compounds isolated from the twigs of A. argentea 
 
 
 
 
 
 
 
 
AT.2 : R = -OH 
AT.4 : R = O 
AT.6 : R = -OAc 
AT.3 : R = -OH 
AT.5 : R = O 
AT.7 : R = -OAc 
xix 
 
The new limonoid xylorumphiin K (RB.1) was isolated from the bark of Xylocarpus 
rumphii, together with, xyloccensin E (RB.2), taraxer-14-en-3-ol (RB.3) and 22S-
hydroxytirucalla-7,24-diene-3,23-dione (RB.4), 25-hydroxy-(20S,24S)-epoxy dammaran-3-
one (AT.5) and a mixture of sitosterol (AT.8) and stigmasterol (AT.9).  The structures were 
determined using NMR spectroscopy and with reference to known compounds.
4-8
  
Compound RB.2 has been isolated from seeds and seed kernels of this species before.
5,9,10
 
 
 
 
                                                                                                        RB.3                                      RB.4 
                      RB.1                                    RB.2                                
 
 
 
                       AT.5                    
Figure 0.2 Compounds isolated from the bark of X. rumphii 
 
 
 
 
 
 
 
 
 
 
 
xx 
 
Eleven tetranortriterpenoids were isolated from the heartwood of X. rumphii and were 
identified as the limonoids, xylorumphiins L (RH.1), E (RH.2) and C (RH.3) and 
tetranortriterpenoids, xylorumphiins M-S (RH.4-10).  Compounds RH.4-10 have a 
hemiacetal group which opens and closes in solution making it impossible to purify.  
Acetylation enabled separation of the R and S forms.  Separation of the acetylated mixtures 
RH.4-10 led to the isolation of four acetylated derivatives of RH.4 (RH.4a-d), two 
acetylated derivatives of RH.5 (RH.5a and 5b), one acetylated derivative of RH.6 (RH.6a), 
two acetylated derivatives of RH.7 (RH.7a and 7b), one acetylated derivative of RH.8 
(RH.8a) and one acetylated derivative of RH.10 (RH.10a).  Compounds RH.1 and RH 4-10 
have not been described previously. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 0.3 Compounds isolated from the heartwood of X. rumphii and their derivatives 
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Table 0.1 Compounds isolated from the twigs of A. argentea 
Code Structure 
Status of 
isolation 
Yield 
Page of 
discussion 
Spectra 
Bioactivity 
test 
AT.1 
 
 
 
 
 
New 10.5 mg 
(0.1%) 
12-14 2.1.1-2.1.9 - 
AT.1a 
 
 
 
 
 
 
 
(Derivative) 
3.5 mg 
(0.03%) 
13-14 2.1a.1-2.1a.9 - 
AT.2 
 
 
 
 
 
 
Known 62.0 mg 
(0.6%) 
15-17 2.2.1-2.2.9 - 
AT.3 
 
 
 
 
 
 
 
Known 97.9 mg 
(0.9%) 
18-19 2.3.1-2.3.9 - 
AT.4 
 
 
 
 
 
 
Known 6.0 mg 
(0.1%) 
20-21 2.4.1-2.4.9 - 
AT.5 
 
 
 
 
 
 
 
Known 7.0 mg 
(0.1%) 
22-24 2.5.1-2.5.9 - 
AT.6 
 
 
 
 
 
 
 
Known 128.2 mg 
(1.2%) 
25-27 2.6.1-2.6.9 - 
 
 
 
xxii 
 
Table 0.1 (continued) 
Code Structure 
Status of 
isolation 
Yield 
Page of 
discussion 
Spectra 
Bioactivity 
test 
AT.7 
 
 
 
 
 
 
 
Known 405.0 mg 
(3.9%) 
28-29 2.7.1-2.7.9 - 
AT.8 
& 
AT.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Known 50.5 mg 
(0.5%) 
31 2.8.1 - 
 
 
 
 
 
 
 
 
 
 
 
 
xxiii 
 
Table 0.2 Compounds isolated from the bark of X. rumphii 
Code Structure 
Status of 
isolation 
Yield 
Page of 
discussion 
Spectra 
Bioactivity 
test 
RB.1 
 
 
 
 
 
 
 
 
New 9.8 mg 
(0.03%) 
44-46 3.1.1-3.1.9 - 
RB.2 
 
 
 
 
 
 
 
 
Known 53.4 mg 
(0.1%) 
47-49 3.2.1-3.2.9 NCI-59 
inactive 
RB.3 
 
 
 
 
 
 
 
Known 10.3 mg 
(0.03%) 
50-51 3.3.1-3.3.9 - 
RB.4 
 
 
 
 
 
 
 
Known 7.9 mg 
(0.02%) 
52-54 3.4.1-3.4.9 - 
AT.5 
 
 
 
 
 
 
 
Known 26.3 mg 
(0.07%) 
22-24 2.5.1-2.5.9 - 
AT.8 
& 
AT.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Known 30.5 mg 
(0.08%) 
31 2.8.1 - 
 
xxiv 
 
Table 0.3 Compounds isolated from the heartwood of X. rumphii 
Code Structure 
Status of 
isolation 
Yield 
Page of 
discussion 
Spectra 
Bioactivity 
test 
RH.1 
 
 
 
 
 
New       
(New X-ray) 
20.5 mg 
(0.07%) 
57-60 3.5.1-3.5.9 NCI-59 
inactive 
RH.2 
 
 
 
 
 
New 5.3 mg 
(0.02%) 
61-63 3.6.1-3.6.9 NCI-59 
inactive 
RH.3 
 
 
 
 
 
Known   
(New X-ray) 
17.8 mg 
(0.06%) 
64-66 3.7.1-3.7.9 NCI-59 
inactive 
RH.4 
 
 
& 
RH.5 
 
 
 
 
 
 
 
 
 
 
 
 
New 102.7 mg 
(0.36%) 
67 3.8.1-3.8.9 NCI-59 
inactive 
RH.4a 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
4.5 mg 
(0.02%) 
71-72 3.8a.1-3.8a.9 - 
 
xxv 
 
Table 0.3 (continued) 
Code Structure 
Status of 
isolation 
Yield 
Page of 
discussion 
Spectra 
Bioactivity 
test 
RH.4b 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
7.6 mg 
(0.03%) 
73-74 3.8b.1-3.8b.9 - 
RH.4c 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
7.3 mg 
(0.02%) 
75-76 3.8c.1-3.8c.9 - 
RH.4d 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
4.9 mg 
(0.02%) 
77-78 3.8d.1-3.8d.9 - 
RH.5a 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
7.5 mg 
(0.03%) 
79-80 3.8e.1-3.8e.9 - 
RH.5b 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
24.3 mg 
(0.08%) 
81-82 3.8f.1-3.8f.9 - 
 
 
 
xxvi 
 
Table 0.3 (continued) 
Code Structure 
Status of 
isolation 
Yield 
Page of 
discussion 
Spectra 
Bioactivity 
test 
RH.6 
 
 
 
 
 
 
New 35.1 mg 
(0.12%) 
83 3.9.1-3.9.9 NCI-59 
inactive 
RH.6a 
 
 
 
 
 
 
 
(Derivative) 
11.6 mg 
(0.04%) 
84-86 3.9a.1-3.9a.9 NCI-59 
inactive 
RH.7 
 
 
 
 
 
 
 
 
 
New 8.8 mg 
(0.03%) 
87 3.10.1 - 
RH.7a 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
3.6 mg 
(0.01%) 
88-91 3.10a.1-3.10a.12 - 
RH.7b 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
0.3 mg 
(0.001%) 
92-93 3.10b.1-3.10b.9 - 
 
 
 
xxvii 
 
Table 0.3 (continued) 
Code Structure 
Status of 
isolation 
Yield 
Page of 
discussion 
Spectra Bioactivity test 
RH.8 
 
 
 
 
 
 
 
 
 
New 7.0 mg 
(0.02%) 
94 3.11.1-3.11.9 - 
RH.8a 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
3.2 mg 
(0.01%) 
95-96 3.11a.1-3.11a.9 - 
RH.9 
 
 
 
 
 
 
 
 
 
New 2.6 mg 
(0.01%) 
97 3.12.1-3.12.9 - 
RH.10 
 
 
 
 
 
 
 
 
New 4.0 mg 
(0.01%) 
98 3.13.1-3.13.9 - 
RH.10a 
 
 
 
 
 
 
 
 
 
 
(Derivative) 
1.9 mg 
(0.01%) 
99-101 3.13a.1-3.13b.9 - 
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CHAPTER ONE: Introduction 
1.1 Natural products 
For thousands of years, natural products have played an important role throughout the world 
in treating and preventing human diseases.  Natural product medicines have come from 
various source materials including terrestrial plants, terrestrial microorganisms, terrestrial 
vertebrates, terrestrial invertebrates and marine organisms.
11
  A crude extract from any one 
of these sources typically contains novel and structurally diverse chemical compounds.  
Chemical diversity in nature is based on biological and geographical diversity, so researchers 
travel around the world obtaining samples to analyse and evaluate in drug discovery screens 
or bioassays.  This present study involves the phytochemical analysis of plants belonging to 
the Meliaceae family. 
1.2 The Meliaceae Family 
The family Meliaceae (Mahogany family, order Sapindales) is an Angiosperm plant family 
of mostly trees and shrubs together with a few herbaceous plants.
12
  With 50 genera and 
more than 1400 species, Meliaceae are distributed in tropical and subtropical regions 
throughout the world.
13
  Species of the Meliaceae produce a wide range of compounds, 
including flavonoids, chromones, coumarins, benzofurans, and mono-, sesqui- and 
diterpenoids.  Sterols of the pregnane and stigmastane classes, dammarane, lupane, oleanane 
and squalane triterpenoids are common, but alkaloids are rare.  Species of the Meliaceae are 
characterised by a group of tetranortriterpenoid derivatives, called limonoids.  The Aglaia 
and the Xylocarpus genera were selected to work on because many types of limonoids have 
been isolated from the Xylocarpus genus and chemical constituents of the Aglaia genus are 
reported to exhibit important biological activities. 
1.2.1 The Aglaia Genus 
The genus Aglaia is the largest genus of the family Meliaceae, comprising about 120 woody 
species ranging from small to large trees up to 40 m high,
12
 mainly distributed in the tropical 
rainforests of Southeast Asia.
2
  Examples of compounds that have been isolated from the 
Aglaia genus include the bisamides, aglaianine [1]
14
 and leptaglin [2],
15
 the dolabellane 
diterpenoids, (1R,3E,7E,10S,11S,12R)-dolabella-3,7-diene-10,18-diol [3]
16
 and 
(1R,3S,7E,11S,12R)-3-hydroperoxydolabella-4(16),7-dien-18-ol [4],
17
 the dimeric triterpene 
alkaloid, silvaglenamin [5],
18
 the rocaglamide flavaglines (cyclopenta[b]benzo furans), 1-O-
2 
 
acetylrocaglamide [6]
19
 and cyclorocaglamide [7],
20
 the aglain flavaglines 
(cyclopenta[bc]benzofurans), elliptifoline [8]
21
 and aglaforbesin [9],
22
 the forbagline 
flavaglines (benzo[b]oxepines), edulisone A [10]
23
 and forbaglin B [11],
24
 the flavonoids, 
2,3-dihydro-5-hydroxy-4',7-dimethoxyflavone [12]
25
 and 4',5,7-tri-O-methylkaempferol [13],
17
 
the trinortriterpenoid, isoeichlerialactone [14],
26
 the triterpenoids, agladupol A [15],
27
 
aglaiaglabretol A [16]
28
 and argenteanol D [17],
29
 the pregnanes, 2,3,20-trihydroxy-16-
acetoxy-20(R)-pregnane [18]
30
 and 2,19-oxymeliavosin [19].
30
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Examples of compounds isolated from the Aglaia genus 
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Chemical constituents from the Aglaia genus are reported to exhibit important biological 
activities such as anticancer,
12,17,31-35
 antineoplastic,
34-36
 antitumor,
12,37
 cytostatic,
12
 anti-
leukemic,
17,35
 cytotoxic,
16,33-36,38
 anti-retrovial,
39
 anti-HSV-1,
33
 antimalarial,
33
 antifungal,
26,36
 
antimycobacterial,
33
 antiviral,
33,36
 anti-apoptotic protein Mcl-1,
34
 anti-inflammatory,
12,17,36,40
 
antiproliferative,
26
 molluscicidal
2
 and insecticidal activities.
2,12,17,36
 
1.2.2 The Xylocarpus Genus 
Xylocarpus is a small genus belonging to the Meliaceae family, comprising three species 
which are very similar, and consequently have often been confused.  In tropical Africa and 
the African Indian Ocean islands only two species are found: X. granatum and X. rumphii 
(Kostel.) Mabb.  In most African floras, X. rumphii is erroneously named X. moluccensis 
(Lam.) M.Roem., which, in fact, is the third species and is restricted to tropical Asia and 
Australia and does not occur in Africa. X. rumphii is not a mangrove species, it grows on 
sandy and rocky coasts and has no ribbon-like surface roots.
41
 
Two reviews on the chemical constituents and general overview of the Xylocarpus genus 
have been recently published by Lakshmi et al. (2008)
42
 and Shen et al. (2009).
43
  Examples 
of compounds that have been isolated from the Xylocarpus genus include the alkaloid, 
xylogranatinin [20],
44
 the flavanol, (+)-catechin [21],
45
 the monoterpenoid, xylomollin [22],
46
 
the phenolic acid, ethyl 3,4-dihydroxybenzoate [23],
47
 the tetranortriterpenoids, 
photogedunin [24]
48
 and moluccensin O [25],
49
 the andirobin limonoids (rings B and D 
opened), methyl angolensate [26]
10,50
 and thaimoluccensin A [27],
51
 the gedunin limonoids 
(ring D opened), 1-hydroxy-1,2-dihydrogedunin [28]52 and 7-oxo-7-deacetoxy gedunin 
[29],
53,54
 the mexicanolide limonoids (modified, rings B and D opened), hainan mexicanolide 
[30],
50,51,55
 swietenine [31],
56
 xylocarpin G [32],
57
 xyloccensin K [33],
10,56
 xylogranatin A 
[34],
38
 xylogranatin C [35],
38,58
 xylogranatin D [36]
38
 and xylorumphiin B [37],
10
 the 
obacunol limonoid (rings A and D opened), 7-acetoxydihydronomilin [38],59 the 
phragmalin limonoids (modified, rings B and D opened), godavarin B [39],
55
 godavarin K 
[40],
60
 granatumin G [41],
61
 hainangranatumin F [42],
62
 moluccensin G [43],
63
 moluccensin I 
[44],
51,64
 xylocarpin I [45]
57,65
 and xyloccensin Q [46],
55,66
 the miscellaneous limonoids, 
moluccensin M [47],
49
 xylocarponoid A [48],
67
 xylogranatin L [49],
68
 xylogranatin Q [50]
68
 
and xylogranatin R [51],
68
 the limonoid-based alkaloids, granatoine [52]
69
 and xylogranatin 
H [53]
68
 and the triterpenoids, grandifoliolenone [54],
70
 hispidol B [55],
70
 odoratone [56],
70
 
protoxylocarpin E [57],
65
 protoxylogranatin B [58]
71
 and sapelin E acetate [59].
70
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Figure 1.2 Examples of compounds isolated from the Xylocarpus genus 
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Figure 1.2 (continued) 
X. granatum has been used as a folk medicine for the treatment of cholera, diarrhoea, 
influenza, malaria and as an antifeedant.
38,43,50,65,72
  X. moluccensis has been used as a cure 
for elephantiasis,  swelling of the breast, breast cancer, dysentery, diarrhoea and other 
abdominal problems, and as an aphrodisiacs, astringent and febrifuge.
43,46,73
 
Chemical constituents from the Xylocarpus genus are reported to exhibit several biological 
activities such as antibacterial,
50,64,74
 anticancer,
50,52
 cytotoxicity,
58,65
 antidiarrhoeal,
43,75,76
 
antiviral,
50
 antimalarial,
77
 anti-secretory,
48
 anti-osteoclastogenic,
78
 anti-inflammatory,
9,51
 
antifungal,
74,79
 antifilarial,
80
 and insecticidal activity.
49,68,81-83
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1.3 Virtual Screening for cytochrome P450 11 Inhibitors 
Pharmacophore-based virtual screening is an established in silico tool used for filtering large 
compound libraries in the search for new lead compounds.
84
  Pharmacophore models consist 
of a defined 3D arrangement of so-called features that represent the chemical functionalities 
of active molecules: hydrogen bond acceptors (HBAs), hydrogen bond donors (HBDs), 
hydrophobic areas (H), positively and negatively ionisable groups (PI/NI), and metal 
coordinating areas (M).  Additional size restrictions in the form of shape or exclusion 
volumes (XVOL) - forbidden areas - can be added to represent the size and the shape of the 
binding pocket.
85
  A pharmacophore model also represents a target-ligand binding site that 
triggers a desired pharmacological effect.
84
 
 
 
 
 
Figure 1.3 Overview of the molecular modelling workflow
86
 
The cytochrome P450 (CYP) enzyme superfamily plays a central role in hepatic drug 
metabolism
87
 or Phase I metabolism of xenobiotics.
88
  While most CYP are extensively 
expressed in the liver, some of them are also detected in the heart with different 
cardiovascular effects.
87
  In a failing human heart, CYP11B1 (11β-hydroxylase) and 
CYP11B2 (3β-hydroxysteroid dehydrogenase, aldosterone synthase) were found in some 
samples.
89
  However, CYP11A (cholesterol side chain cleavage) was detected in healthy and 
failing human hearts.
87,89,90
  In pregnancy, overexpression of CYP11A reduced cell viability 
and induced apoptosis.
91
  Apoptosis is known to contribute in the loss of cardiomyocytes in 
heart failure.
90
  Moreover, the mitochondrial CYP enzymes inhibitor steroid CYP11B1 has 
an effect in the treatment of Cushing’s syndrome.92 
This study involves molecular modelling for CYP11A, CYP11B1 and CYP11B2. 
 
3D pharmacophore 
model development 
and refinement 
Hit list from 3D 
database screening 
Biological evaluation 
of virtual screening 
hits 
Pharmacophore-based 
virtual screening 
Re-scoring by 
shape-similarity 
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1.4 Objectives of the Present Study 
This study is comprised of two parts.   
1. The phytochemical and pharmacological analysis of compounds from two plants, namely 
Aglaia argentea and Xylocarpus rumphii. 
2. The identification of cytochrome P450 11 inhibitors via virtual screening. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
CHAPTER TWO: The phytochemistry of the twigs of Aglaia argentea 
2.1 Introduction 
Aglaia argentea Blume (synonyms A. Iloilo Merr., A. multifoliola Merr. and A. splendens 
Koord. & Valeton.)
93-95
 is a tree that grows in Asia, Papua New Guinea and the Solomon 
Islands
96
 and is placed in the Aglaieae tribe of the Melioidae subfamily of the Meliaceae 
family.
97
  It reaches 25 m high
98
 and its stem bark oozes a milky exudate. It has compound 
leaves
93,94
 that are spaced along branches, its flowers are about 1.5-2.5 mm in diameter
98
 and 
its fruits are cream to brown colour.
94
  The leaves are characterised by brown and white 
scales on the underside, with new growth densely covered with brown scales.
93,94
  A. 
argentea occurs in altitudinal range from 0-150 m above sea level and is restricted to rain 
forests along river flats and lowland rain forest situations.
96
 
       
Picture 2.1 The leaves and twigs of A. argentea 
Chemical constituents from previous studies of the bark, leaves and seeds of A. argentea can 
be classified as aminopyrrolidines,
24
 alkaloids,
24
 apotirucallane triterpenoids,
99
 3,4-
secoapotirucallane triterpenoids
100
 and cycloartane triterpenoids.
29,101
  These compounds and 
their cytotoxicity against KB cell are presented in Table 2.1. 
Table 2.1 Compounds isolated from A. argentea and their cytotoxicity against KB cells 
 Investigated part Compound name Compound type IC50 (μg/mL) 
Bark argentinic acid A [66]
100
 3,4-secoapotirucallane 2.0   
100
 
 argentinic acid B [67]
100
 3,4-secoapotirucallane 2.0   
100
 
 argentinic acid C [68]
100
 3,4-secoapotirucallane 2.0   
100
 
 argentinic acid D [69]
100
 3,4-secoapotirucallane 1.0   
100
 
 argentinic acid E [70]
100
 3,4-secoapotirucallane 3.5   
100
 
 argentinic acid F [71]
100
 3,4-secoapotirucallane 2.0   
100
 
 argentinic acid G [72]
100
 3,4-secoapotirucallane 2.5   
100
 
 argentinic acid H [73]
100
 3,4-secoapotirucallane 2.0   
100
 
 argentinic acid I [74]
100
 3,4-secoapotirucallane N/A   
100
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Table 2.1 (continued) 
 Investigated part Compound name Compound type IC50 (μg/mL) 
Leaves aglain A [75]
24
 aglain flavagline N/A 
 aglain B [76]
24
 aglain flavagline N/A 
 aglain C [77]
24
 aglain flavagline N/A 
 aminopyrrolidine odorine [78]
24
 aminopyrrolidine N/A 
 argenteanol A [79]
29,101
 cycloartane N/A 
 argenteanol B [80]
29
 cycloartane 3.7   
29
 
 argenteanol C [81]
29
 cycloartane 6.2   
29
 
 argenteanol D [17]
29
 cycloartane 4.0   
29
 
 argenteanol E [82]
29
 cycloartane 5.9   
29
 
 argenteanone A [83]
29,101
 cycloartane 7.5   101 
 argenteanone B [84]
29,101
 cycloartane 6.5   101 
 argenteanone C [85]
29
 cycloartane 4.1   29 
 argenteanone D [86]
29
 cycloartane 4.2   29 
 argenteanone E [87]
29
 cycloartane 3.7   29 
Seeds didesmethylrocaglamide [88]
24
 rocaglamide flavagline 0.006   
24
 
 gentinin [89]
99
 apotirucallane triterpene N/A 
 gentinone A [90]
99
 apotirucallane triterpene N/A 
 gentinone B [91]
99
 apotirucallane triterpene N/A 
 gentinone C [92]
99
 apotirucallane triterpene N/A 
 gentinone D [93]
99
 apotirucallane triterpene N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Compounds isolated previously from A. argentea 
 
66 :  R1 = a, R2 = H 
67 :  R1 = b, R2 = H 
68 :  R1 = c, R2 = H 
69 :  R1 = c, R2 = a 
70 :  R1 = c, R2 = b 
71 :  R1 = b, R2 = a 
72 :  R1 = R2 = a 
73 :  R1 = R2 = c 
75 :  R1 = OAc, R2 = H, H-3β, H-4α 
76 :  R1 = H, R2 = OH, H-3β, H-4α 
77 :  R1 = H, R2 = OH, H-3α, H-4β 
81 :  R1 = R2 = β-OH 
83 :  R1 = O, R2 = β-OH 
86 :  R1 = O, R2 = β-OEt 
87 :  R1 = R2 = O 
79 :  R1 = β-OH, R2 = CH2OH 
84 :  R1 = O, R2 = CH2OH 
85 :  R1 = O, R2 = CH3 
10 
 
 
 
 
 
 
 
 
 
Figure 2.1 (continued) 
This work was part of research collaboration with Professor Datin Rohaya Ahmad from 
Universiti Teknologi MARA, Malaysia.  She spent a sabbatical leave with the group at 
University of Surrey and it was decided that an investigation of the twigs would be 
undertaken by the Surrey group while her group worked on other parts. 
 
 
 
 
 
 
 
 
 
 
 
90 :  R = H 
91 :  R1 = Ac 
90 :  R = H 
91 :  R1 = Ac 
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2.2 Structural elucidation of compounds isolated from the twigs of A. argentea 
The new δ-lactam (N-methyl-2Ɛ,4Ɛ-dihydroxypentano-5-lactam, AT.1) and six known 
dammarane triterpenoids, (20S,24R)-epoxydammarane-3,25-diol (AT.2), (20S,24S)-
epoxydammarane-3,25-diol (AT.3), 25-hydroxy-(20S,24R)-epoxydammaran-3-one (AT.4), 
25-hydroxy-(20S,24S)-epoxydammaran-3-one (AT.5), 3-acetoxy-(20S,24R)-epoxydammaran-
25-ol (AT.6), 3-acetoxy-(20S,24S)-epoxydammaran-25-ol (AT.7) were isolated from the 
twigs of A. argentea, together with a mixture of sitosterol (AT.8) and stigmasterol (AT.9).  
Acetylated derivative AT.1a was synthesized for confirming the structure of AT.1.  
Compounds AT.2, AT.4, AT.5 and AT.7 have been isolated from this genus before.
1-3
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Compounds isolated from the twigs of A. argentea 
 
 
 
 
 
 
 
 
AT.2 : R = -OH 
AT.4 : R = O 
AT.6 : R = -OAc 
AT.3 : R = -OH 
AT.5 : R = O 
AT.7 : R = -OAc 
12 
 
2.2.1 Structural elucidation of compound AT.1: N-methyl-2Ɛ,4Ɛ-dihydroxypentano-5-
lactam 
Compound AT.1 was isolated as a colourless solid from the methanol extract of the twigs of 
A. argentea and was identified as the N-methyl-2Ɛ,4Ɛ-dihydroxypentano-5-lactam.  This 
compound has not been reported previously. 
 
 
 
Figure 2.3 Proposed structure of compound AT.1 
The LRMS [Spectrum 2.1.1] gave a [M-H2O]
+
 ion at m/z 127.0 which corresponded to the 
molecular formula C6H11O3N for the molecule and  indicated two double bond equivalents.  
The FTIR spectrum [Spectrum 2.1.2] exhibited absorption bands at 3375 and 1625 cm
-1
 
which were attributed to OH stretch and C=O stretch of a lactam. 
The 
13
C NMR spectrum [Spectrum 2.1.4] displayed six carbon resonances, while the 
HSQCDEPT experiment [Spectrum 2.1.6] confirmed that five out of the six carbons were 
attached to protons.  The types of carbon atoms were determined by performing a DEPT 
experiment [Spectrum 2.1.5], which revealed the presence of one methyl, two methylene, 
two methine and one quaternary carbons. 
The structure of compound AT.1 was determined using the COSY experiment [Spectrum 
2.1.8].  The COSY spectrum showed correlations between the H-3eq (δH 2.45, ddt, J = 13.8, 
7.5, 2.0 Hz) and H-2ax (δH 4.05, dd, J = 10.7, 7.5 Hz), H-3ax (δH 2.18, ddd, J = 13.8, 10.7, 4.8 
Hz) and H-4ax (δH 4.50, m) resonances, indicating that the two H-3 protons were connected 
to H-2 and H-4.  Moreover, the COSY spectrum showed correlations between the H-5ax (δH 
3.82, dd, J = 12.5, 4.6 Hz) and H-4 (δH 4.50, m) and H-5eq (δH 3.07, dt, J = 12.5, 2.0 Hz) 
resonances, indicating that the H-5ax and H-5 eq were connected to H-4. 
H-2 and H-4 cannot be equatorial because of 1,3-diaxial interaction.  The configuration at C-
2 and C-4 was determined using the NOESY experiment [Spectrum 2.1.9].  The NOESY 
spectrum showed correlations between the H-2ax and H-3eq (δH 2.45), H-3ax (δH 2.18), H-4ax 
(δH 4.50) and 3H-NCH3 (δH 3.01) resonances, indicating that H-2ax and H-4ax were on the 
same side.   
13 
 
 
         
 
Figure 2.4 Proposed structures of compound AT.1 
Acetylation enabled confirmation that the structure was a diol (AT.1(a)/AT.1(b)) or an 
epoxide (AT.1(c)/AT.1(d)) (Figure 2.4 and Table 2.3).  After acetylation, two acetyl group 
proton resonances were found in the 
1
H NMR spectrum [Spectrum 2.1a.1], indicating that 
compound AT.1 was the 2,4-dihydroxy lactam (Figure 2.5 and 2.6). 
 
 
 
Figure 2.5 Proposed structure of acetylated derivative of compound AT.1 
From NMR data it was not possible to decide whether AT.1(a) or AT.1(b) was the correct 
structure (Table 2.2).  The compound is not crystalline, and an attempt to benzoylate it is 
effect to obtain crystal for X-ray analysis was unsuccessful.  The compound is not suitable 
for the CD analysis.  Compound AT.1 was a new lactam similar to the 6-oxa-3-
azabicyclo[3.1.1]heptane-2-thione which was synthesized for medicinal chemistry 
research.
102
 
 
 
Figure 2.6 Structure of compound AT.1 and 6-oxa-3-azabicyclo[3.1.1]heptane-2-thione 
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Table 2.2 
1
H and 
13
C NMR assignments for compound AT.1 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, MeOD, J = Hz] and 6-oxa-3-azabicyclo[3.1.1]heptane-2-thione [
13
C NMR 125 
MHz, DMSO-d6]
102
 
No. δC AT.1 δC
102
 δH AT.1 HMBC (H→C) COSY NOESY 
1 173.1 202.3 - - - - 
2ax 72.0 85.0 4.05 dd J = 10.7, 7.5 Hz 1, 3, 4, NCH3 3eq, 3ax 3eq, 3ax, 4ax, NCH3 
3eq 
40.5 32.3 
2.45 ddt J = 13.8, 7.5, 2.0 Hz 1, 4, 5 2ax, 3ax, 4ax 2ax, 3ax, 4ax, 5eq 
3ax 2.18 ddd J = 13.8, 10.7, 4.8 Hz 1, 5 2ax, 3eq, 4ax 2ax, 3eq, 4ax, 5ax 
4ax 71.1 78.2 4.50 m 2, 5 3eq, 3ax, 5ax, 5eq 2ax, 3eq, 3ax, 5ax, 5eq 
5ax 
64.4 47.2 
3.82 dd J = 12.5, 4.6 Hz 2, 3, NCH3 4ax, 5eq 3ax, 4ax, 5eq 
5eq 3.07 dt J = 12.5, 2.0 Hz 2, 3, 4, NCH3 4ax, 5ax 3eq, 4ax, 5ax 
NCH3 44.1 - 3.01 s 2, 5 - 2ax 
 
Table 2.3 
1
H and 
13
C NMR assignments for compound AT.1a [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, MeOD, J = Hz] and compound AT.1 [
13
C NMR 125 MHz, MeOD] 
No. δC AT.1a δC AT.1 δH AT.1a HMBC (H→C) COSY NOESY 
1 170.8 173.1 - - - - 
2ax 70.1 72.0 3.94 dd J =10.5, 7.5 Hz 1, 3, 4, NCH3 3 3, 4ax, NCH3 
3 36.4 40.5 2.47 m 1, 2, 4, 5 2ax, 4ax 2ax, 4ax 
4ax 72.5 71.1 5.31 br s W1/2 = 13.2 Hz 2, 5, 4-OAc (C=O) 3, 5eq, 5ax 2ax, 3, 5eq, NCH3 
5eq 
61.3 64.4 
4.32 dd J = 12.9, 5.2 Hz 2, 3, NCH3 4ax, 5ax 4ax, NCH3 
5ax 2.97 m 3, 4, NCH3 4ax, 5eq - 
NCH3 42.8 44.1 2.98 s 2, 4, 5 - 2ax, 4ax, 5eq 
2-OAc 
175.1 - - - - - 
21.4 - 2.02 s 2, 2-OAc (C=O) - - 
4-OAc 
170.2 - - - - - 
21.1 - 2.07 s 4, 4-OAc (C=O) - - 
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2.2.2 Structural elucidation of compound AT.2: (20S,24R)-epoxydammarane-3,25-diol 
Compound AT.2 was isolated as a white solid from the methanol extract of the twigs of      
A. argentea and was identified as the known 3-epiocotillol II
103
 (also called 3-epi-ocotillol 
II
1,104
 or epyocotillol
105
).  
 
 
 
 
 
Figure 2.7 Structure of compound AT.2 
The HRMS [Spectrum 2.2.1] gave a [M+Na]
+
 ion at m/z 483.3795 which corresponded to 
the molecular formula C30H52O3 for the compound, indicating five double bond equivalents 
in the molecule.  The FTIR spectrum [Spectrum 2.2.2] showed absorption bands at 3446 
and 1068 cm
-1
 attributable to OH and a C-O stretches. 
The 
13
C NMR spectrum [Spectrum 2.2.4] displayed thirty carbon resonances, while the 
HSQCDEPT experiment [Spectrum 2.2.6] confirmed that twenty-four out of the thirty 
carbons were attached to protons.  The types of carbon atoms were determined by performing 
a DEPT experiment [Spectrum 2.2.5], which revealed the presence of eight methyl, ten 
methylene, six methine and six quaternary carbons.  These structural features revealed that 
the compound was a triterpenoid. 
The 
1
H NMR spectrum [Spectrum 2.2.3] showed two oxymethine proton resonances at δ 3.73 
(1H, t, J = 7.3 Hz) and 3.39 (1H, t, J = 2.8 Hz).  It also showed eight methyl group singlet 
proton resonances at δ 1.21, 1.13, 1.12, 0.96, 0.94, 0.89, 0.85 and 0.84. 
The oxymethine proton resonance at δ 3.39 was ascribed to H-3.  The small coupling constant 
(2.8 Hz) of this proton resonance demonstrated the axial (-) orientation of the hydroxyl 
group at C-3.  In the HMBC spectrum [Spectrum 2.2.7], the H-3 resonance showed 
connectivities over 
3
J with resonances at δC 49.8 (C-5), 33.9 (C-1), 28.5 (C-28) and 22.3 (C-
29).  These HMBC correlations confirmed the assignment of the H-3 resonance. 
16 
 
An oxymethine proton resonance at δ 3.73 was assigned to H-24 in the side chain due to 
observed correlations in the HMBC spectrum with the C-26 and C-27 terminal methyl group 
carbons (δC 27.7 and 24.5), and also a fully substituted oxygenated carbon resonance at δC 71.7 
assigned to C-25.  The configuration at C-24 was determined using the NOESY experiment 
[Spectrum 2.2.9].  The NOESY spectrum showed correlations between the H-24 and 3H-26 
(δH 1.21), 3H-21 (δH 1.13) and 3H-27 (δH 1.12) resonances, indicating that 3H-21 and H-24 
were on the same side.  The configuration at C-24 was therefore assigned as R.  Compound 
AT-2 was identified as (20S,24R)-epoxydammarane-3,25-diol. 
Compound AT.2 was previously isolated from Aglaia foveolata (Meliaceae),
1
 Betula 
maximowicziana (Betulaceae)
104
 and Betula platyphylla var. japonica (Betulaceae).
103,106
  
This compound had moderate haemolytic activity at pH 5.5 and 37 
o
C (HC50 62.5 ± 5.6 
μM).105  In addition, 3-epi-ocotillol II showed no P-glycoprotein associated ATPase 
activity.
106
  
 
 
Figure 2.8 Conformation of compound AT.2 
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Table 2.4 
1
H and 
13
C NMR assignments for compound AT.2 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and 3-epi-ocotillol II [
13
C NMR in CDCl3]
104
 
No. δC AT.2 δC
104
 δH AT.2 HMBC (H→C) COSY NOESY 
1a 
33.9 CH2 33.6 
1.41 m 3, 5, 19 1b, 2a, 2b - 
1b 1.29 m 5, 9, 19 1a, 2a, 2b - 
2a 
25.6 CH2 25.4 
1.95 m 10 1a, 1b, 2b, 3 3, 19, 29 
2b 1.54 m 4, 10 1a, 1b, 2a, 3 3 
3 76.5 CH 76.3 3.39 t J = 2.8 Hz 1, 5, 28, 29 2a, 2b 2a, 2b, 28, 29 
4 37.9 C 37.6 - - - - 
5 49.8 CH 49.5 1.26 m  1, 3, 7, 9, 19, 28, 29 6 9 
6 18.5 CH2 18.2 1.41 m 4, 8, 10 5, 7a, 7b - 
7a 
35.4 CH2 35.2 
1.58 m 5, 30 6, 7b - 
7b 1.26 m 5, 9, 14, 30 6, 7a - 
8 40.8 C 40.6 - - - - 
9 50.8 CH 50.6 1.46 m 1, 5, 12, 14, 19, 30 11a, 11b 5, 17, 18 
10 37.5 C 37.3 - - - - 
11a 
21.6 CH2 21.4 
1.54 m 8, 10, 13 9, 11b, 12b - 
11b 1.19 m 13 9, 11a, 12a - 
12a 
27.6 CH2 27.3 
1.77 m 9, 14, 17 11b, 12b 18 
12b 1.26 m 9, 14, 17 11a, 12a, 13 - 
13 43.1 CH 42.9 1.57 m 8, 18 12b, 17 30 
14 50.4 C 50.1 - - - - 
15a 
31.6 CH2 31.4 
1.46 m 8, 13, 17, 18 15b, 16a - 
15b 1.07 m 13, 17, 18 15a, 16a, 16b - 
16a 
25.9 CH2 25.7 
1.78 m 13, 14, 20 15a, 15b, 16b, 17 - 
16b 1.46 m 14, 20 15b, 16a, 17 - 
17 49.7 CH 49.5 1.80 m 12, 14, 21, 22 13, 16a, 16b 9, 18 
18 16.8 CH3 16.5 0.89 s 8, 13, 14, 15 - 9, 12a, 17 
19 16.3 CH3 15.4 0.85 s 1, 5, 9, 10 - 2a, 29, 30 
20 86.7 C 86.4 - - - - 
21 23.8 CH3 23.5 1.13 s 17, 20, 22 - 24, 30 
22a 
35.9 CH2 35.6 
1.71 m 17, 21, 24 22b, 23a, 23b - 
22b 1.62 m 17, 21, 24 22a, 23a, 23b - 
23a 
26.4 CH2 26.1 
1.87 m 20, 24, 25 22a, 22b, 23b, 24 24 
23b 1.79 m 20, 24, 25 22a, 22b, 23a, 24 24 
24 83.5 CH 83.3 3.73 t J = 7.3 Hz 22, 25, 26, 27 23a, 23b 23a, 23b, 21, 26, 27 
25 71.7 C 71.4 - - - - 
26 27.7 CH3 27.4 1.21 s 24, 25, 27 - 24 
27 24.5 CH3 24.2 1.12 s 24, 25, 26 - 24 
28 28.5 CH3 28.3 0.94 s 3, 4, 5, 29 - 3, 29 
29 22.3 CH3 21.1 0.84 s 3, 4, 5, 28 - 2a, 3, 19, 28 
30 15.7 CH3 16.0 0.96 s 7, 8, 9, 14 - 13, 19, 21 
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2.2.3 Structural elucidation of compound AT.3: (20S,24S)-epoxydammarane-3,25-diol 
Compound AT.3 was isolated as a white solid from the methanol extract of the twigs of      
A. argentea and was identified as the known cabraleadiol
107,108
 (also called cavraleone).
109
 
 
 
 
 
 
 
Figure 2.9 Structure of compound AT.3 
The HRMS [Spectrum 2.3.1] gave a [M+Na]
+
 ion at m/z 483.3797, which corresponded to 
the molecular formula C30H52O3 for the compound, the same as for compound AT.2.  A 
double bond equivalence of five was calculated. The FTIR spectrum [Spectrum 2.3.2] 
showed absorption bands at 3458 and 1060 cm
-1
 attributable to OH and C-O stretches.  The 
HRMS and the FTIR spectrum of this compound resembled to those of compound AT.2. 
The 
13
C NMR [Spectrum 2.3.4], DEPT [Spectrum 2.3.5] and HSQCDEPT [Spectrum 
2.3.6] spectra displayed thirty carbon resonances, which included eight methyl, ten 
methylene, six methine and six quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound AT.2 [Spectrum 2.2.4] with that of 
compound AT.3 indicated that the chemical shifts were the same, except for the C-21 and C-
24 resonances, which occurred at δ 23.8 and 83.5 respectively in compound AT.2 but at δ 
27.3 (C-21) and 86.5 (C-24) for compound AT.3.  The 
1
H NMR spectrum also showed a 
significant difference for the H-24 resonance where compound AT.2 exhibited a resonance 
at δ 3.73 (t, J = 7.3 Hz) whereas compound AT.3 exhibited a resonance at δ 3.64 (dd, J = 
10.1, 5.2 Hz).  The NOESY spectrum [Spectrum 2.3.9] showed correlations between the H-
24 resonance (δ 3.64) and 3H-26 (δ 1.19, s) and 3H-27 (δ 1.11, s) resonances but no 
correlation was seen with the 3H-21 (δ 1.14, s) resonance, as was seen for compound AT.2.  
In addition, the 3H-21 resonance showed correlations in the NOESY spectrum with the 3H-
27 (δ 1.11, s) and 3H-30 (δ 0.97, s) resonances, indicating that 3H-21, 3H-27 and 3H-30 
were on the same side.  The configuration at C-24 in compound AT.3 was therefore assigned 
as S.  Compound AT.3 was identified as (20S,24S)-epoxydammarane-3,25-diol. 
19 
 
(20S,24S)-Epoxydammarane-3,25-diol was previously isolated from Commiphora dalzielii 
(Burseraceae),
107
 Dysoxylum lukii (Meliaceae)
109
 and Dysoxylum malabaricum 
(Meliaceae).
108
  This compound exhibited weak cytotoxicity against the human breast cancer 
(MCF-7), human cervical cancer (HeLa), human colon cancer (HCT15), human gastric 
adenocarcinoma (SGC-7901), human gastric carcinoma (BGC-823), human hepatocellular 
carcinoma (HepG2), human lung cancer (A549) and human skin cancer (SK-MEL-2) with 
IC50 values above 70 μM.
109
 
Table 2.5 
1
H and 
13
C NMR assignments for compound AT.3 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz], compound AT.2 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, CDCl3, J = Hz] 
and cabraleadiol [
13
C NMR 90.56
107
 and 125 MHz,
108
 CDCl3] 
No. δC AT.3 δC AT.2 δC
107 δC
108 δH AT.3 δH AT.2 HMBC (H→C) COSY NOESY 
1a 
33.9 CH2 33.9 CH2 33.74 33.6 
1.41 m 1.41 m 3, 5, 9, 19 1b, 2a, 2b - 
1b 1.29 m 1.29 m 3, 5, 9, 19 1a, 2a, 2b - 
2a 
25.6 CH2 25.6 CH2 25.84 25.3 
1.95 m 1.95 m 10 1a, 1b, 2b, 3 3, 19, 29 
2b 1.54 m 1.54 m 3, 4, 10 1a, 1b, 2a, 3 3 
3 76.5 CH 76.5 CH 76.31 76.2 3.39 t J = 2.7 Hz 3.39 t J = 2.8 Hz 1, 5, 28, 29 2a, 2b 2a, 2b, 28, 29 
4 37.8 C 37.9 C 37.66 37.6 - - - - - 
5 49.8 CH 49.8 CH 50.70 49.5 1.25 m 1.26 m 
1, 3, 7, 9, 19, 28, 
29 
6 9 
6 18.5 CH2 18.5 CH2 18.30 18.2 1.41 m 1.41 m 4, 8, 10 5, 7a, 7b - 
7a 
35.4 CH2 35.4 CH2 34.96 35.1 
1.58 m 1.58 m 5, 9, 14, 30 6, 7b - 
7b 1.25 m 1.26 m 5, 9, 14, 30 6, 7a - 
8 40.8 C 40.8 C 40.68 40.6 - - - - - 
9 50.9 CH 50.8 CH 49.88 50.6 1.45 m 1.46 m 1, 5, 12, 14, 19, 30 11a, 11b 5, 18 
10 37.5 C 37.5 C 37.34 37.2 - - - - - 
11a 
21.9 CH2 21.6 CH2 21.70 21.6 
1.54 m 1.54 m 8, 10, 13 9, 11b, 12a, 12b - 
11b 1.20 m 1.19 m 10, 13 9, 11a, 12a - 
12a 
27.2 CH2 27.6 CH2 25.46 27.0 
1.78 m 1.77 m 9, 14, 17 11a, 11b, 12b, 13 - 
12b 1.22 m 1.26 m 9, 14, 17 11a, 12a, 13 - 
13 43.0 CH 43.1 CH 42.88 42.7 1.63 m 1.57 m 8, 11, 18, 20 12a, 12b, 17 30 
14 50.4 C 50.4 C 50.19 50.1 - - - - - 
15a 
31.6 CH2 31.6 CH2 31.44 31.4 
1.46 m 1.46 m 8, 17, 18 15b, 16a, 16b - 
15b 1.06 m 1.07 m 8, 13, 17, 18 15a, 16a, 16b - 
16a 
26.0 CH2 25.9 CH2 28.34 25.8 
1.75 m 1.78 m 13, 14, 20 15a, 15b, 16b, 17 - 
16b 1.30 m 1.46 m 14, 20 15a, 15b, 16a, 17 - 
17 50.0 CH 49.7 CH 49.60 49.8 1.86 m 1.80 m 12, 14, 15, 21, 22 13, 16a, 16b 18 
18 16.7 CH3 16.8 CH3 16.55 16.5 0.89 s 0.89 s 8, 13, 14, 15 - 9, 17 
19 16.3 CH3 16.3 CH3 15.56 16.0 0.86 s 0.85 s 1, 5, 9, 10 - 2a, 30 
20 86.8 C 86.7 C 86.55 86.5 - - - - - 
21 27.3 CH3 23.8 CH3 24.11 27.1 1.14 s 1.13 s 17, 20, 22 - 27, 30  
22a 
35.0 CH2 35.9 CH2 35.27 34.7 
1.86 m 1.71 m 17, 21, 24 22b, 23a, 23b - 
22b 1.67 m 1.62 m 17, 21, 24 22a, 23a, 23b - 
23a 
26.6 CH2 26.4 CH2 27.83 26.3 
1.85 m 1.87 m 20, 25 22a, 22b, 23b, 24 - 
23b 1.76 m 1.79 m 20, 25 22a, 22b, 23a, 24 - 
24 86.5 CH 83.5 CH 86.31 86.2 3.64 dd J = 10.1, 5.2 Hz 3.73 t J = 7.3 Hz 22, 25, 26, 27 23a, 23b 26, 27 
25 70.5 C 71.7 C 70.27 70.2 - - - - - 
26 28.0 CH3 27.7 CH3 26.42 27.8 1.19 s 1.21 s 24, 25, 27 - 24, 27, 30 
27 24.3 CH3 24.5 CH3 27.05 24.0 1.11 s 1.12 s 24, 25, 26 - 21, 24, 26,30 
28 28.5 CH3 28.5 CH3 27.05 28.3 0.94 s 0.94 s 3, 4, 5, 29 - 3, 29 
29 22.3 CH3 22.3 CH3 22.15 22.1 0.84 s 0.84 s 3, 4, 5, 28 - 2a, 3, 28 
30 15.7 CH3 15.7 CH3 16.08 15.5 0.97 s 0.96 s 7, 8, 9, 14 - 13, 19, 21 
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2.2.4 Structural elucidation of compound AT.4: 25-hydroxy-(20S,24R)-epoxydammaran-
3-one 
Compound AT.4 was isolated as a white solid from the methanol extract of the twigs of      
A. argentea and was identified as the known ocotillone.
2,8,110-112
  
 
 
 
 
 
Figure 2.10 Structure of compound AT.4 
The HRMS [Spectrum 2.4.1] gave a [M+Na]
+
 ion at m/z 481.3650, which corresponded to 
the molecular formula C30H50O3 for the compound.  A double bond equivalence of six was 
calculated.  The FTIR spectrum [Spectrum 2.4.2] exhibited absorption bands at 3468 and 
1705 cm
-1
 which were attributed to OH and C=O stretches, respectively. 
The 
13
C NMR spectrum [Spectrum 2.4.4] displayed thirty carbon resonances, while the 
HSQCDEPT experiment [Spectrum 2.4.6] confirmed that twenty-three out of the thirty 
carbons were attached to protons.  The multiplicities of the carbon signals were determined 
by performing the DEPT experiment [Spectrum 2.4.5], which revealed the presence of eight 
methyl, ten methylene, five methine and seven quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound AT.2 with that of compound AT.4 
indicated that the chemical shifts were the same, except for the C-1, C-2, C-3, C-4, C-5 and 
C-28 resonances, which occurred at δC 33.9, 25.6, 76.5, 37.9, 49.8 and 28.5 respectively in 
compound AT.2 but at δ 40.1 (C-1), 34.3 (C-2), 218.3 (C-3), 47.6 (C-4), 55.6 (C-5) and 26.9 
(C-28) for compound AT.4 and that the correlation between the H-24 and 3H-21 resonances 
was present in the NOESY spectrum. 
The 
1
H NMR spectrum showed that the H-3 resonance present in compound AT.2 was 
missing in compound AT.4, but the 
13
C NMR spectrum for compound AT.4 showed a 
carbonyl resonance at δC 218.3, indicating that compound AT.4 has a ketone group at C-3.  
Compound AT.4 was identified as 25-hydroxy-(20S,24R)-epoxydammaran-3-one. 
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Compound AT.4 was previously isolated from Aglaia duperreana (Meliaceae),
2
 Dysoxylum 
richii (Meliaceae),
110
 Juliania adstringens (Julianiaceae),
111
 Panax pseudo-ginseng subsp. 
himalaicus (Araliaceae)
8
 and Shorea javanica (Dipterocarpaceae).
112
 
Ocotillone showed no molluscicidal activity against Pomacea canaliculata (the golden apple 
snail).
2
  This compound also showed no inhibitory effects against the induction of Epstein-
Barr Virus Early Antigen (EBV-EA) activity.
112
  Moreover, ocotillone showed a moderate 
effect against leukemia cells (L-1210: IC50 = 20 μg/mL)
111
 with weak activity against two 
human cell lines; leukemia (HL60: EC50 = 94.2 μM) and melanoma (CRL1579: EC50 = 71.4 
μM).112  In addition, ocotillone showed no P-glycoprotein associated ATPase activity.106  
Table 2.6 
1
H and 
13
C NMR assignments for compound AT.4 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], compound AT.2 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, CDCl3, 
J = Hz] and ocotillone [
13
C NMR 75.46 MHz, CDCl3]
110
  
No. δC AT.4 δC AT.2 δC
110 δH AT.4 δH AT.2 HMBC (H→C) COSY NOESY 
1a 
40.1 CH2 33.9 CH2 39.9 t 
1.91 m 1.41 m 3, 5 1b, 2a, 2b - 
1b 1.45 m 1.29 m 9 1a, 2a, 2b - 
2a 
34.3 CH2 25.6 CH2 34.1 t 
2.49 m 1.95 m 1, 3 1a, 1b, 2b - 
2b 2.44 m 1.54 m 1, 3 1a, 1b, 2a - 
3 218.3 C 76.5 CH 218.1 s - 3.39 t J = 2.8 Hz - - - 
4 47.6 C 37.9 C 47.4 s - - - - - 
5 55.6 CH 49.8 CH 55.4 d 1.37 dd J = 11.5, 2.7 Hz 1.26 m - - - 
6a 
19.9 CH2 18.5 CH2 19.7 t 
1.56 m 
1.41 m 
- - - 
6b 1.46 m 8 - - 
7a 
34.8 CH2 35.4 CH2 34.8 t 
1.57 m 1.58 m - - - 
7b 1.32 m 1.26 m 5 - - 
8 40.5 C 40.8 C 40.3 s - - - - - 
9 50.4 CH 50.8 CH 49.8 d 1.43 m 1.46 m 12, 14 - 18 
10 37.1 C 37.5 C 36.9 s - - - - - 
11a 
22.3 CH2 21.6 CH2 22.3 t 
1.52 m 1.54 m 8, 13 - - 
11b 1.25 m 1.19 m - - - 
12a 
27.6 CH2 27.6 CH2 25.8 t 
1.80 m 1.77 m - - - 
12b 1.26 m 1.26 m - - - 
13 43.3 CH 43.1 CH 43.0 d 1.60 m 1.57 m 16 - - 
14 50.2 C 50.4 C 50.0 s - - - - - 
15a 
31.7 CH2 31.6 CH2 31.4 t 
1.48 m 1.46 m 8, 17 - - 
15b 1.10 m 1.07 m - - - 
16a 
26.3 CH2 25.9 CH2 27.0 t 
1.85 m 1.78 m - - - 
16b  1.46 m - - - 
17 49.7 CH 49.7 CH 50.2 d 1.82 m 1.80 m 14 - - 
18 16.6 CH3 16.8 CH3 16.3 q 0.88 s 0.89 s 8, 13, 14, 15 - 9 
19 16.3 CH3 16.3 CH3 15.2 q 0.94 s 0.85 s 1, 5, 9, 10 - - 
20 86.6 C 86.7 C 86.5 s - - - - - 
21 23.8 CH3 23.8 CH3 24.1 q 1.14 s 1.13 s 17, 20, 22 - 24, 30 
22a 
35.9 CH2 35.9 CH2 34.6 t 
1.71 m 1.71 m 21 - - 
22b 1.64 m 1.62 m 21, 24 - - 
23a 
25.9 CH2 26.4 CH2 26.4 t 
1.87 m 1.87 m - 24 - 
23b 1.79 m 1.79 m - - - 
24 83.5 CH 83.5 CH 86.4 d 3.73 t J = 7.3 Hz 3.73 t J = 7.3 Hz 26, 27 23a 21 
25 71.7 C 71.7 C 70.3 s - - - - - 
26 27.7 CH3 27.7 CH3 26.8 q 1.21 s 1.21 s 24, 25, 27 - - 
27 24.5 CH3 24.5 CH3 27.2 q 1.12 s 1.12 s 24, 25, 26 - - 
28 26.9 CH3 28.5 CH3 27.8 q 1.08 s 0.94 s 3, 4, 5, 29 - - 
29 21.2 CH3 22.3 CH3 21.0 q 1.04 s 0.84 s 3, 4, 5, 28 - - 
30 15.4 CH3 15.7 CH3 16.1 q 0.99 s 0.96 s 7, 8, 9, 14 - 21 
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2.2.5 Structural elucidation of compound AT.5: 25-hydroxy-(20S,24S)-epoxydammaran-
3-one 
Compound AT.5 was isolated as a white solid from the methanol extract of the twigs of      
A. argentea and was identified as the known cabraleone.
2,8,109,110,113
 
 
 
 
 
 
 
Figure 2.11 Structure of compound AT.5 
The HRMS [Spectrum 2.5.1] gave a [M+Na]
+
 ion at m/z 481.3632, which corresponded to 
the molecular formula C30H50O3 for the compound.  A double bond equivalence of six was 
calculated.  The FTIR spectrum [Spectrum 2.5.2] exhibited absorption bands at 3461 and 
1706 cm
-1
 which were attributed to OH and C=O stretches.  The HRMS and the FTIR 
spectrum of compound AT.5 resembled to those of compound AT.4. 
The 
13
C NMR [Spectrum 2.5.4], DEPT [Spectrum 2.5.5] and HSQCDEPT [Spectrum 
2.5.6] spectra displayed thirty carbon resonances, which included eight methyl, ten 
methylene, five methine and seven quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound AT.4 with that of compound AT.5 
indicated that the chemical shifts were the same, except for the C-21 and C-24 resonances, 
which occurred at δC 23.8 and 83.5 respectively in compound AT.4 but at δ 27.4 (C-21) and 
86.6 (C-24) for compound AT.5.  The 
1
H NMR spectrum also showed a significant difference 
for the H-24 resonance where compound AT.4 exhibited a resonance at δ 3.73 (t, J = 7.3 Hz) 
whereas compound AT.5 exhibited a resonance at δ 3.64 (dd, J = 10.0, 5.3 Hz).  The 
NOESY spectrum [Spectrum 2.5.9] showed correlations between the H-24 resonance (δ 3.64, 
dd, J = 10.0, 5.3 Hz) and 3H-26 (δ 1.19, s) and 3H-27 (δ 1.11, s) resonances but no 
correlation was seen with the 3H-21 (δ 1.15, s) resonance, as was seen for compound AT.4.  
In addition, the 3H-21 resonance showed correlations in the NOESY spectrum with the H-13 
(δ 1.67, s), 3H-26 (δ 1.19, s) and 3H-27 (δ 1.11, s) resonances, indicating that H-13, 3H-21, 
3H-26 and 3H-27 were on the same side.  The configuration at C-24 in compound AT.5 was 
23 
 
therefore assigned as S.  This compound was identified as 25-hydroxy-(20S,24S)-
epoxydammaran-3-one. 
Compound AT.5 was previously isolated from Aglaia duperreana (Meliaceae),
2
 Dysoxylum 
lukii (Meliaceae),
109
 D. richii,
110
 Nothofagus dombeyi (Fagaceae)
113
 and Panax pseudo-
ginseng subsp. himalaicus (Araliaceae).
8
 
Cabraleone exhibited weak cytotoxicity against the human breast cancer (MCF-7), human 
cervical cancer (HeLa), human colon cancer (HCT15), human gastric adenocarcinoma (SGC-
7901), human gastric carcinoma (BGC-823), human hepatocellular carcinoma (HepG2), 
human lung cancer (A549) and human skin cancer (SK-MEL-2) cell lines with IC50 values 
above 80 μM.109  This compound also showed no molluscicidal activity against Pomacea 
canaliculata
2
 and no insect antifeeding activity against 5
th
 instar larvae of Ctenopsteustis 
obliquana.
113
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Table 2.7 
1
H and 
13
C NMR assignments for compound AT.5 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], compound AT.4 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, CDCl3, 
J = Hz] and cabraleone [
13
C NMR 25.15 MHz, C5D5N]
8
 
No. δC AT.5 δC AT.4 δC
8 δH AT.5 δH AT.4 HMBC (H→C) COSY NOESY 
1a 
40.1 CH2 40.1 CH2 39.9 
1.92 m 1.91 m 3, 5, 19 1b,2a, 2b 1b, 2a, 2b 
1b 1.46 m 1.45 m 3, 9, 19 1a, 2a, 2b 1a, 2a, 2b 
2a 
34.3 CH2 34.3 CH2 34.2 
2.49 m 2.49 m 3, 10 1a, 1b, 2b 1a, 1b, 2b 
2b 2.44 m 2.44 m 3, 10 1a, 1b, 2a 1a, 1b, 2a 
3 218.4 C 218.3 C 216.4 - - - - - 
4 47.6 C 47.6 C 47.4 - - - - - 
5 55.5 CH 55.6 CH 55.3 1.38 m 1.37 dd J = 11.5, 2.7 Hz 1, 7, 19, 28, 29 6a, 6b 9 
6a 
19.9 CH2 19.9 CH2 19.9 
1.56 m 1.56 m 8, 10 5, 6b, 7b - 
6b 1.46 m 1.46 m 8, 10 5, 6a, 7a, 7b - 
7a 
34.8 CH2 34.8 CH2 34.8 
1.57 m 1.57 m 5, 9, 14, 30 6b, 7b - 
7b 1.31 m 1.32 dd J = 9.1, 3.2 Hz 5, 9, 14, 30 6a, 6b, 7a - 
8 40.5 C 40.5 C 40.5 - - - - - 
9 50.4 CH 50.4 CH 50.2 1.43 m 1.43 m 1, 7, 12, 14, 19, 30 11a, 11b 5, 18 
10 37.1 C 37.1 C 37.2 - - - - - 
11a 
22.5 CH2 22.3 CH2 22.4 
1.52 m 1.52 m 8, 10, 13 9, 11b, 12a, 12b - 
11b 1.26 m 1.25 m 8 9, 11a, 12a, 12b - 
12a 
27.2 CH2 27.6 CH2 26.1 
1.82 m 1.80 m 9, 14, 17 11a, 11b, 12b, 13 - 
12b 1.24 m 1.26 m - 11a, 11b, 12a, 13 - 
13 43.2 CH 43.3 CH 43.3 1.67 m 1.60 m 18, 20  12a, 12b, 17 21, 30 
14 50.2 C 50.2 C 50.2 - - - - - 
15a 
31.6 CH2 31.7 CH2 31.7 
1.48 m 1.48 m 8, 17, 18 15b, 16 - 
15b 1.08 m 1.10 m 13, 17, 18 15a, 16 - 
16 26.6 CH2 26.3 CH2 27.4 1.78 m 1.85 m 13, 14, 20 15a, 15b, 17 - 
17 50.0 CH 49.7 CH 50.2 1.88 m 1.82 m 12, 21, 22 13, 16 - 
18 16.5 CH3 16.6 CH3 16.5 0.88 s 0.88 s 8, 13, 14, 15 - 9, 17 
19 16.3 CH3 16.3 CH3 15.3 0.94 s 0.94 s 1, 5, 9, 10 - 30 
20 86.7 C 86.6 C 86.4 - - - - 18, 29 
21 27.4 CH3 23.8 CH3 26.3 1.15 s 1.14 s 17, 20, 22 - 13, 26, 27 
22a 
35.0 CH2 35.9 CH2 35.4 
1.87 m 1.71 m 17, 21, 24 22b, 23a, 23b - 
22b 1.68 m 1.64 m 17, 21, 24 22a, 23a, 23b - 
23a 
26.0 CH2 25.9 CH2 26.8 
1.81 m 1.79 m 20, 25 22a, 22b, 23b, 24 - 
23b 1.76 m 1.48 m 20 22a, 22b, 23a, 24 - 
24 86.6 CH 83.5 CH 87.4 3.64 dd J = 10.0, 5.3 Hz 3.73 t J = 7.3 Hz 22, 25, 26, 27 23a, 23b 26, 27 
25 70.5 C 71.7 C 70.4 - - - - - 
26 28.0 CH3 27.7 CH3 26.8 1.19 s 1.21 s 24, 25, 27 - 21, 24 
27 24.3 CH3 24.5 CH3 26.8 1.11 s 1.12 s 24, 25, 26 - 21, 24 
28 27.0 CH3 26.9 CH3 27.1 1.08 s 1.08 s 3, 4, 5, 29 - 29 
29 21.2 CH3 21.2 CH3 21.1 1.04 s 1.04 s 3, 4, 5, 28 - 19, 28 
30 15.4 CH3 15.4 CH3 16.1 1.01 s 0.99 s 7, 8, 9, 14 - 13, 19 
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2.2.6 Structural elucidation of compound AT.6: 3-acetoxy-(20S,24R)-epoxydammaran-
25-ol 
Compound AT.6 was isolated as a white solid from the methanol extract of the twigs of      
A. argentea. 
 
 
 
 
 
 
Figure 2.12 Structure of compound AT.6 
The HRMS [Spectrum 2.6.1] gave a [M+Na]
+
 ion at m/z 525.3907, which indicated the 
molecular formula C32H54O4 for the compound.  A double bond equivalence of six was 
calculated.  The FTIR spectrum [Spectrum 2.6.2] showed the presence of a hydroxyl 
absorption at 3567 and ester carbonyl absorptions at 1731 and 1248 cm
-1
. 
The 
13
C NMR spectrum [Spectrum 2.6.4] displayed thirty-two carbon resonances, while the 
HSQCDEPT experiment [Spectrum 2.6.6] confirmed that twenty-five out of the thirty-two 
carbons were attached to protons.  The types of carbon atoms were determined by 
performing a DEPT experiment [Spectrum 2.6.5], which revealed the presence of nine 
methyl, ten methylene, six methine and seven quaternary carbons.  These structural features 
revealed that it was a triterpenoid.  Therefore, the unsaturation index exhibited by the 
molecular formula (C32H54O4) was satisfied by the four rings of a dammarane skeleton, the 
cyclized side chain at C-17 and an ester carbonyl group (δC 171.1). 
A comparison of the 
13
C NMR spectrum for compound AT.2 (thirty carbons) with that of 
compound AT.6 (thirty-two carbons) indicated that the chemical shifts were different for C-2 
and C-3 carbon resonances, which occurred at δ 25.6 and 76.5 in compound AT.2 but at δ 
23.0 (C-2), 78.5 (C-3) for compound AT.6.  Additional acetyl group carbon resonances for 
compound AT.6 occurred at δ 170.9 (carbonyl carbon resonance of an acetyl group) and 21.5 
(methyl carbon resonance of an acetyl group). 
The 
1
H NMR spectra also showed significant differences for the H-3 resonance and additional 
acetyl group proton resonance.  The H-3 proton resonance occurred at δ 3.39 (t, J = 2.8 Hz) 
in compound AT.2 but shifted downfield to δ 4.59 (t, J = 2.4 Hz) in compound AT.6 and an 
26 
 
extra acetate methyl group proton resonance occurred at δ 2.05 (s) in compound AT.6.  In 
the HMBC spectrum [Spectrum 2.6.7] of compound AT.6, the H-3 proton resonance 
showed two bond correlations with δC 23.1 (C-2) and 37.0 (C-4), and connectivities over 
3
J 
with δC 22.0 (C-29), 28.1 (C-28), 34.5(C-1), 51.0 (C-5) and 171.1 (C-OAc).  These HMBC 
correlations confirmed the site of esterification at C-3. 
The presence of a correlation in the NOESY spectrum [Spectrum 2.6.9] between the H-24 
(δ 3.70, t, J = 7.3 Hz) resonance with 3H-21 (δ 1.10, s), 3H-26 (δ 1.18, s), 3H-27 (δ 1.09, s), 
suggesting that 3H-21 and H-24 were on the same side.  The configuration at C-24 in 
compound AT.6 was therefore assigned as R.  Compound AT.6 was identified as 3-
acetoxy-(20S,24R)-epoxydammaran-25-ol. 
Compound AT.6 was previously isolated from Betula platyphylla var. japonica 
(Betulaceae).
106
  This compound showed no haemolytic activity
105
 and no P-glycoprotein 
associated ATPase activity.
106
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Table 2.8 
1
H and 
13
C NMR assignments for compound AT.6 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound AT.2 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC AT.6 δC AT.2 δH AT.6 δH AT.2 HMBC (H→C) COSY NOESY 
1a 
34.4 CH2 33.9 CH2 
1.40 m 1.41 m 3, 5, 9 1b, 2b - 
1b 1.13 m 1.29 m 5, 9 1a, 2a - 
2a 
23.0 CH2 25.6 CH2 
1.85 m 1.95 m - 1b, 2b, 3 3 
2b 1.55 m 1.54 m 3, 4, 10 1a, 2a, 3 3 
3 78.5 CH 76.5 CH 4.59 t J = 2.4 Hz 3.39 t J = 2.8 Hz 1, 3', 5, 28 2a, 2b 2a, 2b, 28, 29 
4 36.9 C 37.9 C - - - - - 
5 50.9 CH 49.8 CH 1.19 m 1.26 m 3, 4, 7, 9, 19, 29 6 9 
6 18.2 CH2 18.5 CH2 1.38 m 1.41 m 4, 8, 10 5, 7a, 7b - 
7a 
35.2 CH2 35.4 CH2 
1.56 m 1.58 m 5, 9, 14, 30 6, 7b - 
7b 1.23 m 1.26 m 5, 9, 14, 30 6, 7a - 
8 40.7 C 40.8 C - - - - - 
9 50.7 CH 50.8 CH 1.40 m 1.46 m 1, 5, 7, 14 11a, 11b 5, 17, 18 
10 37.3 C 37.5 C - - - - - 
11a 
21.5 CH2 21.6 CH2 
1.49 m 1.54 m 8, 13 9, 11b - 
11b 1.16 m 1.19 m 8, 10, 13 9, 11a, 12 - 
12a 
27.5 CH2 27.6 CH2 1.75 m 
1.77 m 
9, 14, 17 11b, 13 - 
12b 1.26 m 
13 43.0 CH 43.1 CH 1.54 m 1.57 m 8, 18, 20 12, 17 30 
14 50.3 C 50.4 C - - - - - 
15a 
31.6 CH2 31.6 CH2 
1.44 m 1.46 m 8, 13, 16, 17, 18 15b, 16a - 
15b 1.05 m 1.07 m 13, 17, 18 15a - 
16a 
25.9 CH2 25.9 CH2 
1.76 m 1.78 m 13, 14, 20 15a, 16b - 
16b 1.44 m 1.46 m 13, 14, 20 16a, 17 - 
17 49.6 CH 49.7 CH 1.77 m 1.80 m 12, 14, 15, 21, 22 13, 16b 9 
18 16.8 CH3 16.8 CH3 0.89 s 0.89 s 8, 13, 14, 15 - 9 
19 16.2 CH3 16.3 CH3 0.83 s 0.85 s 1, 5, 9, 10 - 30 
20 86.6 C 86.7 C - - - - - 
21 23.7 CH3 23.8 CH3 1.10 s 1.13 s 17, 20, 22 - 24 
22a 
35.8 CH2 35.9 CH2 
1.69 m 1.71 m 17, 20, 21, 24 22b, 23a, 23b - 
22b 1.59 m 1.62 m 17, 20, 21, 24 22a, 23a, 23b - 
23a 
26.2 CH2 26.4 CH2 
1.83 m 1.87 m 20, 25 22a, 22b, 24 - 
23b 1.76 m 1.79 m 20, 25 22a, 22b, 24 - 
24 83.4 CH 83.5 CH 3.70 t J = 7.3 Hz 3.73 t J = 7.3 Hz 22, 25, 26, 27 23a, 23b 21, 26, 27 
25 71.6 C 71.7 C - - - - - 
26 27.6 CH3 27.7 CH3 1.18 s 1.21 s 24, 25, 27 - 24 
27 24.5 CH3 24.5 CH3 1.09 s 1.12 s 24, 25, 26 - 24 
28 28.0 CH3 28.5 CH3 0.80 s 0.94 s 3, 4, 5, 29 - 3 
29 21.9 CH3 22.3 CH3 0.85 s 0.84 s 3, 4, 5, 28 - 3 
30 15.6 CH3 15.7 CH3 0.93 s 0.96 s 7, 8, 9, 14  - 13, 19 
3-OAc 
170.9 C - - - - - - 
21.5 CH3 - 2.05 s - 3, 3-OAc (C=O) - - 
 
 
 
 
 
 
28 
 
2.2.7 Structural elucidation of compound AT.7: 3-acetoxy-(20S,24S)-epoxydammaran-
25-ol 
Compound AT.7 was isolated as a white solid from the methanol extract of the twigs of      
A. argentea and was identified as the known cabraleadiol monoacetate
3,107,108,114
 (also called 
3-O-acetylcabraleadiol)
113
, the acetylated derivative of AT.3. 
  
 
 
 
 
 
Figure 2.13 Structure of compound AT.7 
The HRMS [Spectrum 2.7.1] gave a [M+Na]
+
 ion at m/z 525.3909, which indicated the 
molecular formula of C32H54O4 for the compound.  A double bond equivalence of six was 
calculated.  The FTIR spectrum [Spectrum 2.7.2] showed the presence of a hydroxyl 
absorption at 3482 and an ester carbonyl absorption at 1732 and 1246 cm
-1
.  The HRMS and 
the FTIR spectrum of compound AT.7 resembled to those of compound AT.6. 
The 
13
C NMR [Spectrum 2.7.4], DEPT [Spectrum 2.7.5] and HSQCDEPT [Spectrum 
2.7.6] spectra displayed thirty-two carbon resonances, which included nine methyl, ten 
methylene, six methine and seven quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound AT.6 with that of compound AT.7 
indicated that the chemical shifts were the same, except for the C-21 and C-24 carbon 
resonances, which occurred at δ 23.7 and 83.4 respectively in compound AT.6 but at δ 27.4 
(C-21) and 86.6 (C-24) for compound AT.7.  The 
1
H NMR spectra also showed a slight 
difference for the H-24 resonance where compound AT.6 exhibited the resonance at δ 3.70 
(t, J = 7.3 Hz) whereas compound AT.7 exhibited the resonance at δ 3.64 (dd, J = 10.1, 5.2 
Hz).  The NOESY spectrum [Spectrum 2.7.9] showed a correlation between the H-24 (δ 
3.64), 3H-26 (δ 1.19, s) and 3H-27 (δ 1.11, s) proton resonances but no correlation was seen 
with the 3H-21 resonance, as was seen for compound AT.6.  In addition, the 3H-21 proton 
resonance showed a correlation in the NOESY spectrum with the 3H-26 (δ 1.19, s) 
resonance, indicating that 3H-21 and 3H-26 were on the same side.  The configuration at C-24 in 
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compound AT.7 was therefore assigned as S.  Compound AT.7 was identified as 3-
acetoxy-(20S,24S)-epoxydammaran-25-ol. 
Compound AT.7 has been isolated previously from Aglaia lawii (Meliaceae),
3
 Commiphora 
dalzielii (Burseraceae),
107
 Commiphora holtziana,
114
 Dysoxylum malabaricum (Meliaceae)
108
 
and Nothofagus pumilio (Fagaceae).
113
  This compound showed significant insect antifeeding 
activity against 5
th
 instar larvae of Ctenopsteustis obliquana (Feeding index = +26).
113
 
Table 2.9 
1
H and 
13
C NMR assignments for compound AT.7 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], compound AT.6 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, CDCl3, 
J = Hz] and cabraleadiol monoacetate [
13
C NMR 75
3
 and 100 MHz,
114
 CDCl3]  
No. δc AT.7 δc AT.6 δc
3 δc
114 δH AT.7 δH AT.6 HMBC (H→C) COSY NOESY 
1a 
34.5 CH2 34.4 CH2 33.9 t 38.8 
1.44 m 1.40 m 3, 5, 9, 19 1b, 2a, 2b - 
1b 1.17 m 1.13 m 5, 9, 19 1a, 2a, 2b - 
2a 
23.1 CH2 23.0 CH2 22.5 t 24.7 
1.89 m 1.85 m - 1a, 1b, 2b, 3 3 
2b 1.58 m 1.55 m 3, 4, 10 1a, 1b, 2a, 3 3 
3 78.6 CH 78.5 CH 77.8 d 81.0 4.62 t J = 2.7 Hz 4.59 t J = 2.4 Hz 1, 3', 5, 28, 29 2a, 2b 2a, 2b, 28, 29 
4 37.0 C 36.9 C 36.3 s 37.6 - - - - - 
5 51.0 CH 50.9 CH 50.3 d 54.7 1.23 m 1.19 m 1, 4, 7, 9, 19, 28 6 9 
6 18.3 CH2 18.2 CH2 17.7 t 18.3 1.42 m 1.38 m 4, 8, 10 5, 7a, 7b - 
7a 
35.3 CH2 35.2 CH2 34.7 t 34.8 
1.58 m 1.56 m 30 6, 7b - 
7b 1.27 m 1.23 m 5, 9, 30 6, 7a - 
8 40.8 C 40.7 C 40.1 s 41.4 - - - - - 
9 50.8 CH 50.7 CH 50.2 d 51.1 1.44 m 1.40 m 1, 5, 7, 12, 19, 30 11b 5, 18 
10 37.4 C 37.3 C 36.7 s 37.4 - - - - - 
11a 
21.9 CH2 21.5 CH2 21.2 t 22.0 
1.53 m 1.49 m 8, 13 11b, 12a, 12b - 
11b 1.21 m 1.16 m 8, 10 9, 11a, 12a - 
12a 
27.2 CH2 27.5 CH2 26.8 t 27.0 
1.81 m 1.75 m 14, 17 11a, 11b, 12b, 13 - 
12b 1.23 m  9, 14 11a, 12a, 13 - 
13 43.0 CH 43.0 CH 42.4 d 43.2 1.65 m 1.54 m 12, 18 12a, 12b, 17 - 
14 50.4 C 50.3 C 49.7 s 50.0 - - - - - 
15a 
31.7 CH2 31.6 CH2 31.1 t 32.4 
1.48 m 1.44 m 8, 18 15b, 16a, 16b - 
15b 1.07 m 1.05 m 17, 18 15a, 16a, 16b - 
16a 
26.1 CH2 25.9 CH2 25.5 t 25.8 
1.77 m 1.76 m 20 15a, 15b, 16b, 17 - 
16b 1.31 m 1.44 m 14, 20 15a, 15b, 16a, 17 - 
17 50.1 CH 49.6 CH 49.4 d 49.7 1.87 m 1.77 m 12, 21, 22 13, 16a, 16b 18 
30 15.7 CH3 15.6 CH3 15.1 q 16.0 0.98 s 0.93 s 7, 9, 14 - 19 
19 16.3 CH3 16.2 CH3 15.6 q 16.6 0.87 s 0.83 s 1, 5, 9 - 30 
20 86.8 C 86.6 C 86.0 s 86.6 - - - - - 
21 27.4 CH3 23.7 CH3 26.6 q 24.4 1.15 s 1.10 17, 20, 22 - 26 
22a 
35.0 CH2 35.8 CH2 34.4 t 35.5 
1.88 m 1.69 m 17, 21, 24 22b, 23b - 
22b 1.67 m 1.59 m 17, 21, 24 22a, 23a, 23b - 
23a 
26.6 CH2 26.2 CH2 26.0 t 26.8 
1.86 m 1.83 m 20, 25 22b, 23b, 24 - 
23b 1.76 m 1.76 m 20 22a, 22b, 23a, 24 - 
24 86.6 CH 83.4 CH 85.9 d 86.2 
3.64 dd J = 10.1, 
5.2 Hz 
3.70 t J = 7.3 Hz 25, 26 23a, 23b 26, 27 
25 70.5 C 71.6 C 69.8 s 73.0 - - - - - 
26 28.1 CH3 27.6 CH3 27.2 q 26.6 1.19 s 1.18 s 24, 25, 27 - 21, 24 
27 24.3 CH3 24.5 CH3 23.9 q 27.0 1.11 s 1.09 s 24, 25, 26 - 24 
28 28.1 CH3 28.0 CH3 27.5 q 16.6 0.84 s 0.80 s 3, 4, 5, 29 - 3 
29 22.0 CH3 21.9 CH3 21.4 q 28.0 0.89 s 0.85 s 3, 4, 5, 28 - 3 
18 16.8 CH3 16.8 CH3 16.2 q 17.3 0.92 s 0.89 s 8, 13, 15 - 9, 17 
3-OAc 
171.1 C 170.9 C N/A 171.1 - - - - - 
21.6 CH3 21.5 CH3 20.9 22.8 2.09 s 2.05 s 3, 3-OAc (C=O) - - 
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Table 2.10 
13
C NMR (125 MHz) assignments for compounds AT.2-7 in CDCl3 
No. δC AT.2 δC AT.3 δC AT.4 δC AT.5 δC AT.6 δC AT.7 
1 33.9 CH2 33.9 CH2 40.1 CH2 40.1 CH2 34.4 CH2 34.5 CH2 
2 25.6 CH2 25.6 CH2 34.3 CH2 34.3 CH2 23.0 CH2 23.1 CH2 
3 76.5 CH 76.5 CH 218.3 C 218.4 C 78.5 CH 78.6 CH 
4 37.9 C 37.8 C 47.6 C 47.6 C 36.9 C 37.0 C 
5 49.8 CH  49.8 CH  55.6 CH  55.5 CH  50.9 CH 51.0 CH 
6 18.5 CH2 18.5 CH2 19.9 CH2 19.9 CH2 18.2 CH2 18.3 CH2 
7 35.4 CH2 35.4 CH2 34.8 CH2 34.8 CH2 35.2 CH2 35.3 CH2 
8 40.8 C 40.8 C 40.5 C 40.5 C 40.7 C 40.8 C 
9 50.8 CH 50.9 CH 50.4 CH 50.4 CH 50.7 CH 50.8 CH 
10 37.5 C 37.5 C 37.1 C 37.1 C 37.3 C 37.4 C 
11 21.6 CH2 21.9 CH2 22.3 CH2 22.5 CH2 21.5 CH2 21.9 CH2 
12 27.6 CH2 27.2 CH2 27.6 CH2 27.2 CH2 27.5 CH2 27.2 CH2 
13 43.1 CH 43.0 CH 43.3 CH 43.2 CH 43.0 CH 43.0 CH 
14 50.4 C 50.4 C 50.2 C 50.2 C 50.3 C 50.4 C 
15 31.6 CH2 31.6 CH2 31.7 CH2 31.6 CH2 31.6 CH2 31.7 CH2 
16 25.9 CH2 26.0 CH2 26.3 CH2 26.6 CH2 25.9 CH2 26.1 CH2 
17 49.7 CH 50.0 CH 49.7 CH 50.0 CH 49.6 CH 50.1 CH 
18 16.8 CH3 16.7 CH3 16.6 CH3 16.5 CH3 16.8 CH3 16.8 CH3 
19 16.3 CH3 16.3 CH3 16.3 CH3 16.3 CH3 16.2 CH3 16.3 CH3 
20 86.7 C 86.8 C 86.6 C 86.7 C 86.6 C 86.8 C 
21 23.8 CH3 27.3 CH3 23.8 CH3 27.4 CH3 23.7 CH3 27.4 CH3 
22 35.9 CH2 35.0 CH2 35.9 CH2 35.0 CH2 35.8 CH2 35.0 CH2 
23 26.4 CH2 26.6 CH2 25.9 CH2 26.0 CH2 26.2 CH2 26.6 CH2 
24 83.5 CH 86.5 CH 83.5 CH 86.6 CH 83.4 CH 86.6 CH 
25 71.7 C 70.5 C 71.7 C 70.5 C 71.6 C 70.5 C 
26 27.7 CH3 28.0 CH3 27.7 CH3 28.0 CH3 27.6 CH3 28.1 CH3 
27 24.5 CH3 24.3 CH3 24.5 CH3 24.3 CH3 24.5 CH3 24.3 CH3 
28 28.5 CH3 28.5 CH3 26.9 CH3 27.0 CH3 28.0 CH3 28.1 CH3 
29 22.3 CH3 22.3 CH3 21.2 CH3 21.2 CH3 21.9 CH3 22.0 CH3 
30 15.7 CH3 15.7 CH3 15.4 CH3 15.4 CH3 15.6 CH3 15.7 CH3 
3-OAc 
- - - - 170.9 C 171.1 C 
- - - - 21.5 CH3 21.6 CH3 
 
Table 2.11 
1
H NMR (500 MHz) assignments for compounds AT.2-7 in CDCl3 
No. δH AT.2 δH AT.3 δH AT.4 δH AT.5 δH AT.6 δH AT.7 
1 1.41 m, 1.29 m 1.41 m, 1.29 m 1.91 m, 1.45 m 1.92 m, 1.46 m 1.40 m, 1.13 m 1.44 m, 1.17 m 
2 1.95 m, 1.54 m 1.95 m, 1.54 m 2.49 m, 2.44 m 2.49 m, 2.44 m 1.85 m, 1.55 m 1.89 m, 1.58 m 
3 3.39 t J = 2.8 Hz 3.39 t J = 2.7 Hz - - 4.59 t J = 2.4 Hz 4.62 t J = 2.7 Hz 
5 1.26 m 1.25 m 
1.37 dd J = 11.5, 
2.7 Hz 
1.38 m 1.19 m 1.23 m 
6 1.41 m 1.41 m 1.56 m, 1.46 m 1.56 m, 1.46 m 1.38 m 1.42 m 
7 1.58 m, 1.26 m 1.58 m, 1.25 m 1.57 m, 1.32 m 1.57 m, 1.31 m 1.56 m, 1.23 m 1.58 m, 1.27 m 
9 1.46 m 1.45 m 1.43 m 1.43 m 1.40 m 1.44 m 
11 1.54 m, 1.19 m 1.54 m, 1.20 m 1.52 m, 1.25 m 1.52 m, 1.26 m 1.49 m, 1.16 m 1.53 m, 1.21 m 
12 1.77 m, 1.26 m 1.78 m, 1.22 m 1.80 m, 1.26 m 1.82 m, 1.24 m 1.75 m 1.81 m, 1.23 m 
13 1.57 m 1.63 m 1.60 m 1.67 m 1.54 m 1.65 m 
15 1.46 m, 1.07 m 1.46 m, 1.06 m 1.48 m, 1.10 m 1.48 m, 1.08 m 1.44 m, 1.05 m 1.48 m, 1.07 m 
16 1.78 m, 1.46 m 1.75 m, 1.30 m 1.85 m 1.78 m 1.76 m, 1.44 m 1.77 m, 1.31 m 
17 1.80 m 1.86 m 1.82 m 1.88 m 1.77 m 1.87 m 
18 0.89 s 0.89 s 0.88 s 0.88 s 0.89 s 0.92 s 
19 0.85 s 0.86 s 0.94 s 0.94 s 0.83 s 0.87 s 
21 1.13 s 1.14 s 1.14 s 1.15 s 1.10 s 1.15 s 
22 1.71 m, 1.62 m 1.86 m, 1.67 m 1.71 m, 1.64 m 1.87 m, 1.68 m 1.69 m, 1.59 m 1.88 m, 1.67 m 
23 1.87 m, 1.79 m 1.85 m, 1.76 m 1.87 m, 1.79 m 1.81 m, 1.76 m 1.83 m, 1.76 m 1.86 m, 1.76 m 
24 3.73 t J = 7.3 Hz 3.64 dd J = 10.1, 5.2 Hz 3.73 t J = 7.3 Hz 3.64 dd J = 10.0, 5.3 Hz 3.70 t J = 7.3 Hz 3.64 dd J = 10.1, 5.2 Hz 
26 1.21 s 1.19 s 1.21 s 1.19 s 1.18 s 1.19 s 
27 1.12 s 1.11 s 1.12 s 1.11 s 1.09 s 1.11 s 
28 0.94 s 0.94 s 1.08 s 1.08 s 0.80 s 0.84 s 
29 0.84 s 0.84 s 1.04 s 1.04 s 0.85 s 0.89 s 
30 0.96 s 0.97 s 0.99 s 1.01 s 0.93 s 0.98 s 
 3-OAc - - - - 2.05 s 2.09 s 
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2.2.8 Structural elucidation of the mixture AT.8 and 9 
Compounds AT.8 and 9 were isolated as a white solid inseparable mixture from the methanol 
extract of the twigs of A. argentea and were identified as a mixture of sitosterol and 
stigmasterol. 
 
 
 
 
Figure 2.14 Structures of compounds AT.8 and 9 
The 
1
H NMR spectrum [Spectrum 2.8.2] showed the characteristic proton resonances for the 
mixture of sitosterol (AT.8) and stigmasterol (AT.9).  They are two major phytosterols 
generally present in plant cell membranes.
115
 
The acetic acid-induced writhing test showed sitosterol decreased the number of squirms 
induced by acetic acid by 70.0% at a dose of 100 mg/kg mouse.
116
  The hot plate method 
confirmed their analgesic activity, as sitosterol exhibited a 300% increase in pain tolerance, 
while mefenamic acid, a known analgesic, showed a 171% increase.
116
  Sitosterol induced 
swelling in antiinflammatory activity using the carrageenan-induced mouse paw oedema 
assay.
116
  It also exhibited anthelminthic and antimutagenic activities.  In vitro tests using 
live Ascaris suum as test animals showed that the behaviour of worms treated with sitosterol 
approximated that of the positive controls, Combantrin and Antiox.  An in vivo micronucleus 
test showed that sitosterol inhibited the mutagenicity of tetracycline by 65.3% at a dose of 
0.5 mg/kg mouse.  At the same dose, it did not exhibit chromosome-breaking activity.
116
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CHAPTER THREE: The phytochemistry of Xylocarpus rumphii 
3.1 Xylocarpus rumphii 
Xylocarpus rumphii (Kostel.) Mabb belongs to the Xylocarpeae tribe of the Cedreloideae 
subfamily of the Meliaceae family.
97
  X. rumphii is a small sized, evergreen tree that grows 
to 6-10 metres in height.  The bark is brown, rough, fissured and peeling in thick narrow 
strips.  Leaflets are two to four pairs.  Flowers are small in size, 0.8 to 1.0 cm in diameter, 
with a four-lobed yellowish-green calyx and four creamy to greenish-white petals.  The fruit 
is round, about 15 to 20 cm in diameter, green in colour, glossy and contains four to ten 
seeds.  Seeds are buoyant and dispersed by currents.  The wood is strong, hard and durable.  
The heartwood is brown and red in colour with streaks.
117
  X. rumphii, unlike other 
Xylocarpus species, is not a mangrove species, it grows on sandy and rocky coasts.
41
 
       
Picture 3.1 The bark and heartwood of X. rumphii 
Compounds isolated from the seeds and seed kernels of X. rumphii in previous studies are 
shown in Figure 3.1.  Compounds 94 and 101 have been shown to exhibit anti-inflammatory 
activity with IC50 values of 24.5 and 31.3 μM, respectively.
9,10
 
 
 
 
 
 
 
 
 
Figure 3.1 Compounds isolated previously from X. rumphii 
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As this species produces complex mixture of limonoids, it was decided to investigate further 
the limonoid content of the bark and the heartwood of this species. 
3.2 Classes of limonoids and their biosynthesis 
Structurally, the limonoids are derived from tetracyclic triterpenoids similar to euphane 
(20R) or tirucallane (20S) by a series of oxidative changes interspersed with molecular 
rearrangements.
42,118,119
  Modification of the parent triterpene skeleton takes place by 
oxidation, often with ring fission and recyclization involving any of the four rings, to give 
heterocyclic systems.  As shown in Figure 3.2, the Δ7-bond is oxidized to a 7-epoxide, 
which is then opened, causing a Wagner-Meerwein shift of the 14-Me to C-8, formation of 
the 7-OH group, and introduction of a double bond at C-14.
72,119
 
 
 
 
 
 
 
 
Figure 3.2 Biosynthetic pathways leading to the formation of a protolimonoid 
The triterpene side chain is oxidised, eventually forming a β-substituted furan ring.  The 
usual definition of a limonoid is that it is a triterpene derivative in which the side chain has 
become a furan ring by the loss of four carbon atoms, hence an alternative name, the 
tetranortriterpenoids, for the limonoids.
118
 
 
 
 
 
Figure 3.3 Side chain oxidation of protolimonoids 
 
1,3 - H-shift 
Wagner-Meerwein shift 
apo-euphol or  
apo-tirucallol rearangement 
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Champagne et al. (1992) suggested the biosynthetic pathway for the furan ring formation is 
as follows.  Cyclization of the side chain most commonly proceeds through oxidation of the 
C-21 methyl and leads to a 21/23 or, more rarely, 21/24 oxides, from which the 17α-furan 
ring is formed with the loss of four carbons.
72
 
 
 
 
Figure 3.4 Proposed biosynthetic pathways leading to the formation of a furan ring 
The limonoids have been classified on the basis of which of the four rings in the triterpene 
nucleus have been oxidised.
118
 
3.2.1 Protolimonoids and related triterpenes 
This group possesses an intact triterpene side chain, which is usually highly oxidised and 
often cyclised to form an ether ring as shown in Figure 3.5.
118
 
 
 
 
Figure 3.5 Example of protolimonoids 
3.2.2 Havanensin group (all rings intact) 
This group consists of compounds with a furan ring side chain and all rings of the nucleus 
remain intact as shown in Figure 3.6.
118
 
 
 
 
Figure 3.6 Havanensin 
 
C-23 – C-24 
cleavage 
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3.2.3 Gedunin group (Ring D opened) 
This group consists of compounds with a furan ring side chain and a ring D lactone as shown 
in Figure 3.7. 
 
 
 
Figure 3.7 Gedunin 
The biosynthesis of the lactone ring D in gedunin seems to be well understood.  A series of 
potential intermediates between the cyclopentene ring of deoxyhavanensin and the epoxy 
lactone having been isolated in both the gedunin and the khivorin series, and the hypothetical 
linking stages have been carried out in the laboratory as shown in Figure 3.8.
118
 
 
 
 
Figure 3.8 Partial synthesis of gedunin 
3.2.4 Andirobin group (rings B and D opened) 
This group consists of compounds with a furan ring side chain, a lactone ring D and ring B 
opened as shown in Figure 3.9. 
 
 
 
 
Figure 3.9 Andirobin 
The 7-keto group in the B ring is oxidised to a lactone and then ring opening and methylation 
occurs.  This biosynthetic pathway was confirmed by laboratory experiments as shown in 
Figure 3.10.
118
 
Baeyer-Villiger 
oxidation 
epoxidation oxidation 
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Figure 3.10 Partial synthesis of opened ring B 
3.2.5 Mexicanolide group (modified, ring B opened and recyclised) 
This group consists of compounds with a furan ring side chain, a lactone ring D and a 
bicyclo[3.3.1]nonane (a bicyclic between ring A and B) as shown in Figure 3.11. 
 
 
 
Figure 3.11 Mexicanolide 
Compounds of this group are derived from 1,3-diketodiene lactones of the andirobin group 
by spontaneous Michael cyclisation between C-2 and C-30, producing mexicanoline in the 
simplest case.
118
  Experimental analysis confirmed the biosynthetic pathway as shown in 
Figure 3.12.
118
 
 
 
 
 
Figure 3.12 Partial synthesis of mexicanolide 
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It is probable that xyloccensin A is formed from 8,14α-oxide derivatives of mexicanolide-
type compound opened with acid to give the 14-en-1,8-ketal.  Taylor (1984) confirmed this 
assumption by experimental analysis as shown in Figure 3.13. 
 
 
 
 
 
Figure 3.13 Partial synthesis of 1,8-ketal 
3.2.6 Phragmalin group (modified, ring B opened and recyclised) 
Spectroscopic identification of members of the phragmalin group is fairly easy because of 
the presence of only three methyl groups, the characteristic singlets due to H-3 and H-30, 
and an orthoacetate carbon resonance at  119.118  The phragmalin group consists of 
compounds with a furan ring side chain, a ring D lactone, a ring A bridged and an ortho ester 
as shown in Figure 3.14. 
 
 
 
Figure 3.14 Phragmalin 
Taylor (1984) suggested the biosynthetic pathway leading to the formation of a phragmalin 
as shown in Figure 3.15.  Initially the C-29 methyl group is oxidised, but since the C-1 
ketone is also reduced the transformation from mexicanolide is actually an isomerisation.  It 
has been suggested that the precursor is a ketal, which yields an oxygen radical.  This can 
then oxidise C-29 to a radical which can attack the ketonic form of the C-1 ketal, giving a 
second oxygen radical which finally oxidises C-9.  C-8 oxidation is necessary to produce the 
original ketal.
118,120
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Figure 3.15 Proposed route for the biosynthesis of phragmalin 
3.2.7 Methyl ivorensate group (rings A, B and D opened) 
This group consists of compounds with a furan ring side chain, ring A and D lactone rings 
and ring B opened as shown in Figure 3.16. 
 
 
 
Figure 3.16 Methyl ivorensate 
Methyl ivorensate is found in small amount in Khaya ivorensis and was synthesised by 
Baeyer-Villiger oxidation of methyl angolensate with perbenzoic acid as shown in Figure 
3.17.
118
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Figure 3.17 Proposed biosynthesis of methyl ivorensate 
3.2.8 Obacunol group (ring A and D oxidised) 
This group consists of compounds with a furan ring side chain and ring A and D lactone 
rings as shown in Figure 3.18. 
 
 
 
Figure 3.18 Obacunol 
The obacunol group is characteristic of the Rutaceae and rare in the Meliaceae.
118
  The 
ketone group in 7-deacetylgedunin is oxidised to a lactone in obacunol as shown in Figure 
3.19. 
 
 
 
 
Figure 3.19 Proposed biosynthesis of obacunol 
 
 
Baeyer-Villiger 
oxidation 
Baeyer-Villiger 
oxidation 
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3.2.9 Nimbin group (ring C opened) 
This group consists of compounds with a furan ring and ring C opened as shown in Figure 
3.20. 
 
 
 
Figure 3.20 Nimbin 
The nimbin group is a large and important group containing some very complex 
compounds.
118
  It has been reported to exhibit anti-inflammatory, analgesic activities and 
NF-κB modulation activities.121,122  This type of compound has undergone ring C opening 
and the ring can be recyclised as shown in Figure 3.21.
123
 
 
 
 
 
Figure 3.21 Proposed biosynthesis of nimbin 
 
3.2.10 Toonafolin group (ring B opened)  
This group consists of compounds with a furan ring side chain and a ring B lactone as shown 
in Figure 3.22. 
 
 
 
Figure 3.22 Toonafolin 
Toonafolin is the ring B lactone compound corresponding to havanensin with theformation 
of a 1,11α-ether bridge.  Consequently, the toonafolin group could be synthesized as shown 
in Figure 3.23. 
41 
 
 
 
 
 
 
 
 
Figure 3.23 Proposed biosynthesis of toonafolin derivatives 
3.2.11 Evodulone group (ring A opened) 
This group consists of compounds with a furan ring side chain and a ring A lactone as shown 
in Figure 3.24. 
 
 
 
Figure 3.24 Evodulone 
A proposed biosynthetic pathway for the formation of an evodulone-type compound is given 
in Figure 3.25 below. 
 
 
 
 
 
 
Figure 3.25 Proposed biosynthesis of evodulone 
 
Hydroxylation Dehydration 
Oxidation Baeyer-Villiger 
Oxidation of ring B 
Baeyer-Villiger 
oxidation 
Acetylation Oxidation 
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3.2.12 Prieurianin group (ring A and B opened) 
This group consists of compounds with a furan ring, ring A a lactone and ring B opened as 
shown in Figure 3.26. 
 
 
 
 
Figure 3.26 Prieurianin 
This group is reported to exhibit biological activity such as anti-HIV, anti-adipogenic, 
antifeedant, anti-tobacco mosaic virus and cytotoxic activities.
124-127
  The prieurianin group 
is derived from evodulone group.
118
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3.3 Structural elucidation of compounds isolated from the bark of X. rumphii 
The bark (5.0 kg) was extracted with methanol (extract mass: 174.3 g) and was partition with 
ethyl acetate to give an ethyl acetate extract (36.7 g).  After initial fractionation over silica 
gel (ethyl acetate/hexane), which yielded the new limonoid xylorumphiin K (RB.1, 9.8 mg), 
xyloccensin E (RB.2, 53.4 mg), taraxer-14-en-3-ol (RB.3, 10.3 mg) and 22S-
hydroxytirucalla-7,24-diene-3,23-dione (RB.4, 7.9 mg), further fractionation over Sephadex 
LH 20 (1:1 dichloromethane: methanol), yielded 25-hydroxy-(20S,24S)-epoxydammaran-3-
one (AT.5, 26.3 mg) and a mixtures of sitosterol (AT.8) and stigmasterol (AT.9) (30.5 mg).  
The structures were determined using NMR spectroscopy and with reference to known 
compounds.
4-8
  Compound RB.2 has been isolated from seeds and seed kernels of this 
species before.
5,9,10
 
 
 
 
                                                                                             RB.3                                      RB.4 
                      RB.1                                    RB.2                                
 
 
 
                   AT.5                                                                                                                        
Figure 3.27 Compounds isolated from the bark of X. rumphii 
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3.3.1 Structural elucidation of compound RB.1: xylorumphiin K 
Compound RB.1 was isolated as a colourless solid from the methanol extract of the bark of 
X. rumphii and was identified as the new xylorumphiin K. 
 
 
 
 
 
Figure 3.28 Structure of compound RB.1 
The HRMS [Spectrum 3.1.1] gave a [M + H]
+ 
ion at m/z 671.34268, corresponding to the 
molecular formula C37H50O11 for the compound and indicated thirteen double bond 
equivalents.  The FTIR spectrum [Spectrum 3.1.2] showed absorption bands at 3417 and 
1732 cm
-1
 corresponding to the OH and C=O stretches. 
The 
13
C NMR spectrum displayed thirty-seven carbon resonances, while the HSQCDEPT 
experiment [Spectrum 3.1.6] confirmed that twenty-six out of the thirty-seven carbons were 
attached to protons.  The types of carbon atoms were determined by performing a DEPT 
experiment [Spectrum 3.1.5], which revealed the presence of nine methyl, five methylene, 
twelve methine and eleven quaternary carbons. 
The 
1
H NMR spectrum [Spectrum 3.1.3] showed the characteristic proton resonances of 
protons of a -substituted furan ring at δ 7.49 (br s, W1/2 = 3.4 Hz), 7.41 (br s, W1/2 = 4.1 Hz) 
and 6.43 (br s, W1/2 = 3.9 Hz) which were assigned as H-21, H-23 and H-22, respectively.  An 
oxymethine proton resonance at δ 5.03 (s) was assigned as H-17.  In the HMBC spectrum 
[Spectrum 3.1.7], the H-17 proton resonance showed correlations with resonances at δC 
159.7 (C-14), 141.4 (C-21), 120.2 (C-20), 110.2 (C-22), 39.1 (C-13), 25.1 (C-12) and 19.9 (C-
18).  These HMBC correlations confirmed the assignment of the H-17 resonance (δ 5.03, s), 
indicating that this compound was a D-seco limonoid (ring D opened). 
A proton resonance at δ 6.00 (s) was assigned to H-15 due to observed correlations in the 
HMBC spectrum with the C-8 (δ 81.8), C-13 (δ 39.1), C-14 (δ 159.7), C-16 (δ 163.7) and C-
45 
 
18 (δ 19.9) carbon resonances, indicating that H-15 was an olefinic proton at the α-position 
of an α,β-unsaturated ring D lactone. 
The three proton resonance at  3.76 (s) was assigned to protons of a group of a methyl ester 
at C-7 characteristic of a B-seco limonoid (ring B opened).  The H-2 proton resonance at δ 2.88 
(1H, dd, J = 9.2, 4.2 Hz) showed correlations with C-1 (δ 107.7), C-3 (δ 73.7), C-4 (δ 38.0), 
C-10 (δ 43.1) and C-30 (δ 76.4) resonances in the HMBC spectrum indicating the presence 
of a mexicanolide type of limonoid.  The COSY spectrum [Spectrum 3.1.8] also supported 
this proposal by showing correlations between H-2 (δ 2.88) and H-3 (δ 5.13) and H-30 (δ 
5.57). 
The proton resonances at δ 2.27 (m, H-2'), 1.65 (m, H-4a'), 1.38 (m, H-4b'), 1.13 (d, J = 7.0 
Hz, 3H-3') and 0.89 (t, J = 7.4 Hz, 3H-5') and 2.23 (m, H-2"), 1.65 (m, H-4a"), 1.33 (m, H-
4b"), 1.05 (d, J = 6.8 Hz, 3H-3") and 0.90 (t, J = 7.4 Hz, 3H-5") were assigned to protons of 
the two 2-methylbutyryloxy groups.  Additionally, the strong HMBC cross-peaks from H-3 to 
a 2-methylbutyryloxy carbonyl resonance at δC 175.8 (C-1') and from H-30 to another 2-
methylbutyryloxy carbonyl resonance at δC 176.2 (C-1") confirmed the location of the 2-
methylbutyryloxy groups at C-3 and C-30, respectively. 
Compound RB.1 is a mexicanolide limonoid (B,D-seco limonoid) and a new compound 
similar to the known xylorumphiin C which was previously isolated from the same species.
10
  
The absolute configuration at C-2' of the 2-methylbutyryloxy group of xylorumphiin C was 
characterized as S, suggesting that the configuration at C-2' and C-2" in compound RB.1 
may also be S. 
 
 
 
 
 
Figure 3.29 Structure of compound RB.1 and xylorumphiin C 
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Table 3.1 
1
H and 
13
C NMR assignments for compound RB.1 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and xylorumphiin C [
13
C NMR 100 MHz, CDCl3]
10
  
No. δC RB.1 δC
10
 δH RB.1 HMBC (H→C) COSY NOESY 
1 107.7 C 107.5 C - - - - 
2 53.6 CH 53.2 CH 2.88 dd J = 9.2, 4.2 Hz 1, 3, 4, 10, 30 3, 30 1-OH, 3, 30 
3 73.7 CH 73.8 CH 5.13 d J = 9.2 Hz 1', 2, 4, 5, 29, 30 2 2, 28, 29 
4 38.0 C 37.8 C - - - - 
5 40.8 CH 40.6 CH 2.63 dd J = 10.2, 1.5 Hz 3, 4, 6, 7, 9, 10, 19, 29 6a, 6b 6a, 6b, 11a, 28, 30 
6a 
32.3 CH2 32.1 CH2 
2.35 m 4, 5, 7 5, 6b 5, 6b, 19, 28, 29 
6b 2.15 m 4, 7, 10 5, 6a 5, 6a 
7 174.0 C 173.8 C - - - - 
8 81.8 C 81.5 C - - - - 
9 51.8 CH 51.5 CH 2.15 m 5, 8, 11, 14, 19, 30 11b 18, 19 
10 43.1 C 42.9 C - - - - 
11a 
15.3 CH2 15.0 CH2 
2.35 m 12, 13 11b 5, 11b, 12a, 30 
11b 1.80 m - 9, 11a, 12b 11a, 12a 
12a 
25.1 CH2 24.9 CH2 
2.17 m 14 12b 11a, 11b, 12b, 17, 30 
12b 1.40 m 9, 14 11b, 12a 12a 
13 39.1 C 38.9 C - - - - 
14 159.7 C 159.7 C - - - - 
15 118.0 CH 117.6 CH 6.00 s 8, 13, 14, 16, 18 - - 
16 163.7 C 163.7 C - - - - 
17 81.4 CH 81.3 CH 5.03 s 12, 13, 14, 18, 20, 21, 22 21 12a, 21, 22 
18 19.9 CH3 19.7 CH3 1.21 s 12, 13, 14, 17 - 9, 22 
19 20.7 CH3 20.5 CH3 1.06 s 1, 9, 10 - 1-OH, 6a, 9 
20 120.2 C 120.0 C - - - - 
21 141.4 CH 142.9 CH 7.49 br s W1/2 = 3.4 Hz 20, 22, 23 17, 23 17 
22 110.2 CH 109.9 CH 6.43 br s W1/2 = 3.9 Hz 20, 21, 23 23 17, 18, 23 
23 143.1 CH 141.2 CH 7.41 br s W1/2 = 4.1 Hz 20, 21 21, 22 22 
28 24.8 CH3 21.9 CH3 0.77 s 3, 4, 5, 29 - 3, 5, 6a, 29 
29 22.1 CH3 24.6 CH3 1.24 s 3, 4, 5, 28 - 1-OH, 3, 6a, 28 
30 76.4 CH 76.2 CH 5.57 d J = 4.2 Hz 1, 1", 2, 3, 8, 9 2 2, 5, 11a, 12a 
1-OH - - 3.51 s 1, 2, 10 - 2, 19, 29 
7-OMe 52.2 CH3 51.9 CH3 3.69 s 7 - - 
3-acyl       
1' 175.8 C 175.8 C - - - - 
2' 41.2 CH 41.1 CH 2.27 m 1', 3', 4', 5' 3', 4a', 4b' 3', 4a' 
3' 16.4 CH3 16.1 CH3 1.13 d J = 7.0 Hz 1', 2', 4' 2' 2' 
4a' 
26.3 CH2 26.2 CH2 
1.65 m 1', 3', 5' 2', 4b', 5' 2', 4b', 5' 
4b' 1.38 m 1', 3', 5' 2', 4a', 5' 4a', 5' 
5' 11.7 CH3 11.5 CH3 0.89 t J = 7.4 Hz 2', 4' 4a', 4b' 4a', 4b' 
30-acyl       
1" 176.2 C 176.4 C - - - - 
2" 40.9 CH 34.1 CH 2.23 m  1", 3", 4", 5" 3", 4a", 4b" 3", 4a" 
3" 15.9 CH3 18.8 CH3 1.05 d J = 6.8 Hz 1", 2", 4" 2" 2" 
4a" 
26.6 CH2 18.9 CH3 
1.65 m 1", 2", 3", 5" 2", 4b", 5" 2", 4b", 5" 
4b" 1.33 m 1" 2", 4a", 5" 4a", 5" 
5" 11.9 CH3 - 0.90 t J = 7.4 Hz 2", 4" 4a", 4b" 4a", 4b" 
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3.3.2 Structural elucidation of compound RB.2: xyloccensin E 
Compound RB.2 was isolated as a white solid from the methanol extract of the bark of        
X. rumphii and was identified as the known xyloccensin E.
4,5,10,51,120,128
 
 
 
 
 
 
Figure 3.30 Structure of compound RB.2 
The HRMS spectrum [Spectrum 3.2.1] gave a [M + Na]
+ 
ion at m/z 709.2438, 
corresponding to the molecular formula of C35H42O14 for the compound and indicated fifteen 
double bond equivalents.  The FTIR spectrum [Spectrum 3.2.2] showed an absorption band 
at 1739 cm
-1
 that was ascribed to the ester carbonyl groups stretch. 
The 
13
C NMR [Spectrum 3.2.4], DEPT [Spectrum 3.2.5] and HSQCDEPT [Spectrum 3.2.6] 
spectra displayed thirty-five carbon resonances, which included fourteen quaternary, eight 
methine, five methylene and eight methyl carbon resonances. 
A comparison of the 
1
H NMR spectrum for compound RB 1 [Spectrum 3.1.3] with that of 
compound RB 2 [Spectrum 3.2.3] indicated that the chemical shifts were the same for the  
-substituted furan ring.  The oxymethine proton resonance at δ 5.55 (s) was ascribed to the 
H-17 proton.  In the HMBC spectrum [Spectrum 3.2.7], the H-17 proton resonance showed 
correlations with the C-12 (δ 29.3), C-13 (δ 34.6), C-14 (δ 43.4), C-18 (δ 19.7), C-20 (δ 
121.3), C-21 (δ 141.0) and C-22 (δ 109.9) carbon resonances, indicating that this compound 
was a D-seco limonoid.  The 
1
H NMR spectrum also showed the three proton resonance at  
3.69 (s) due to a methyl ester at C-7 typical of ring B-seco limonoid.  These structural 
features revealed that the compound was a B,D-seco limonoid. 
Compound RB.2 possesses a ring A bridge.  The presence of this type of compound was 
deduced from the characteristic pair of coupled doublets (δH 1.97, d, J = 11.2 Hz, 1H and δH 
1.67, d, J = 11.2 Hz, 1H), assigned to the 2H-29 proton due to observed correlations in the 
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HMBC spectrum with the C-2 (δ 85.4), C-3 (δ 81.3), C-5 (δ 35.7) and C-10 (δ 45.9) 
resonances. 
The 
13
C NMR spectrum showed a quaternary carbon resonance at δ 119.0 which was 
assigned to the orthoacetate carbon C-31.  An oxymethine carbon resonance at δ 69.5 (C-30) 
and four oxyquaternary carbon resonances at δ 87.0 (C-1), 86.1 (C-8), 85.5 (C-9) and 85.4 
(C-2) could be assigned.  These are two possibilities for orthoacetates, which are a 1,8,9-
orthoacetate or a 8,9,30-orthoacetate linkage.  An oxymethine proton resonance at δ 6.31 (s) 
was assigned to H-30 due to an observed correlation in the HMBC spectrum with a carbonyl 
carbon resonance at δ 168.8 (30-OAc (C=O)), indicating that compound RB.2 was an 1,8,9-
orthoacetate phragmalin limonoid.  The relative stereo structure of compound RB.2 was 
supported by X-ray analysis. 
 
 
 
 
 
 
 
Figure 3.31 X-ray structure of compound RB.2 
Compound RB.2 was previously isolated from Chukrasia tabularis (Meliaceae),
4
 Xylocarpus 
moluccensis (Meliaceae)
51,120,128
 and Xylocarpus rumphii (Meliaceae).
5,10
  This compound 
showed no anti-inflammatory effects from monitoring the inhibition of nitric oxide (NO) 
production at a screening dose (50 μM).51 
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Table 3.2 
1
H and 
13
C NMR assignments for compound RB.2 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and xyloccensin E [CDCl3]
4
 [
13
C NMR 100 MHz, CDCl3]
5
  
No. δC RB.2 δC
4
 δC
5 δH RB.2 HMBC (H→C) COSY NOESY 
1 87.0 C 86.9 C 86.8 C - - - - 
2 85.4 C 85.3 C 85.2 C - - - - 
3 81.3 CH 81.1 CH 81.1 CH 5.11 s 3-OAc (C=O), 5, 28, 29, 30 - 28, 29a 
4 46.4 C 46.2 C 46.2 C - - - - 
5 35.7 CH 35.5 CH 35.5 CH 2.98 dd J = 9.9, 1.5 Hz 1, 3, 7, 19, 29 6a, 6b 6a, 6b, 30 
6a 
33.5 CH2 33.3 CH2 33.3 CH2 
2.47 dd J = 16.5, 9.9 Hz 4, 5, 7, 10 5, 6b 5, 6b, 19, 28 
6b 2.24 m 4, 5, 7, 10 5, 6a 5, 6a, 19 
7 172.8 C 172.7 C 172.7 C - - - - 
8 86.1 C 86.0 C 85.9 C - - - - 
9 85.5 C 85.3 C 85.3 C - - - - 
10 45.9 C 45.8 C 45.7 C - - - - 
11a 
25.6 CH2 25.4 CH2 25.4 CH2 
2.07 m 13 11b, 12a, 12b 11b 
11b 1.65 m 8, 10, 12 11a, 12a, 12b 11a 
12a 
29.3 CH2 29.2 CH2 29.1 CH2 
1.55 m 11, 13, 17, 18 11a, 11b, 12b 11a, 11b, 12b 
12b 1.30 m 11, 13 11a, 11b, 12a 11a, 11b, 12a 
13 34.6 C 34.4 C 34.3 C - - - - 
14 43.4 CH 43.2 CH 43.1 CH 2.06 m 9, 16, 17, 18, 30 15a, 15b 15a, 15b 
15a 
26.8 CH2 26.6 CH2 26.5 CH2 
3.29 d J = 20.2 Hz 13, 14, 16 14, 15b 14, 15b 
15b 2.71 dd J = 20.2, 10.8 Hz 14, 16 14, 15a 14, 15a 
16 170.5 C 170.3 C 170.4 C - - - - 
17 78.8 CH 78.6 CH 78.6 CH 5.55 s 12, 13, 14, 18, 20, 21, 22 21 21, 30 
18 19.7 CH3 19.6 CH3 19.9 CH3 1.07 s 12, 14, 17 - 21, 22 
19 16.8 CH3 16.6 CH3 16.5 CH3 1.15 s 1, 5, 9 - 6a, 6b, 29a 
20 121.3 C 121.2 C 121.1 C - - - - 
21 141.0 CH 140.8 CH 140.8 CH 7.52 s 20, 22, 23 17, 23 17, 18 
22 109.9 CH 109.8 CH 109.7 CH 6.45 d J = 1.0 Hz 20, 21, 23 23 18, 23 
23 143.2 CH 143.0 CH 143.0 CH 7.41 t J = 1.7 Hz 20, 21, 22 21, 22 22 
28 14.8 CH3 14.6 CH3 14.6 CH3 0.89 s 3, 5, 29 - 3, 6a 
29a 
40.4 CH2 40.2 CH2 40.2 CH2 
1.97 d J = 11.2 Hz 2, 3, 5, 10, 28 29b 29b, 19 
29b 1.67 d J = 11.2 Hz 2, 3, 5, 10 29a 3, 29a 
30 69.5 CH 69.3 CH 69.3 CH 6.31 s 30-OAc (C=O), 2, 3, 9 - 5, 17 
31 119.2 C 119.1 C 119.0 C - - - - 
32 21.2 CH3 21.1 CH3 21.0 CH3 1.67 s 1, 31 - - 
7-OMe 52.3 CH3 52.1 CH3 N/A 3.69 s 7 - - 
2-OAc 
170.4 C 170.2 C 170.2 C - - - - 
21.3 CH3 21.1 CH3 21.1 CH3 2.26 s 2-OAc (C=O) - - 
3-OAc 
170.6 C 170.3 C 170.2 C - - - - 
21.9 CH3 21.7 CH3 21.7 CH3 2.15 s 3-OAc (C=O) - - 
30-OAc 
168.8 C 168.6 C 168.6 C - - - - 
21.8 CH3 21.6 CH3 21.6 CH3 1.95 s 30, 30-OAc (C=O) - - 
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3.3.3 Structural elucidation of compound RB.3: taraxer-14-en-3β-ol 
Compound RB.3 was isolated as a white solid from the methanol extract of the bark of        
X. rumphii and was identified as the known taraxer-14-en-3β-ol129-131 (also called 
taraxerol
6,132-134
 or 3β-taraxerol135,136). 
 
 
 
 
Figure 3.32 Structure of compound RB.3 
The EIMS spectrum [Spectrum 3.3.1] gave a M
+
 ion at m/z 426.3866, corresponding to the 
molecular formula C30H50O for the compound and indicated six double bond equivalents.  
The FTIR spectrum [Spectrum 3.3.2] showed a broad absorption band at 3444 cm
-1
 
corresponding to the OH stretches. 
The 
13
C NMR spectrum [Spectrum 3.3.3] displayed thirty carbon resonances and the 
1
H NMR 
spectrum [Spectrum 3.3.2] showed eight methyl group singlet proton resonances at δ 1.09 
(C-26), 0.98 (C-23), 0.95 (C-29), 0.93 (C-25), 0.91 (C-27 and C-30), 0.82 (C-28) and 0.80 
(C-24).  These structural features revealed that this compound was a triterpenoid. 
The olefinic proton resonance at δ 5.53 (1H, dd, J = 8.2, 3.0 Hz, H-15) and the carbon 
resonances of C-14 (δ 158.3) and C-15 (δ 117.1) suggested a taraxerane triterpenoid.129,137  
The oxymethine proton resonance at δ 3.19 (1H, dd, J = 10.7, 3.4 Hz, H-3) was placed in the 
axial position because of the coupling constants.6  Compound RB.3 was identified as taraxer-
14-en-3β-ol. 
Compound RB.3 was previously isolated from many sources
6,129,130,132-136
 for example 
Helmiopsis sphaerocarpa (Sterculiaceae),
132
 Mangifera indica (Anacardiaceae),
136
 
Minquartia guianensis (Olacaceae),
133
 Myrica rubra (Myricaceae),
6
 Strobilanthes crispus 
(Acanthaceae)
134
 and Sterculia foetida (Sterculiaceae).
131
 
Taraxerol showed antimalarial activity against chloroquine-resistant Plasmodium falciparum 
(W2 clone) with 64 and 34% parasitemia reduction at 50 and 25 μg/mL by an in vitro 
assay.
133
  This compound indicated potent antibacterial activity against Bacillus subtilis and 
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Staphylococcus aureus with a minimum inhibitory concentration (MIC) value of 15.6 μg/mL 
and also against Escherichia coli, Klebsiella pneumonia and Salmonella typhimurium with a 
MIC value of 62.5 μg/mL.134  Taraxerol showed weak inhibitory effects against 
acetylcholinesterase with an IC50 of 52 μg/mL.
134
  Moreover, desensitization toward insulin 
stimulated glucose uptake induced by DEX was observed to be effectively restored by 
taraxerol via the restoration of phosphoinositide 3-kinase (PI3K) and glucose transporter 4 
(GLUT4) expression.
136
  In addition, this compound showed no cytotoxic effects on the DEX 
induced insulin resistant model
136
 and no antiproliferative activity against the human ovarian 
cancer cell line (A2780) at 20 μg/mL.132 
Table 3.3 
1
H and 
13
C NMR assignments for compound RB.3 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and taraxerol [
13
C NMR 25 MHz, CDCl3]
6
  
No. δC RB.3 δC
6 δH RB.3 HMBC (H→C) COSY NOESY 
1a (β) 
37.9 CH2 38.1 CH2 
1.62 m 3, 5, 9, 25 - 25 
1b () 0.95 m 3, 5 2 - 
2 27.4 CH2 27.3 CH2 1.59 m 3, 10 1b, 3 - 
3 79.3 CH 79.2 CH 3.19 dd J = 10.7, 3.4 Hz - 2 5, 23 
4 39.0 C 39.1 C - - - - 
5 55.8 CH 55.7 CH 0.79 m 1, 3, 4, 7, 9, 23, 24, 25 6a, 6b 3, 9 
6a 
19.0 CH2 19.0 CH2 
1.61 m 4, 8, 10 5, 7a 7a 
6b 1.47 m - 5, 7a 7a 
7a (β) 
41.5 CH2 35.3 CH2 
2.03 dt J = 12.7, 3.2 Hz 5, 9, 26 6a, 6b, 7b 6a, 6b, 7b, 15 
7b () 1.34 m 14, 26 7a 7a, 15 
8 39.2 C 38.9 C - - - - 
9 49.5 CH 48.9 CH 1.41 m 1, 25, 26 11a, 11b 5, 27 
10 38.2 C 37.9 C - - - - 
11a 
17.7 CH2 17.7 CH2 
1.63 m 8, 10, 12, 13 9, 11b - 
11b 1.48 m - 9, 11a - 
12a 
33.9 CH2 35.9 CH2 
1.61 m 9, 14, 18, 27 - - 
12b 1.54 m 13, 27 - - 
13 37.8 C 37.9 C - - - - 
14 158.3 C 158.1 C - - - - 
15 117.1 CH 117.0 CH 5.53 dd J = 8.2, 3.0 Hz 8, 13, 14, 17, 18, 26 16a, 16b 7a, 7b, 16a, 16b 
16a () 
38.0 CH2 36.9 CH2 
1.92 dd J = 14.7, 3.0 Hz 14, 15, 17, 18, 22, 28 15, 16b 15, 16b, 21a, 27, 30 
16b (β) 1.62 m 14, 15, 17, 18, 22, 28 15, 16a 15, 16a 
17 36.0 C 38.1 C - - - - 
18 49.0 CH 49.4 CH 0.95 m 20, 22, 27, 28 19a 28 
19a 
36.9 CH2 41.4 CH2 
1.31 m 13, 17, 29, 30 18, 19b - 
19b 0.97 m 13, 17, 20, 21, 30 19a 27, 30 
20 29.0 C 29.0 C - - - - 
21a 
33.3 CH2 33.9 CH2 
1.34 m 17, 29, 30 21b, 22b 16a 
21b 1.25 m 17, 19, 29 21a, 22a, 22b - 
22a 
35.3 CH2 33.2 CH2 
1.37 m 28 21b, 22b - 
22b 1.01 m 18, 20 21a, 21b, 22a - 
23 28.2 CH3 28.1 CH3 0.98 s 3, 4, 5, 24 - 3, 24 
24 15.7 CH3 15.6 CH3 0.80 s 3, 4, 5, 23 - 23, 25 
25 15.6 CH3 15.6 CH3 0.93 s 1, 5, 9, 10 - 1a, 24, 26 
26 26.1 CH3 30.1 CH3 1.09 s 7, 8, 9, 14 - 25, 28 
27 21.5 CH3 26.0 CH3 0.91 s 12, 13, 14, 18 - 9, 16a 
28 30.1 CH3 30.1 CH3 0.82 s 16, 18, 22 - 18, 26 
29 33.6 CH3 33.5 CH3 0.95 s 19, 20, 21, 30 - 30 
30 30.1 CH3 21.5 CH3 0.91 s 19, 20, 21, 29 - 29 
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3.3.4 Structural elucidation of compound RB.4: 22S-hydroxytirucalla-7,24-diene-3,23-
dione 
Compound RB.4 was isolated as a white solid from the methanol extract of the bark of        
X. rumphii and was identified as the known 22S-hydroxytirucalla-7,24-diene-3,23-dione, 
which was previously isolated from Aucoumea klaineana (Burseraceae).
7,138
 
 
 
 
 
Figure 3.33 Structure of compound RB.4 
The HRMS [Spectrum 3.4.1] gave a [M + Na]
+ 
ion at m/z 477.3333, corresponding to the 
molecular formula C30H46O3 for the compound and indicated eight double bond equivalents.  
The FTIR spectrum [Spectrum 3.4.2] exhibited absorption bands at 3417 and 1711 cm
-1
 
which were attributed to OH and C=O stretches. 
The 
13
C NMR spectrum [Spectrum 3.4.4] displayed thirty carbon resonances and the 
1
H NMR 
spectrum [Spectrum 3.4.3] showed seven methyl group singlet proton resonances at δ 2.23 
(3H-27), 1.98 (3H-26), 1.12 (3H-29), 1.07 (3H-30), 1.06 (3H-28), 1.01 (3H-19) and 0.87 (3H-18).  
In addition, a methyl group doublet proton resonance occurred at δ 0.64 (d, J = 6.6 Hz), 
which corresponded to 3H-21.  These structural features revealed that this compound was a 
tirucallane or euphane triterpenoid. 
The isolation of several tirucallane triterpenoids with an oxidised C-21 was significant 
chemotaxonomic evidence in favour of the link between the Burseraceae and its supposed 
allies in the Rutales (Rutaceae, Meliaceae and Simaroubaceae).  Accordingly, this compound 
was assumed to be a tirucallane triterpenoids (20S, H-20α) rather than the corresponding 
euphane triterpenoids (20R, H-20) from biogenetic arguments.7  The configuration at C-20 
was assigned as S. 
The H-1α (δ 2.00), 3H-28 (δ 1.06) and 3H-29 (δ 1.12) proton resonances showed correlations 
in the HMBC spectrum [Spectrum 3.4.7] with a carbon resonance at δ 217.1 that was 
assigned as the carbon of a keto group at C-3.  The second keto group (C-23, δC 201.6) was 
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placed on the side chain and further analysis of the NMR spectra [Table 3.4] supported the 
presence of a –CH(CH3)CH(OH)COCH=C(CH3)2 group.  These structural features revealed 
that the compound was a tirucalla-3,23-dione. 
An olefinic proton resonance at δ 6.08 (s) was assigned to H-24 in the side chain due to 
observed correlations in the HMBC spectrum with the C-23 (δ 201.6), C-26 (δ 28.3) and C-27 
(δ 21.6) carbon resonances, indicating that H-24 was an olefinic proton at the α-position of 
an α,-unsaturated ketone.  An olefinic proton resonance at δ 5.33 (dd, J = 6.3, 3.3 Hz) was 
ascribed to H-7.  In the HMBC spectrum, the H-7 resonance showed connectivities over 
3
J 
with carbon resonances at δ 52.6 (C-5), 51.6 (C-14) and 48.7 (C-9).  These HMBC 
correlations confirmed the assignment of the H-7 resonance.  These structural features 
revealed that the compound was a tirucalla-7,24-diene-3,23-dione. 
An oxymethine proton resonance at δ 4.17 (dd, J = 5.0, 1.5 Hz) was assigned to H-22 in the 
side chain due to observed correlations in the HMBC spectrum with the C-17 (δ 49.3), C-20 
(δ 39.8), C-21 (δ 12.2) and C-23 (δ 201.6) resonances.  These HMBC correlations confirmed 
the assignment of the H-22 resonance, indicating that the compound was a 22-
hydroxytirucalla-7,24-diene-3,23-dione. 
Compound RB.4 was the known 22S-hydroxytirucalla-7,24-diene-3,23-dione which was 
previously isolated from Aucoumea klaineana (Burseraceae)
138
 and it was also similar to the 
known dymacrin A which was previously isolated from the bark of Dysoxylum macranthum 
C. DC (Meliaceae).
139
  The absolute configuration at C-22 of the side chain of 22S-
hydroxytirucalla-7,24-dien-3,23-dione was characterized as S using single crystal x-ray 
studies,
138
 confirming that the configuration at C-22 in compound RB.4 was also S. 
 
 
 
 
 
 
Figure 3.34 Structure of compound RB.4 and dymacrin A 
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Table 3.4 
1
H and 
13
C NMR assignments for compound RB.4 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], 22-hydroxytirucalla-7,24-diene-3,23-dione [
13
C NMR 90.56 MHz, 
CDCl3]
7
 and dymacrin A [
13
C NMR 75 MHz, CDCl3]
139
 
No. δC RB.4 δC
7
 δC
139 δH RB.4 HMBC (H→C) COSY NOESY 
1α 
38.8 CH2 38.4 CH2 37.7 CH2 
2.00 m 3, 5, 19 1β, 2α, 2β 1β, 2α, 2β 
1β 1.46 m 9, 19 1α, 2α, 2β 1α, 2α, 2β 
2α 
35.2 CH2 34.8 CH2 35.7 CH2 
2.25 m 1, 3, 4, 10 1α, 1β, 2β 1α, 1β, 2β 
2β 2.76 td J = 14.5, 5.5 Hz 1, 3, 10 1α, 1β, 2α 1α, 1β, 2α, 19, 28 
3 217.1 C 216.8 C 216.4 C - - - - 
4 48.1 C 47.8 C 53.4 C - - - - 
5 52.6 CH 52.3 CH 53.6 CH 1.74 dd J = 9.2, 8.2 Hz 9, 10, 19, 28, 29 6 9, 29 
6 24.6 CH2 24.3 CH2 24.8 CH2 2.16 m 4, 5, 7, 8, 10 5, 7 7 
7 118.2 CH 117.8 CH 118.1 CH 5.33 dd J = 6.3, 3.3 Hz 5, 9, 14 6 6 
8 146.1 C 145.7 C 146.1 C - - - - 
9 48.7 CH 48.4 CH 48.4 CH 2.29 m - 11 5, 18 
10 35.3 C 34.9 C 35.1 C - - - - 
11 18.5 CH2 18.1 CH2 18.6 CH2 1.57 m 8, 9, 12, 13 9, 12 - 
12 33.7 CH2 33.4 CH2 33.5 CH2 1.85 m 17, 18 11 - 
13 43.6 C 43.2 C 43.4 C - - - - 
14 51.6 C 51.3 C 51.5 C - - - - 
15 34.2 CH2 33.9 CH2 34.1 CH2 1.56 m 8, 13, 14, 30 16a, 16b - 
16a 
28.3 CH2 27.9 CH2 28.1 CH2 
2.16 m 13 15, 16b, 17 16b 
16b 1.44 m 14, 20 15, 16a, 17 16a 
17 49.3 CH 49.0 CH 49.1 CH 2.01 m 12, 13, 18 16a, 16b, 20 20, 30 
18 22.2 CH3 12.7 CH3 22.1 CH3 0.87 s 12, 13, 14, 17 - 2, 20 
19 13.0 CH3 21.5 CH3 13.6 CH3 1.01 s 1, 5, 9, 10 - 2β 
20 39.8 CH 39.4 CH 39.6 CH 1.85 m 17, 21 17, 21, 22 17, 18, 21, 22 
21 12.2 CH3 11.9 CH3 12.1 CH3 0.64 d J = 6.6 Hz 17, 20, 22 20 17, 20 
22 79.0 CH 78.6 CH 78.9 CH 4.17 dd J = 5.0, 1.5 Hz 17, 20, 21, 23 20, 22-OH 16a, 16b, 20, 22-OH, 24 
23 201.6 C 201.2 C 201.4 C - - - - 
24 119.4 CH 119.1 CH 119.2 CH 6.08 s 23, 26, 27 26, 27 22, 26 
25 159.8 C 159.4 C 159.7 C - - - - 
26 28.3 CH3 24.4 CH3 28.2 CH2 1.98 s 24, 25, 27 24 24 
27 21.6 CH3 21.3 CH3 21.5 CH3 2.23 s 23, 24, 25, 26 24 - 
28 24.8 CH3 28.0 CH3 20.6 CH3 1.06 s 3, 4, 5, 29 - 2β 
29 21.8 CH3 21.8 CH3 65.8 CH2 1.12 s 3, 4, 5, 28 - 5 
30 27.8 CH3 27.5 CH3 27.7 CH3 1.07 s 8, 13, 14, 15 - 17 
22-OH - - - 3.63 d J = 5.0 Hz 20, 22, 23 22 22 
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3.4 Structural elucidation of compounds isolated of the heartwood of X. rumphii 
Ten tetranortriterpenoids were isolated from the heartwood of X. rumphii and were identified 
as the limonoids, xylorumphiins L (RH.1), E (RH.2) and C (RH.3) and protolimonoids, 
xylorumphiins M-S (RH.4-10).  Compounds RH.4-10 have a hemiacetal group which opens 
and closes in solution making it impossible to purify.  Acetylation enabled separation of the R 
and S forms.  Column chromatographic separation of the acetylated mixture of impure RH.4-
10 led to the isolation of four acetylated derivatives of RH.4 (RH.4a-d), two acetylated 
derivatives of RH.5 (RH.5a and 5b), one acetylated derivative of RH.6 (RH.6a), two 
acetylated derivatives of RH.7 (RH.7a and 7b), one acetylated derivative of RH.8 (RH.8a) 
and one acetylated derivative of RH.10 (RH.10a).  Compound RH.1 and RH 4-10 have not 
been described previously. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35 Compounds isolated from the heartwood of X. rumphii and their derivatives 
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Figure 3.36 
1
H NMR spectra for compounds RH.4-4d 
Compound RH.4d 
Compound RH.4c 
Compound RH.4b 
Compound RH.4a 
Compound RH.4 
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H-23 
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3.4.1 Structural elucidation of compound RH.1: xylorumphiin L 
Compound RH.1 was isolated as a colourless solid from the methanol extract of the heartwood 
of X. rumphii and was identified as the new xylorumphiin L. 
 
 
 
 
 
Figure 3.37 Structure of compound RH.1 
The HRMS [Spectrum 3.5.1] gave a [M + Na]
+ 
ion at m/z 679.3082, which indicated the 
molecular formula of C36H48O11 for the compound.  A double bond equivalence of thirteen 
was calculated.  The FTIR spectrum [Spectrum 3.5.2] showed strong absorption bands at 
1765 and 1724 cm
-1
 corresponding to a C=O stretching of an ester and C=O stretching of a 
ketone, respectively.  The presence of five carbonyl carbon resonances at  213.6 (C-1), 
176.0 (C-1'), 174.9 (C-1"), 174.0 (C-7) and 169.4 (C-16) in the 
13
C NMR spectrum 
[Spectrum 3.5.4] supported the above conclusion. 
The 
13
C NMR, DEPT [Spectrum 3.5.5] and HSQCDEPT [Spectrum 3.5.6] spectra 
displayed thirty-six carbon resonances, which included eleven quaternary, eleven methine, 
five methylene and nine methyl carbon resonances. 
A comparison of the 
13
C NMR spectrum for compound RB.1 with that of compound RH.1 
indicated that the chemical shifts were the same as for the characteristic D-seco limonoids 
(ring D lactone and -substituted furan ring), except for the C-14 and C-15 carbon 
resonances, which occurred at δ 159.7 and 118.0 respectively in compound RB.1 and at δ 
67.6 (C-14) and 35.6 (C-15) for compound RH.1.  The 
1
H NMR spectrum also showed a 
significant difference for the H-15 proton resonance.  Compound RB.1 [Spectrum 3.1.3] 
exhibited a resonance at δ 6.00 (s, 2H-15) whereas compound RH.1 [Spectrum 3.5.3] 
exhibited two resonances at δ 3.72 (d, J = 17.1 Hz, H-15β) and 2.90 (d, J = 17.1 Hz, H-15α), 
indicating that compound RH.1 was a saturated ring D lactone. 
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Two oxyquaternary carbon resonances at δ 62.8 and 67.6 were assigned to C-8 and C-14.  In 
the HMBC spectrum [Spectrum 3.5.7], the H-15β resonance showed connectivities with 
resonances at δC 169.4 (C-16), 67.6 (C-14) and 62.8 (C-8).  The H-15α resonance showed 
connectivities with resonances at δC 169.4 (C-16), 78.0 (C-17), 67.6 (C-14) and 37.9 (C-13).  
The 3H-18 resonance showed connectivities with resonances at δC 78.0 (C-17), 67.6 (C-14), 
37.9 (C-13) and 26.0 (C-12).  These HMBC correlations confirmed the assignment of the C-8 
and C-14 resonances, indicating that compound RH.1 was an 8,14-epoxy limonoid. 
A comparison of the 
13
C NMR spectrum for compound RB.1 with that of compound RH.1 
indicated that the chemical shifts were the same as for a characteristic mexicanolide limonoid 
(B-seco limonoids), except for the C-1 carbon resonance, which occurred at δ 107.7 in 
compound RB.1 but at δ 213.6 for compound RH.1, indicating that compound RH.1 has a 
ketone group at C-1. 
The proton resonances at δ 2.39 (m, H-2'), 1.81 (sextet, J = 7.2 Hz, H-4a'), 1.49 (sextet, J = 
7.2 Hz, H-4b'), 1.16 (d, J = 7.2 Hz, 3H-3') and 1.02 (t, J = 7.2 Hz, H-5') were assigned to 
protons of a 2'-methylbutyryloxy group.  In the HMBC spectrum, the H-2' proton resonance 
showed correlations with carbon resonances at δ 176.0 (C-1'), 26.7 (C-4'), 17.6 (C-3') and 11.8 
(C-5').  An oxymethine proton resonance at δ 5.20 (d, J = 10.8 Hz) was assigned to H-3 due 
to observed correlations in the HMBC spectrum with the C-1' (δ 176.0), C-2 (δ 52.5), C-4 (δ 
39.3), C-5 (δ 41.8), C-29 (δ 20.9) and C-30 (δ 70.9) carbon resonances, indicating that the 2'-
methylbutyryloxy group was at C-3. 
The proton resonances at δ 2.50 (m, H-2"), 1.15 (d, J = 6.6 Hz, H-4") and 1.13 (d, J = 6.3 
Hz, H-3") were assigned to an isobutyryloxy group.  In the HMBC spectrum, the H-4" 
proton resonance showed correlations with carbon resonances at δ 174.9 (C-1"), 33.8 (C-2") 
and 18.8 (C-3").  An oxymethine proton resonance at δ 5.34 (d, J = 2.4 Hz) was assigned to 
H-30 due to observed correlations in the HMBC spectrum with the C-1 (δ 213.6), C-1" (δ 174.9), 
C-2 (δ 52.5), C-3 (δ 76.6), C-8 (δ 62.8), C-9 (δ 47.4) and C-14 (δ 67.6) carbon resonances, 
indicating that isobutyryloxy group was at C-30. 
The absolute configuration at C-2' of the 2-methylbutyryloxy group was determined as S, 
supported by X-ray analysis. 
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Figure 3.38 X-ray data of compound RH.1 (mirror image) 
Compound RH.1 was found to be a mexicanolide limonoid (B,D-seco limonoid) and a new 
compound similar to the known xyloccensin G which was previously isolated from X. 
moluccensis.
120
 
 
 
 
 
 
 
 
 
Figure 3.39 Structure of compound RH.1 and xyloccensin G 
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Table 3.5 
1
H and 
13
C NMR assignments for compound RH.1 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], xyloccensin G
120
 and compound RB.1 [
13
C NMR 125 MHz, 
CDCl3] 
No. δC RH.1 δC
120 δC RB.1 δH RH.1 HMBC (H→C) COSY NOESY 
1 213.6 C 213.5 C 107.7 C - - - - 
2 52.5 CH 52.2 CH 53.6 CH 3.08 dd J = 10.8, 2.4 Hz 1, 3, 4, 8, 10, 30 3, 30 3, 30 
3 76.6 CH 76.7 CH 73.7 CH 5.20 d J = 10.8 Hz 1', 2, 4, 5, 29, 30 2 2, 28, 29 
4 39.3 C 39.3 C 38.0 C - - - - 
5 41.8 CH 41.8 CH 40.8 CH 3.37 dd J = 9.9, 3.3 Hz 3, 4, 6, 7, 9, 10, 19, 29 6 28 
6 33.3 CH2 33.3 CH2 32.3 CH2 2.47 m 5, 7, 10 5 - 
7 174.0 C 174.0 C 174.0 C - - - - 
8 62.8 C 62.8 C 81.8 C - - - - 
9 47.4 CH 47.5 CH 51.8 CH 2.26 m 5, 8, 11, 12, 14 11 - 
10 51.5 C 51.5 C 43.1 C - - - - 
11 16.8 CH2 N/A 15.3 CH2 1.62 m 8, 9, 10, 12, 13 9 - 
12 26.0 CH2 26.0 CH2 25.1 CH2 1.60 m 9, 11, 13, 17, 18 - - 
13 37.9 C 37.9 C 39.1 C - - - - 
14 67.6 C 67.6 C 159.7 C - - - - 
15α 
35.6 CH2 35.5 CH2 118.0 CH 
3.72 d J = 17.1 Hz 13, 14, 16, 17 15β 15β, 30 
15β 2.90 d J = 17.1 Hz 8, 14, 16 15α 15α, 17, 30 
16 169.4 C 169.4 C 163.7 C - - - - 
17 78.0 CH 78.0 CH 81.4 CH 5.91 s 12, 13, 14, 18, 20, 21, 22 - 15β 
18 14.4 CH3 14.4 CH3 19.9 CH3 1.05 s 12, 13, 14, 17 - - 
19 17.8 CH3 17.6 CH3 20.7 CH3 1.20 s 1, 5, 9, 10 - - 
20 119.8 C 119.8 C 120.2 C - - - - 
21 142.1 CH 142.1 CH 141.4 CH 7.62 s  20, 22, 23 - - 
22 110.4 CH 110.3 CH 110.2 CH 6.50 s 20, 21, 23 23 - 
23 142.6 CH 142.6 CH 143.1 CH 7.39 s 20, 21, 22 22 - 
28 23.6 CH3 23.6 CH3 24.8 CH3 0.78 s 3, 4, 5, 29 - 3, 5 
29 20.9 CH3 20.9 CH3 22.1 CH3 0.88 s 3, 4, 5, 28 - 3 
30 70.9 CH 70.9 CH 76.4 CH 5.34 d J = 2.4 Hz 1, 1", 2, 3, 8, 9, 14 2 2, 15α, 15β 
7-OMe 52.4 CH3 52.35 CH3 52.2 CH3 3.76 s 7 - - 
3-acyl        
1' 176.0 C 175.9 C 175.8 C - - - - 
2' 41.6 CH 41.6 CH 41.2 CH 2.39 m 1', 3', 4', 5' 3' - 
3' 17.6 CH3 17.5 CH3 16.4 CH3 1.16 d J = 7.2 Hz 1', 2', 4' 2' - 
4a' 
26.7 CH2 26.7 CH2 26.3 CH2 
1.81 sextet J = 7.2 Hz 1', 2', 3', 5' 4b', 5' - 
4b' 1.49 sextet J = 7.2 Hz 1', 2', 3', 5' 4a', 5' - 
5' 11.8 CH3 11.7 CH3 11.7 CH3 1.02 t J = 7.2 Hz 2', 4' 4a', 4b' - 
30-acyl        
1" 174.9 C 174.0 C 176.2 C - - - - 
2" 33.8 CH  33.8 CH 40.9 CH 2.50 m 1", 3" 3", 4" - 
3" 18.8 CH3 18.8 CH3 15.9 CH3 1.13 d J = 6.3 Hz 1", 2" 2" - 
4" 16.3 CH3 26.5 CH2 26.6 CH2 1.15 d J = 6.6 Hz 1", 2", 3" 2" - 
5" - 16.8 CH3 11.9 CH3 - - - - 
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3.4.2 Structural elucidation of compound RH.2: xylorumphiin E 
Compound RH.2 was isolated as a colourless solid from the methanol extract of the heartwood 
of X. rumphii and was identified as the known xylorumphiin E.
9
 
 
 
 
 
 
Figure 3.40 Structure of compound RH.2 
The HRMS [Spectrum 3.6.1] gave a [M+Na]
+
 ion at m/z 667.3084, which indicated the 
molecular formula of C35H48O11 for the compound.  A double bond equivalence of twelve 
was calculated.  The FTIR spectrum [Spectrum 3.6.2] showed absorption bands at 3385 and 
1727 cm
-1
 corresponding to the OH and C=O stretches. 
The 
13
C NMR [Spectrum 3.6.4], DEPT [Spectrum 3.6.5] and HSQCDEPT [Spectrum 
3.6.6] spectra displayed thirty-five carbon resonances, which included nine methyl, four 
methylene, twelve methine and ten quaternary carbons. 
The 
1
H NMR spectrum [Spectrum 3.6.3] showed the characteristic proton resonances of 
protons of a -substituted furan ring at δ 7.52 (br s, W1/2 = 4.3 Hz), 7.38 (br s, W1/2 = 4.2 Hz) 
and 6.38 (br s, W1/2 = 4.4 Hz) which were assigned as H-21, H-23 and H-22, respectively.  An 
oxymethine proton resonance at δ 5.25 (s) was assigned as H-17, a proton attached to a 
carbon adjacent to a furan ring.  In the HMBC spectrum [Spectrum 3.6.7], the H-17 proton 
resonance showed correlations with resonances at δC 141.7 (C-21), 121.1 (C-20), 110.2 (C-
22), 46.7 (C-14), 36.5 (C-13), 36.0 (C-12) and 22.4 (C-18).  These HMBC correlations 
confirmed the assignment of the H-17 resonance, indicating that this compound was a D-seco 
limonoid (ring D opened). 
A methine proton resonance at δ 2.20 (d, J = 9.3 Hz) was assigned as H-14.  In the HMBC 
spectrum, the H-14 resonance showed connectivities with the C-8 (δ 82.4), C-9 (δ 63.5), C-12 
(δ 36.0), C-13 (δ 36.5), C-15 (δ 29.2), C-16 (δ 170.4), C-17 (δ 77.3), C-18 (δ 22.4) and C-30 
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(δ 76.0).  These HMBC correlations confirmed the assignment of the H-14 resonance, 
indicating that H-14 was a methine proton at the -position of a ring D lactone.  The COSY 
spectrum [Spectrum 3.6.8] showed correlations between the H-14 (δ 2.20) and H-15a (δ 3.25) 
and H-15b (δ 2.73) resonances, indicating that 2H-15 (H-15a and H-15b) were methylene 
protons at the α-position of a ring D lactone. 
The three proton resonance at  3.69 (s) was assigned to protons of a group of a methyl ester 
at C-7 characteristic of a B-seco limonoid (ring B opened).  The H-2 proton resonance at δ 2.63 
(1H, m) showed correlations with C-1 (δ 106.8), C-3 (δ 73.9), C-4 (δ 38.3), C-10 (δ 43.9) 
and C-30 (δ 76.0) resonances in the HMBC spectrum indicating the presence of a 
mexicanolide type of limonoid.  The COSY spectrum also supported this proposal by 
showing correlations between H-2 (δ 2.63) and H-3 (δ 5.10) and H-30 (δ 6.16). 
An oxymethine proton resonance at δ 5.10 (d, J = 9.0 Hz) was assigned to H-3 due to observed 
correlations in the HMBC spectrum with the C-1' (δ 177.7), C-2 (δ 57.2), C-4 (δ 38.3), C-5 
(δ 40.8), C-29 (δ 22.6) and C-30 (δ 76.0) carbon resonances.  The H-2' resonance also 
showed correlations with the C-1' (δ 177.7), C-3' (δ 18.5) and C-4' (δ 20.2) carbon 
resonances, indicating that compound RH.2 had an isobutyryloxy group at C-3. 
An oxymethine proton resonance at δ 6.16 (d, J = 4.2 Hz) was assigned to H-30 due to observed 
correlations in the HMBC spectrum with the C-1 (δ 106.8), C-1" (δ 175.2), C-2 (δ 57.2), C-3 
(δ 73.9), C-8 (δ 82.4) and C-9 (δ 63.5) carbon resonances.  The H-2" resonance also showed 
correlations with the C-1" (δ 175.2), C-3" (δ 17.7) and C-4" (δ 19.3) carbon resonances, 
indicating that this compound had an isobutyryloxy group at C-30. 
Compound RH.2 was identified as the known xylorumphiin E.  This compound was 
previously isolated from the same species.
9
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Table 3.6 
1
H and 
13
C NMR assignments for compound RH.2 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and xylorumphiin E [
13
C NMR 100 MHz, CDCl3]
9
 
No. δC RH.2 δC
9 δH RH.2 HMBC (H→C) COSY NOESY 
1 106.8 C 106.7 C - - - - 
2 57.2 CH 57.1 CH 2.63 m 1, 3, 4, 10, 30 3, 30 3 
3 73.9 CH 73.4 CH 5.10 d J = 9.0 Hz 1', 2, 4, 5, 29, 30 2 2, 29 
4 38.3 C 38.1 C - - - - 
5 40.8 CH 40.5 CH 2.60 d J = 9.9 Hz 1, 3, 4, 6, 7, 9, 10, 19, 29 6a, 6b 6a, 6b, 28, 30 
6a 
32.7 CH2 32.5 CH2 
2.35 dd J = 16.4, 9.9 Hz 4, 5, 7 5, 6b 18,19, 29 
6b 2.26 d J = 16.4 Hz 4, 5, 7, 10 5, 6a 18, 19 
7 174.2 C 173.9 C - - - - 
8 82.4 C 82.4 C - - - - 
9 63.5 CH 64.4 CH 1.43 dd J = 13.4, 2.6 Hz 5, 8, 10, 11, 12, 14, 19, 30 11a, 11b 11a, 12a, 12b, 14, 18, 19 
10 43.9 C 43.7 C - - - - 
11a 
19.8 CH2 19.6 CH2 
1.90 dd J = 13.4, 3.0 Hz 8, 9 9, 11b, 12a, 12b 11b, 30 
11b 1.67 m - 9, 12a, 12b 9, 11a, 12a, 14 
12a 
36.0 CH2 35.9 CH2 
1.83 m 9, 13, 14, 17 11a, 11b, 12b 11b, 12b, 14, 17, 18, 19 
12b 1.32 m 9, 11, 13, 15, 17, 18 11a, 11b, 12a 9, 12a 
13 36.5 C 36.3 C - - - - 
14 46.7 CH 46.6 CH 2.20 d J = 9.3 Hz 8, 9, 12, 13, 15, 16, 17, 18, 30 15a, 15b 9, 11b, 15a, 15b, 18, 19 
15a 
29.2 CH2 29.0 CH2 
3.25 d J = 19.6 Hz 8, 13, 14, 16 14, 15b 15b 
15b 2.73 dd J = 19.6, 9.3 Hz 8, 14, 16 14, 15a 15a 
16 170.4 C 169.9 C - - - - 
17 77.3 CH 77.1 CH 5.25 s 12, 13, 14, 18, 20, 21, 22 - 12a, 21, 22, 30 
18 22.4 CH3 21.0 CH3 1.03* 12, 13, 14, 17 - 9, 14 
19 21.3 CH3 22.2 CH3 1.04* 1, 5, 9, 10 - 9, 14 
20 121.1 C 121.0 C - - - - 
21 141.7 CH 141.5 CH 7.52 br s W1/2 = 4.3 Hz 20, 22, 23 22, 23 17 
22 110.2 CH 110.0 CH 6.38 br s W1/2 = 4.4 Hz 17, 20, 21, 23 21, 23 17, 23 
23 143.2 CH 142.9 CH 7.38 br s W1/2  = 4.2 Hz 20, 21, 22 21, 22 22 
28 24.9 CH3 24.6 CH3 0.75 s 3, 4, 5, 29 - 5, 29 
29 22.6 CH3 22.1 CH3 1.19 s 3, 4, 5, 28 - 3, 28 
30 76.0 CH 75.9 CH 6.16 d J = 4.2 Hz 1, 1", 2, 3, 8, 9 2 5, 11a, 17 
7-OMe 52.0 CH3 51.9 CH3 3.69 s 7 - - 
3-acyl       
1' 177.7 C 177.0 C - - - - 
2' 34.2 CH 33.3 CH 2.65 m 1', 3', 4' 3', 4' - 
3' 18.5 CH3 18.3 CH3 1.10 d J = 6.9 Hz 1', 2', 4' 2' - 
4' 20.2 CH3 20.0 CH3 1.21 d J = 7.1 Hz 1', 2', 3' 2' - 
30-acyl       
1" 175.2 C 174.9 C - - - - 
2" 33.5 CH 33.9 CH 2.53 septet J = 7.5 Hz 1", 3", 4" 3" - 
3" 17.7 CH3 17.5 CH3 1.04* 1", 2", 4" 2" - 
4" 19.3 CH3 19.1 CH3 0.91 d J = 7.5 Hz 1", 2", 3" - - 
*Refer to overlapped proton resonances 
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3.4.3 Structural elucidation of compound RH.3: xylorumphiin C 
Compound RH.3 was isolated as a colourless solid from the methanol extract of the heartwood 
of X. rumphii and was identified as the known xylorumphiin C. 
 
 
 
 
 
Figure 3.41 Structure of compound RH.3 
The HRMS [Spectrum 3.7.1] gave a [M+Na]
+
 ion at m/z 679.3081, which indicated the 
molecular formula of C36H48O11 for the compound.  A double bond equivalence of thirteen 
was calculated.  The FTIR spectrum [Spectrum 3.7.2] showed absorption bands at 3354, 
1725 and 1706 cm
-1
 corresponding to the OH and C=O stretches. 
The 
13
C NMR, DEPT [Spectrum 3.7.5] and HSQCDEPT [Spectrum 3.7.6] spectra 
displayed thirty-six carbon resonances, which included eleven quaternary, twelve methine, 
four methylene and nine methyl carbon resonances. 
A comparison of the 
13
C NMR and DEPT spectra for compound RB.1 with those of 
compound RH.3 indicated that the chemical shifts were the same, except for the C-2", C-3", 
C-4" and C-5" resonances, which occurred at δC 40.9 (CH, C-2"), 15.9 (CH3, C-3"), 26.6 
(CH2, C-4") and 11.9 (CH3, C-5") in compound RB.1 but at δC 34.3 (CH, C-2"), 19.2 (CH, 
C-3") and 19.0 (CH3, C-4").  In compound RH.3, C-5" was missing indicating that 
compound RH.3 has a different ester group on C-30. 
The COSY spectrum [Spectrum 3.7.8] of compound RH.3 showed correlations between the 
H-2" (δ 2.45, m) and 3H-3" (δ 1.10, d, J = 7.0 Hz) and 3H-4" (δ 1.10, d, J = 7.0 Hz) 
resonances.  An oxymethine proton resonance at δ 5.55 (d, J = 4.3 Hz) was assigned to H-30 
due to observed correlations in the HMBC spectrum with the C-1 (δ 107.7), C-1" (δ 176.6), 
C-2 (δ 53.5), C-3 (δ 73.9), C-8 (δ 81.8) and C-9 (δ 51.8) carbon resonances.  The H-2" 
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resonance also showed correlations with the C-1" (δ 176.6), C-3" (δ 19.2) and C-4" (δ 19.0) 
carbon resonances, indicating that this compound had an isobutyryloxy group at C-30. 
The absolute configuration at C-2' of the 2-methylbutyryloxy group was determined as S, 
supported by X-ray analysis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.42 X-ray data of compound RH.3 
Compound RH.3 was identified as the known xylorumphiin C.  This compound was 
previously isolated from the same species.
10
  The bioactivity of xylorumphiin C has not been 
evaluated before. 
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Table 3.7 
1
H and 
13
C NMR assignments for compound RH.3 [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], compound RB.1 [
13
C NMR 125 MHz, CDCl3] and xylorumphiin C 
[
1
H NMR 400 MHz, 
13
C NMR 100 MHz, CDCl3, J = Hz]
10
 
No. δC RH.3 δC RB.1 δC
10 δH RH.3 δH
10 HMBC (H→C) COSY NOESY 
1 107.7 C 107.7 C 107.5 C - - - - - 
2 53.5 CH 53.6 CH 53.2 CH 2.91 dd J = 9.2, 4.3 Hz 2.91 dd J = 9.1, 4.3 Hz 1, 3, 4, 10, 30 3, 30 3, 30 
3 73.9 CH 73.7 CH 73.8 CH 5.11 d J = 9.2 Hz 5.11 d J = 9.1 Hz 1', 2, 4, 5, 29, 30 2 2 
4 38.0 C 38.0 C 37.8 C - - - - - 
5 40.8 CH 40.8 CH 40.6 CH 2.64 m 2.62 d J = 10.2 Hz 3, 4, 6, 7, 9, 10, 19, 28, 29 6a, 6b 30 
6a 
32.3 CH2 32.3 CH2 32.1 CH2 
2.35 m 2.35 m 4, 5, 7, 10 5, 6b - 
6b 2.17 m 2.16 m 4, 5, 7, 10 5, 6a - 
7 174.0 C 174.0 C 173.8 C - - - - - 
8 81.8 C 81.8 C 81.5 C - - - - - 
9 51.8 CH 51.8 CH 51.5 CH 2.14 m 2.14 m 5, 8, 10, 14, 19, 30 11a, 11b 18, 19 
10 43.1 C 43.1 C 42.9 C - - - - - 
11a 
15.2 CH2 15.3 CH2 15.0 CH2 
2.38 m 2.36 m 10, 13 9, 11b, 12a - 
11b 1.82 m 1.81 m 8 9, 11a, 12a, 12b - 
12a 
25.1 CH2 25.1 CH2 24.9 CH2 
2.18 m 
2.19 m 
14, 17 11a, 11b, 12b - 
12b 1.41 m 9, 11, 13, 14, 18 11b, 12a - 
13 39.1 C 39.1 C 38.9 C - - - - - 
14 159.8 C 159.7 C 159.7 C - - - - - 
15 117.9 CH 118.0 CH 117.6 CH 6.00 s 6.00 s 8, 13, 14, 16, 18 - - 
16 163.8 C 163.7 C 163.7 C - - - - - 
17 81.4 CH 81.4 CH 81.3 CH 5.02 s 5.02 s 12, 13, 14, 18, 20, 21, 22 21 - 
18 19.9 CH3 19.9 CH3 19.7 CH3 1.21 s 1.20 s 12, 13, 14, 17 - 9 
19 20.7 CH3 20.7 CH3 20.5 CH3 1.06 s 1.07 s 1, 5, 9, 10 - 9 
20 120.2 C 120.2 C 120.0 C - - - - - 
21 141.5 CH 141.4 CH 142.9 CH 7.49 s 7.41 s 20, 22, 23 17, 22, 23 - 
22 110.2 CH 110.2 CH 109.9 CH 6.43 s 6.42 s 20, 21, 23 21, 23 23 
23 143.1 CH 143.1 CH 141.2 CH 7.41 s 7.49 s 20, 21, 22 21, 22 22 
28 24.8 CH3 24.8 CH3 21.9 CH3 0.78 s 1.25 s 3, 4, 5, 29 - - 
29 22.1 CH3 22.1 CH3 24.6 CH3 1.24 s 0.78 s 3, 4, 5, 28 - - 
30 76.4 CH 76.4 CH 76.2 CH 5.55 d J = 4.3 Hz 5.54 d J = 4.3 Hz 1, 1", 2, 3, 8, 9 2 2, 5 
1-OH - - - 3.90 s - 1, 2, 10 - - 
7-OMe 52.1 CH3 52.2 CH3 51.9 CH3 3.69 s 3.68 s 7 - - 
3-acyl         
1' 175.9 C 175.8 C 175.8 C - - - - - 
2' 41.3 CH 41.2 CH 41.1 CH 2.27 m 2.28 m 1', 3', 4', 5' 3', 4a' - 
3' 16.4 CH3 16.4 CH3 16.1 CH3 1.13 d J = 7.1 Hz 1.13 d J = 7.4 Hz 1', 2' 2' - 
4a' 
26.4 CH2 26.3 CH2 26.2 CH2 
1.64 m 
1.64 m 
1', 2', 3', 5' 2', 4b', 5' - 
4b' 1.40 m 1', 2', 3', 5' 4a', 5' - 
5' 11.7 CH3 11.7 CH3 11.5 CH3 0.89 t J = 7.4 Hz 0.88 t J = 7.4 Hz 2' 4a', 4b' - 
30-acyl         
1" 176.6 C 176.2 C 176.4 C - - - - - 
2" 34.3 CH 40.9 CH 34.1 CH 2.45 m  2.47 m 1", 3", 4" 3", 4" - 
3" 19.2 CH3 15.9 CH3 18.8 CH3 1.10 d J = 7.0 Hz 1.10 d J = 6.8 Hz 1", 2", 4" 2" - 
4" 19.0 CH3 26.6 CH2 18.9 CH3 1.10 d J = 7.0 Hz 1.10 d J = 6.8 Hz 1", 2", 3" 2" - 
5" - 11.9 CH3 - - - - - - 
 
 
 
 
 
 
 
 
 
 
67 
 
3.4.4 Structural elucidation of compounds RH.4 and 5: xylorumphiins M and N 
A mixture contained RH.4 and 5 which were isolated as a colourless solid from the methanol 
extract of the heartwood of X. rumphii and were identified as the new C-23 epimeric 
tetranortriterpenoids xylorumphiins M and N. 
 
 
 
 
 
 
 
Figure 3.43 Structures of compounds RH.4 and 5 
Compounds RH.4 and 5 were found to be positional isomers with acyl groups at C-3 and C-30 
being interchangeable.  The presence of a hemiacetal group in compounds RH.4 and 5 which 
opens and closes in solution made them impossible to purify.  The mixtures of RH.4 and 5 
gave cluttered spectra [Spectrum 3.8.1 – 3.8.7].  Acetylation enabled separation of the two 
isomers and their R and S forms.  Column chromatographic separation of the acetylated 
fraction of mixtures RH.4 and 5 led to the isolation of four acetylated derivatives of 
compound RH.4 (compounds RH.4a-d) and two acetylated derivatives of compound RH.5 
(compounds RH.5a and 5b). 
  
 
RH.4a : R1 = CH3, R2 = H, R3 = OAc (S), R4 = H 
RH.4b : R1 = CH3, R2 = H, R3 = OAc (R), R4 = H 
RH.4c : R1 = CH3, R2 = H, R3 = OAc (S), R4 = Ac 
RH.4d : R1 = CH3, R2 = H, R3 = OAc (R), R4 = Ac 
 
RH.5a : R1 = H, R2 = CH3, R3 = OAc (S), R4 = H 
RH.5b : R1 = H, R2 = CH3, R3 = OAc (R), R4 = H 
 
Figure 3.44 Structures of acetylated derivatives of RH.4 and 5 
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Table 3.8 
13
C NMR (125 MHz) assignments for compounds RH.4a-d and RH.5a-b in CDCl3 
No. δC RH.4a δC RH.4b δC RH.4c δC RH.4d δC RH.5a δC RH.5b 
1 107.7 C 107.7 C 108.6 C 108.6 C 107.7 C 107.7 C 
2 53.4 CH 53.4 CH 47.9 CH 47.9 CH 53.3 CH 53.3 CH 
3 73.6 CH 73.7 CH 72.7 CH 72.7 CH 73.9 CH 73.9 CH 
4 38.0 C 38.0 C 37.8 C 37.8 C 38.0 C 38.0 C 
5 40.8 CH 40.8 CH 40.6 CH 40.5 CH 40.9 CH 40.8 CH 
6 32.5 CH2 32.5 CH2 32.4 CH2 32.4 CH2 32.5 CH2 32.5 CH2 
7 173.7 C 173.7 C 173.5 C 173.5 C 173.7 C 173.7 C 
8 81.6 C 81.5 C 82.7 C 82.7 C 81.5 C 81.4 C 
9 51.5 CH 51.5 CH 50.5 CH 50.4 CH 51.5 CH 51.4 CH 
10 43.1 C 43.1 C 45.2 C 45.2 C 43.1 C 43.1 C 
11 15.3 CH2 15.3 CH2 15.1 CH2 15.1 CH2 15.3 CH2 15.2 CH2 
12 25.1 CH2 25.1 CH2 25.1 CH2 25.1 CH2 25.1 CH2 25.1 CH2 
13 39.2 C 39.3 C 39.3 C 39.3 C 39.2 C 39.3 C 
14 159.6 C 159.6 C 158.6 C 158.6 C 159.8 C 159.8 C 
15 117.4 CH 117.5 CH 118.0 CH 118.0 CH 117.4 CH 117.4 CH 
16 162.5 C 162.6 C 162.2 C 162.3 C 162.7 C 162.7 C 
17 78.9 CH 79.2 CH 78.8 CH 79.1 CH 78.9 CH 79.2 CH 
18 19.9 CH3 19.9 CH3 19.9 CH3 19.9 CH3 19.9 CH3 19.9 CH3 
19 20.7 CH3 20.7 CH3 21.2 CH3 21.2 CH3 20.7 CH3 20.7 CH3 
20 134.2 C 134.2 C 134.2 C 134.2 C 134.1 C 134.1 C 
21 168.0 C 168.4 C 168.0 C 168.5 C 168.0 C 168.4 C 
22 147.8 CH 148.3 CH 147.8 CH 148.4 CH 147.8 CH 148.4 CH 
23 92.3 CH 93.0 CH 92.3 CH 93.0 CH 92.3 CH 93.0 CH 
28 24.8 CH3 24.8 CH3 24.4 CH3 24.4 CH3 24.8 CH3 24.8 CH3 
29 22.1 CH3 22.1 CH3 21.8 CH3 21.8 CH3 22.2 CH3 22.2 CH3 
30 76.5 CH 76.5 CH 76.0 CH 76.0 CH 76.5 CH 76.5 CH 
7-OMe 52.2 CH3 52.2 CH3 52.2 CH3 52.2 CH3 52.2 CH3 52.2 CH3 
1-OAc 
- - 167.5 C 167.6 C - - 
- - 22.3 CH3 22.3 CH3 - - 
23-OAc 
168.8 C 169.1 C 168.8 C 169.2 C 168.8 C 169.2 C 
20.9 CH3 20.8 CH3 20.8 CH3 20.8 CH3 20.8 CH3 20.8 CH3 
3-acyl       
1' 176.1 C 176.0 C 175.7 C 175.8 C 176.3 C 176.3 C 
2' 41.1 CH 41.1 CH 41.1 CH 41.0 CH 34.2 CH 34.2 CH 
3' 16.6 CH3 16.6 CH3 16.7 CH3 16.7 CH3 19.1 CH3 19.1 CH3 
4' 26.3 CH2 26.3 CH2 26.3 CH2 26.2 CH2 19.0 CH3 19.0 CH3 
5' 11.7 CH3 11.7 CH3 11.6 CH3 11.6 CH3 - - 
30-acyl       
1" 176.2 C 176.4 C 176.5 C 176.2 C 176.2 C 176.3 C 
2" 34.2 CH 34.2 CH 34.1 CH 34.2 CH 41.1 CH 41.2 CH 
3" 19.1 CH3 19.1 CH3 19.1 CH3 19.1 CH3 16.6 CH3 16.6 CH3 
4" 19.0 CH3 19.0 CH3 19.1 CH3 18.9 CH3 26.3 CH2 26.3 CH2 
5" - - - - 11.6 CH3 11.7 CH3 
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Table 3.9 
1
H NMR (500 MHz) assignments for compounds RH.4a-d and RH.5a-b in CDCl3 
No. δH RH.4a δH RH.4b δH RH.4c δH RH.4d δH RH.5a δH RH.5b 
2 
2.90 dd J = 9.2, 4.2 
Hz 
2.90 dd J = 9.2, 4.2 
Hz 
4.07 dd J = 9.2, 4.4 
Hz 
4.06 dd J = 9.0, 4.5 
Hz ** 
2.91 dd J = 9.2, 4.2  
Hz 
2.90 dd J = 9.2, 4.2 
Hz 
3 5.12 d J = 9.2 Hz 5.11 d J = 9.2 Hz 5.08 d J = 9.2 Hz 5.09** 5.12 d J = 9.2 Hz 5.12 d J = 9.2 Hz 
5 
2.59 dd J = 10.3, 2.0 
Hz 
2.59 dd J = 10.3, 1.5 
Hz 
2.60 m 2.60 m 
2.58 dd J = 10.1, 1.6 
Hz 
2.58 dd J = 10.0, 1.7 
Hz 
6 2.35 m, 2.15 m 2.35 m, 2.13 m 2.33 m, 2.15 m 2.33 m, 2.14 m 2.34 m, 2.15 m 2.34 m, 2.14 m 
9 2.12 m 2.11 m 2.10 m 2.10 m 2.12 m 2.10 m 
11 2.39 m, 1.85 m 2.39 m, 1.82 m 2.38 m, 1.86 m 2.38 m, 1.84 m 2.39 m, 1.84 m 2.38 m, 1.83 m 
12 2.50 m, 1.36 m 
2.48 m, 1.33 dd 
J = 13.9, 8.5 Hz 
2.51m, 1.37 m 2.51 m, 1.34 m 2.46 m, 1.35 m 2.47 m, 1.32 m 
15 5.98 s 5.98 s 6.07 s 6.07 s** 5.98** 5.97 s 
17 5.04 s 5.06 s 5.03 s 5.06* 5.03** 5.06 s 
18 1.27 s 1.24 s 1.27 s 1.25 s 1.27 s 1.24 s 
19 1.06 s 1.06 s 1.06 s 1.06 s 1.06 s 1.06 s 
22 7.40 s 7.42 s 
7.39 br s W1/2 = 3.8 
Hz 
7.42 t J = 1.0 Hz 7.39 br s W1/2 = 3.8 Hz 7.42 s 
23 6.93 s 7.04 s 
6.93 br s W1/2 = 4.4 
Hz 
7.04 d J = 1.0 Hz 6.93 br s W1/2 = 4.5 Hz 7.03 s 
28 0.78 s 0.77 s 0.76 s 0.77 s 0.77 s 0.77 s 
29 1.23 s 1.23 s 1.12 s 1.12 s 1.24 s 1.23 s 
30 5.52 d J = 4.2 Hz 5.51 d J = 4.2 Hz 5.55 d J = 4.4 Hz 5.56 d J = 4.5 Hz ** 5.51 d J = 4.2 Hz 5.50 d J = 4.2 Hz 
1-OH 3.58** 3.59 s - - 4.30 s 4.28 s 
7-OMe 3.69 s 3.69 s 3.69 s 3.69 s 3.69 s 3.69 s 
1-OAc 
- - - - - - 
- - 2.14 s 2.15 s - - 
23-OAc 
- - - - - - 
2.17 s 2.16 s 2.17 s 2.16 s 2.17 s 2.15 s 
3-acyl       
1' - - - - - - 
2' 2.29 m 2.29 m 2.28 m 2.27 m 2.46 m 2.47 m 
3' 1.12 d J = 7.1 Hz 1.12 d J = 7.0 Hz 1.09* 1.13* 1.09 d J = 7.0 Hz 1.08 d J = 6.9 Hz 
4' 1.63 m, 1.38 m 1.63 m, 1.38 m 1.60 m, 1.36 m 1.63 m, 1.41 m 1.06 d J = 6.9 Hz 1.08 d J = 6.9 Hz 
5' 0.87 t J = 7.5 Hz 0.87 t J = 7.4 Hz 0.85* 0.87** - - 
30-acyl       
1" - - - - - - 
2" 2.43 m 2.46 m 2.46 m 2.47 m 2.30 m 2.29 m 
3" 1.09 d J = 7.1 Hz 1.10 d J = 6.9 Hz 1.14* 1.15** 1.12 d J = 7.1 Hz 1.12 d J = 7.1 Hz 
4" 1.07 d J = 7.0 Hz 1.07* 1.06* 1.06** 1.62 m, 1.37 m 1.62 m, 1.38 m 
5" - - - - 0.86 t J = 7.4 Hz 0.87 t J = 7.4 Hz 
*Refer to overlapped proton resonances 
**Superimposed with impurity 
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Mono acetylated compounds RH.4a and 4b were C-23 epimers whereas compounds RH.4c 
and 4d were further acetylated derivatives of compounds RH.4a and 4b respectively.  
Compound RH.5a and 5b were also acetylated C-23 epimers.  The configuration at C-23 for 
compounds RH.4a-5b could not be solved by conventional NMR methods (
3
JHH and NOE or 
NOESY) due to the r
-6
 dependence of this effect and the distance of the chiral center at C-23 
from the C-18 methyl group. Professor Roberto R. Gil, our collaboration at the Department 
of Chemistry, Carnegie Mellon University, Pittsburgh, USA, used Residual Dipolar 
Couplings (RDCs) to solve the problem.  One-bond proton-carbon coupling constants (
1
JCH) 
and total proton-carbon splitting in anisotropic conditions (
1
TCH) were extracted from F1 
1
H-
coupled J-Scaled HSQC spectra.
140
  Anisotropic conditions were obtained using cross-linked 
poly(methyl methacrylate) (PMMA) gels swollen in CDCl3 using the reversible 
compression/relaxation method previously described.
141,142 
 The structures of the two epimers 
at C-23 (RH.5a and RH.5b) were generated and minimized with the hybrid functional 
B3LYP and 6-31G as the basis set. Singular value decomposition (SVD) fitting of the RDC 
data of compounds RH.5a and RH.5b to the above computer generated structures was 
performed using MSpin.
143
  As a result, the configuration at C-23 was determined as S for 
compound RH.5a and R for compound RH.5b.  In consequence, it is now possible to state 
that all of the other compounds with H-23 resonating at 6.93 ppm have an S configuration 
(compounds RH.4a and RH.4c), while the compounds with H-23 resonating at 7.04 ppm 
have an R configuration (compounds RH.4b and RH.4d).  
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3.4.4.1 Structural elucidation of compound RH.4a: 23S-O-acetylxylorumphiin M 
 
 
 
 
 
 
 
Figure 3.45 Structure of compound RH.4a 
The HRMS [Spectrum 3.8a.1] gave a [M+Na]
+
 ion at m/z 753.3088, which indicated the 
molecular formula of C38H50O14 for the compound.  A double bond equivalence of fourteen 
was calculated.  The FTIR spectrum [Spectrum 3.8a.2] showed absorption bands at 3416, 
1782 and 1732 cm
-1
 corresponding to the OH stretching, C=O stretching of a 5-membered 
lactone ring and C=O stretching of a saturated ester, respectively. 
The 
13
C NMR [Spectrum 3.8a.4], DEPT [Spectrum 3.8a.5] and HSQCDEPT [Spectrum 
3.8a.6] spectra displayed thirty-eight carbon resonances, which included thirteen quaternary, 
eleven methine, four methylene and ten methyl carbon resonances. 
A comparison of the 
1
H NMR [Spectrum 3.8a.3], 
13
C NMR and DEPT spectra for 
compound RH.3 with those of compound RH.4a indicated that the chemical shifts were the 
same, except for the ring E which was a β-substituted furan ring in compound RH.3 but was 
a substituted 5-membered lactone ring for compound RH 4a. 
The 
1
H NMR spectrum of compound RH.4a showed the characteristic proton resonances of 
protons of a α-substituted 5-membered lactone ring at δ 7.40 (s), 6.93 (s) and 2.17 (s) which 
were assigned as H-22, H-23 and acetate methyl group protons, respectively.  In the HMBC 
spectrum [Spectrum 3.8a.7], the H-22 resonance showed correlations with the acetate 
carbonyl carbon (δ 168.8), C-17 (δ 78.9), C-20 (δ 134.2), C-21 (δ 168.0) and C-23 (δ 92.3) 
carbon resonances.  The H-23 resonance also showed connectivities over 
3
J with resonances at 
δ 168.8 (acetate carbonyl carbon), 168.0 (C-21) and 134.2 (C-20).  The acetate methyl group 
protons resonance showed correlations with the acetate carbonyl carbon (δ 168.8) and C-23 
(δ 92.3).  These HMBC correlations confirmed the assignment of the H-22, H-23 and acetate 
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methyl group protons resonances, indicating that compound RH.4a has the ring E lactone.  
The configuration at C-23 was unambiguously determined as explained on page 69 using 
RDCs measured by Professor Roberto R. Gil in compressed poly(methylmethacrylate) 
(PMMA) which swells in CDCl3.
144
  It was found that the compounds that had H-23 
resonating at δ 6.93 have the C-23 S configuration.  Compound RH.4a was identified as 23S-
O-acetylxylorumphiin M. 
Table 3.10 
1
H and 
13
C NMR assignments for compound RH.4a [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RH.3 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.4a δC RH.3 δH RH.4a δH RH.3 HMBC (H→C) COSY NOESY 
1 107.7 C 107.7 C - - - - - 
2 53.4 CH 53.5 CH 2.90 dd J = 9.2, 4.2 Hz 2.91 dd J = 9.2, 4.3 Hz 1, 3, 4, 10, 30 3, 30 3, 30 
3 73.6 CH 73.9 CH 5.12 d J = 9.2 Hz 5.11 d J = 9.2 Hz 1', 2, 4, 5, 29, 30 2 2, 28, 29 
4 38.0 C 38.0 C - - - - - 
5 40.8 CH 40.8 CH 2.59 dd J = 10.3, 2.0 Hz 2.64 m 4, 6, 7, 9, 10, 19, 29 6a, 6b 28, 30 
6a 
32.5 CH2 32.3 CH2 
2.35 m 2.35 m 4, 5, 7 5, 6b - 
6b 2.15 m 2.17 m 4, 5, 7, 10 5, 6a - 
7 173.7 C 174.0 C - - - - - 
8 81.6 C 81.8 C - - - - - 
9 51.5 CH 51.8 CH 2.12 m 2.14 m 5, 8, 10, 11, 14, 19, 30 11a, 11b 18, 19 
10 43.1 C 43.1 C - - - - - 
11a 
15.3 CH2 15.2 CH2 
2.39 m 2.38 m 13 9, 11b 11b 
11b 1.85 m 1.82 m 8 9, 11a, 12a, 12b 11a 
12a 
25.1 CH2 25.1 CH2 
2.50 m 2.18 m - 11b, 12b 12b 
12b 1.36 m 1.41 m 9, 11, 13, 14, 18 11b, 12a 12a 
13 39.2 C 39.1 C - - - - - 
14 159.6 C 159.8 C - - - - - 
15 117.4 CH 117.9 CH 5.98 s 6.00 s 8, 13, 14, 16 - - 
16 162.5 C 163.8 C - - - - - 
17 78.9 CH 81.4 CH 5.04 s 5.02 s 13, 14, 18, 20, 21, 22 22, 23 - 
18 19.9 CH3 19.9 CH3 1.27 s 1.21 s 12, 13, 14, 17 - 9, 22 
19 20.7 CH3 20.7 CH3 1.06 s 1.06 s 1, 5, 9, 10 - 1-OH, 9 
20 134.2 C 120.2 C - - - - - 
21 168.0 C 141.5 CH - 7.49 s - - - 
22 147.8 CH 110.2 CH 7.40 s 6.43 s 17, 20, 21, 23 17, 23 18, 23 
23 92.3 CH 143.1 CH 6.93 s 7.41 s 20, 21, 23-OAc (C=O) 17, 22 22 
28 24.8 CH3 24.8 CH3 0.78 s 0.78 s 3, 4, 5, 29 - 3, 5, 29 
29 22.1 CH3 22.1 CH3 1.23 s 1.24 s 3, 4, 5, 28 - 3, 28 
30 76.5 CH 76.4 CH 5.52 d J = 4.2 Hz 5.55 d J = 4.3 Hz 1, 1", 2, 3, 8, 9 2 2, 5 
1-OH - - 3.58** 3.90 s 1, 2, 10 - 19 
7-OMe 52.2 CH3 52.1 CH3 3.69 s 3.69 s 7 - - 
23-OAc 
168.8 C - - - - - - 
20.9 CH3 - 2.17 s - 23, 23-OAc (C=O) - - 
3-acyl        
1' 176.1 C 175.9 C - - - - - 
2' 41.1 CH 41.3 CH 2.29 m 2.27 m 1', 3', 4', 5' 3', 4a', 4b' - 
3' 16.6 CH3 16.4 CH3 1.12 d J = 7.1 Hz 1.13 d J = 7.1 Hz 1', 2', 4' 2' - 
4a' 
26.3 CH2 26.4 CH2 
1.63 m 1.64 m 1', 2', 3', 5' 2', 4b', 5' 4b', 5' 
4b' 1.38 m 1.40 m 1', 2', 3', 5' 2', 4a', 5' 4a', 5' 
5' 11.7 CH3 11.7 CH3 0.87 t J = 7.5 Hz 0.89 t J = 7.4 Hz 2', 4' 4a', 4b' 4a', 4b' 
30-acyl        
1" 176.2 C 176.6 C - - - - - 
2" 34.2 CH 34.3 CH 2.43 m 2.45 m  1", 3", 4" 3", 4" - 
3" 19.1 CH3 19.2 CH3 1.09 d J = 7.1 Hz 1.10 d J = 7.0 Hz 1", 2", 4" 2" - 
4" 19.0 CH3 19.0 CH3 1.07 d J = 7.0 Hz 1.10 d J = 7.0 Hz 1", 2", 3" 2" - 
*Refer to overlapped proton resonances 
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3.4.4.2 Structural elucidation of compound RH.4b: 23R-O-acetylxylorumphiin M 
 
 
 
 
 
 
 
Figure 3.46 Structure of compound RH.4b 
The HRMS [Spectrum 3.8b.1] gave a [M+Na]
+
 ion at m/z 753.3088, which indicated the 
molecular formula of C38H50O14 for the compound.  A double bond equivalence of fourteen 
was calculated.  The FTIR spectrum [Spectrum 3.8b.2] showed absorption bands at 3431, 
1776, 1730 and 1640 cm
-1
 corresponding to the OH stretching, C=O stretching of a 5-
membered lactone ring, C=O stretching of a saturated ester and C=O stretching of an α,-
unsaturated ester, respectively. 
The 
13
C NMR [Spectrum 3.8b.4], DEPT [Spectrum 3.8b.5] and HSQCDEPT [Spectrum 
3.8b.6] spectra displayed thirty-eight carbon resonances, which included ten methyl, four 
methylene, eleven methine and thirteen quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound RH.4a with that of compound RH.4b 
indicated that the chemical shifts were the same, except for the C-23 resonance which occurred 
at δ 92.3 in compound RH.4a but at δ 93.0 for compound RH.4b.  The 1H NMR spectrum 
also showed a significant difference for the H-23 resonance where compound RH.4a 
exhibited a resonance at δ 6.93 (s) whereas compound RH.4b exhibited a resonance at δ 7.04 
(s), indicating that the configuration at H-23 in compound RH.4b was different from 
compound RH.4a.  Compound RH.4b was identified as 23R-O-acetylxylorumphiin M. 
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Table 3.11 
1
H and 
13
C NMR assignments for compound RH.4b [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RH.4a [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.4b δC RH.4a δH RH.4b δH RH.4a HMBC (H→C) COSY NOESY 
1 107.7 C 107.7 C - - - - - 
2 53.4 CH 53.4 CH 2.90 dd J = 9.2, 4.2 Hz 2.90 dd J = 9.2, 4.2 Hz 1, 4, 10, 30 3, 30 3 
3 73.7 CH 73.6 CH 5.11 d J = 9.2 Hz 5.12 d J = 9.2 Hz 1', 2, 4, 5, 29, 30 2 2 
4 38.0 C 38.0 C - - - - - 
5 40.8 CH 40.8 CH 2.59 dd J = 10.3, 1.5 Hz 2.59 dd J = 10.3, 2.0 Hz 3, 4, 6, 7, 9, 10, 29 6a, 6b 28, 30 
6a 
32.5 CH2 32.5 CH2 
2.35 m 2.35 m 4, 5, 7 5, 6b - 
6b 2.13 m 2.15 m 4, 5, 7, 10 5, 6a - 
7 173.7 C 173.7 C - - - - - 
8 81.5 C 81.6 C - - - - - 
9 51.5 CH 51.5 CH 2.11 m 2.12 m 5, 8, 10, 11, 19, 30 11a, 11b 18, 19 
10 43.1 C 43.1 C - - - - - 
11a 
15.3 CH2 15.3 CH2 
2.39 m 2.39 m 9, 12, 13 9, 11b - 
11b 1.82 m 1.85 m 8 9, 11a, 12a, 12b - 
12a 
25.1 CH2 25.1 CH2 
2.48 m 2.50 m 18 11b, 12b - 
12b 1.33 dd J = 13.9, 8.5 Hz 1.36 m 9, 13, 14 11b, 12a - 
13 39.3 C 39.2 C - - - - - 
14 159.6 C 159.6 C - - - - - 
15 117.5 CH 117.4 CH 5.98 s 5.98 s 8, 13, 14, 16 - - 
16 162.6 C 162.5 C - - - - - 
17 79.2 CH 78.9 CH 5.06 s 5.04 s 13, 14, 18, 20, 21, 22 22 - 
18 19.9 CH3 19.9 CH3 1.24 s 1.27 s 13, 14, 17 - 9, 22 
19 20.7 CH3 20.7 CH3 1.06 s 1.06 s 1, 5, 9, 10 - 9 
20 134.2 C 134.2 C - - - - - 
21 168.4 C 168.0 C - - - - - 
22 148.3 CH 147.8 CH 7.42 s 7.40 s 17, 20, 21, 23 17, 23 18, 23 
23 93.0 CH 92.3 CH 7.04 s 6.93 s 20, 21, 23-OAc (C=O) 22 22 
28 24.8 CH3 24.8 CH3 0.77 s 0.78 s 3, 4, 5, 29 - 5 
29 22.1 CH3 22.1 CH3 1.23 s 1.23 s 3, 4, 5, 28 - - 
30 76.5 CH 76.5 CH 5.51 d J = 4.2 Hz 5.52 d J = 4.2 Hz 1", 3, 8 2 5 
1-OH - - 3.59 s 3.58** 1, 2, 10 - - 
7-OMe 52.2 CH3 52.2 CH3 3.69 s 3.69 s 7 - - 
23-OAc 
169.1 C 168.8 C - - - - - 
20.8 CH3 20.9 CH3 2.16 s 2.17 s 23, 23-OAc (C=O) - - 
3-acyl        
1' 176.0 C 176.1 C - - - - - 
2' 41.1 CH 41.1 CH 2.29 m 2.29 m 1', 3', 4', 5' 3', 4b' - 
3' 16.6 CH3 16.6 CH3 1.12 d J = 7.0 Hz 1.12 d J = 7.1 Hz 1', 2', 4' 2' - 
4a' 
26.3 CH2 26.3 CH2 
1.63 m 1.63 m 1', 2' 4b', 5' 4b', 5' 
4b' 1.38 m 1.38 m 1', 2' 2', 4a', 5' 4a', 5' 
5' 11.7 CH3 11.7 CH3 0.87 t J = 7.4 Hz 0.87 t J = 7.5 Hz 2', 4' 4a', 4b' 4a', 4b' 
30-acyl        
1" 176.4 C 176.2 C - - - - - 
2" 34.2 CH 34.2 CH 2.46 m 2.43 m 1", 3", 4" 3"', 4"' - 
3" 19.1 CH3 19.1 CH3 1.10 d J = 6.9 Hz 1.09 d J = 7.1 Hz 1", 2", 4" 2"' - 
4" 19.0 CH3 19.0 CH3 1.07** 1.07 d J = 7.0 Hz 1", 2", 3" 2"' - 
*Refer to overlapped proton resonances 
**Superimposed with impurity 
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3.4.4.3 Structural elucidation of compound RH.4c: 1,23S-di-O-acetylxylorumphiin M 
 
 
 
 
 
 
 
 
Figure 3.47 Structure of compound RH.4c 
The HRMS [Spectrum 3.8c.1] gave a [M+Na]
+
 ion at m/z 795.3201, which indicated the 
molecular formula of C40H52O15 for the compound.  A double bond equivalence of fifteen 
was calculated.  The FTIR spectrum [Spectrum 3.8c.2] showed absorption bands at 1774 
and 1735 cm
-1
 corresponding to the C=O stretching of a 5-membered lactone ring and C=O 
stretching of a saturated ester. 
The 
13
C NMR [Spectrum 3.8c.4], DEPT [Spectrum 3.8c.5] and HSQCDEPT [Spectrum 
3.8c.6] spectra displayed forty carbon resonances, which included eleven methyl, four 
methylene, eleven methine and fourteen quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound RH.4a (thirty-eight carbons) with 
that of compound RH.4c (forty carbons) indicated that the chemical shifts were different on 
C-2 and an acetyl group carbon resonances, which occurred at δ 47.9 and no an acetyl group 
carbon resonance in compound RH.4a but at δ 53.4 (C-2), 167.5 (acetate carbonyl carbon) 
and 22.3 (acetate methyl carbon) for compound RH.4c.  The 
1
H NMR spectra also showed 
significant differences for the H-2 resonance and the acetyl group proton resonance whereas 
compound RH.4a exhibited a resonance at δ 2.90 (dd, J = 9.2, 4.2 Hz, H-2) and an acetyl 
group proton resonance was absent whereas compound RH.4c exhibited proton resonances 
at δ 4.07 (dd, J = 9.2, 4.4 Hz, H-2) and 2.14 (s, acetate methyl group protons).  In the HMBC 
spectrum [Spectrum 3.8c.7] of compound RH.4c, the acetate methyl group protons proton 
resonance showed a two bond correlation with δC 167.5 (acetate carbonyl carbon) and 
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connectivity with δC 108.6 (C-1).  These HMBC correlations defined the site of esterification 
at C-1.  Compound RH.4c was identified as 1,23S-di-O-acetylxylorumphiin M. 
Table 3.12 
1
H and 
13
C NMR assignments for compound RH.4c [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RH.4a [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.4c δC RH.4a δH RH.4c δH RH.4a HMBC (H→C) COSY NOESY 
1 108.6 C 107.7 C - - - - - 
2 47.9 CH 53.4 CH 4.07 dd J = 9.2, 4.4 Hz 2.90 dd J = 9.2, 4.2 Hz 1, 3, 4, 10, 30 3, 30 3 
3 72.7 CH 73.6 CH 5.08 d J = 9.2 Hz 5.12 d J = 9.2 Hz 1', 2, 5, 29, 30 2 2, 29 
4 37.8 C 38.0 C - - - - - 
5 40.6 CH 40.8 CH 2.60 m 2.59 dd J = 10.3, 2.0 Hz 3, 4, 6, 7, 9, 10, 19, 29 6a 30 
6a 
32.4 CH2 32.5 CH2 
2.33 m 2.35 m 4, 5, 7, 10 5, 6b - 
6b 2.15 m 2.15 m 4, 5, 7, 10 6a - 
7 173.5 C 173.7 C - - - - - 
8 82.7 C 81.6 C - - - - - 
9 50.5 CH 51.5 CH 2.10 m 2.12 m 5, 8, 10, 11, 19, 30 11a, 11b 18, 19 
10 45.2 C 43.1 C - - - - - 
11a 
15.1 CH2 15.3 CH2 
2.38 m 2.39 m 12, 13 9, 11b - 
11b 1.86 m 1.85 m 8 9, 11a, 12b - 
12a 
25.1 CH2 25.1 CH2 
2.51 m 2.50 m 13, 17 12b - 
12b 1.37 m 1.36 m 9, 14, 18 11b, 12a - 
13 39.3 C 39.2 C - - - - - 
14 158.6 C 159.6 C - - - - - 
15 118.0 CH 117.4 CH 6.07 s 5.98 s 8, 13, 14, 16 - - 
16 162.2 C 162.5 C - - - - - 
17 78.8 CH 78.9 CH 5.03 s 5.04 s 13, 14, 18, 20, 21, 22 - 23 
18 19.9 CH3 19.9 CH3 1.27 s 1.27 s 12, 13, 14, 17 - 9, 22 
19 21.2 CH3 20.7 CH3 1.06 s 1.06 s 1, 5, 9, 10 - 9 
20 134.2 C 134.2 C - - - - - 
21 168.0 C 168.0 C - - - - - 
22 147.8 CH 147.8 CH 7.39 br s W1/2 = 3.8 Hz 7.40 s 17, 20, 21, 23 17, 23 18 
23 92.3 CH 92.3 CH 6.93 br s W1/2 = 4.4 Hz 6.93 s 20, 23-OAc (C=O) 17, 22 17 
28 24.4 CH3 24.8 CH3 0.76 s 0.78 s 3, 4, 5, 29 - 29 
29 21.8 CH3 22.1 CH3 1.12 s 1.23 s 3, 4, 5, 28 - 3, 28 
30 76.0 CH 76.5 CH 5.55 d J = 4.4 Hz 5.52 d J = 4.2 Hz 1", 3, 8 2 5 
7-OMe 52.2 CH3 52.2 CH3 3.69 s 3.69 s 7 - - 
1-OH - - - 3.58** - - - 
1-OAc 
167.5 C - - - - - - 
22.3 CH3 - 2.14 s - 1, 1-OAc (C=O) - - 
23-OAc 
168.8 C 168.8 C - - - - - 
20.8 CH3 20.9 CH3 2.17 s 2.17 s 23, 23-OAc (C=O) - - 
3-acyl        
1' 175.7 C 176.1 C -  - - - 
2' 41.1 CH 41.1 CH 2.28 m 2.29 m 1', 3', 4', 5' 3' - 
3' 16.7 CH3 16.6 CH3 1.09** 1.12 d J = 7.1 Hz 1', 2', 4' 2' - 
4a' 
26.3 CH2 26.3 CH2 
1.60 m 1.63 m 1', 2', 5' 4b', 5' - 
4b' 1.36 m 1.38 m 1', 3', 5' 4a', 5' - 
5' 11.6 CH3 11.7 CH3 0.85** 0.87 t J = 7.5 Hz 2', 4' 4a', 4b' - 
30-acyl        
1" 176.5 C 176.2 C - - - - - 
2" 34.1 CH 34.2 CH 2.46m 2.43 m 1", 3", 4" 3", 4" - 
3" 19.1 CH3 19.1 CH3 1.14* 1.09 d J = 7.1 Hz 1", 2", 4" 2" - 
4" 19.1 CH3 19.0 CH3 1.06* 1.07 d J = 7.0 Hz 1", 2", 3" 2" - 
*Refer to overlapped proton resonances 
**Superimposed with impurity 
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3.4.4.4 Structural elucidation of compound RH.4d: 1,23R-di-O-acetylxylorumphiin M 
 
 
 
 
 
 
 
 
Figure 3.48 Structure of compound RH.4d 
The HRMS [Spectrum 3.8d.1] gave a [M+Na]
+
 ion at m/z 795.3176, which indicated the 
molecular formula of C40H52O15 for the compound.  A double bond equivalence of fifteen 
was calculated.  The FTIR spectrum [Spectrum 3.8d.2] showed absorption bands at 1777 
and 1736 cm
-1
 corresponding to the C=O stretches. 
The 
13
C NMR [Spectrum 3.8d.3], DEPT [Spectrum 3.8d.4] and HSQCDEPT [Spectrum 
3.8d.5] spectra displayed forty carbon resonances, which included eleven methyl, four 
methylene, eleven methine and fourteen quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound RH.4c with that of compound RH.4d 
indicated that the chemical shifts were the same, except for the C-23 resonance which occurred 
at δ 92.3 in compound RH.4c but at δ 93.0 for compound RH.4d.  The 1H NMR spectrum 
also showed a significant difference for the H-23 resonance where in compound RH.4c 
exhibited a resonance at δ 6.93 (br s, W1/2 = 4.4 Hz) whereas compound RH.4d exhibited a 
resonance at δ 7.04 (d, J = 1.0 Hz), indicating that the configuration at H-23 in compound 
RH.4d was different from compound RH.4c.  Compound RH.4d was identified as 1,23R-di-
O-acetylxylorumphiin M. 
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Table 3.13 
1
H and 
13
C NMR assignments for compound RH.4d [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RH.4c [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.4d δC RH.4c δH RH.4d δH RH.4c HMBC (H→C) COSY NOESY 
1 108.6 C 108.6 C - - - - - 
2 47.9 CH 47.9 CH 4.06 dd J = 9.0, 4.5 Hz ** 4.07 dd J = 9.2, 4.4 Hz 1, 3, 4, 10, 30 3, 30 3, 30 
3 72.7 CH 72.7 CH 5.09** 5.08 d J = 9.2 Hz 1', 2, 4, 5, 30 2 2 
4 37.8 C 37.8 C - - - - - 
5 40.5 CH 40.6 CH 2.60* 2.60 m 4, 6, 7, 9, 10, 19 6a, 6b 11a, 28, 30 
6a 
32.4 CH2 32.4 CH2 
2.33* 2.33 m 4, 5, 7 5, 6b - 
6b 2.14* 2.15 m 4, 5, 7, 10 5, 6a - 
7 173.5 C 173.5 C - - - - - 
8 82.7 C 82.7 C - - - - - 
9 50.4 CH 50.5 CH 2.10* 2.10 m 5, 8, 10, 11, 14, 19, 30 11a, 11b 18, 19 
10 45.2 C 45.2 C - - - - - 
11a 
15.1 CH2 15.1 CH2 
2.38* 2.38 m - 9, 11b 5, 11b 
11b 1.84* 1.86 m - 9, 11a, 12a, 12b 11a 
12a 
25.1 CH2 25.1 CH2 
2.51* 2.51 m - 11b, 12b - 
12b 1.34* 1.37 m 9, 13, 14, 18 11b, 12a - 
13 39.3 C 39.3 C - - - - - 
14 158.6 C 158.6 C - - - - - 
15 118.0 CH 118.0 CH 6.07 s** 6.07 s 8, 13, 14, 16 - - 
16 162.3 C 162.2 C - - - - - 
17 79.1 CH 78.8 CH 5.06* 5.03 s 14, 18, 20, 21, 22 22 - 
18 19.9 CH3 19.9 CH3 1.25 s 1.27 s 12, 13, 14, 17 - - 
19 21.2 CH3 21.2 CH3 1.06 s 1.06 s 1, 5, 9, 10 - - 
20 134.2 C 134.2 C - - - - - 
21 168.5 C 168.0 C - - - - - 
22 148.4 CH 147.8 CH 7.42 t J = 1.0 Hz 7.39 br s W1/2 = 3.8 Hz 17, 20, 21, 23 17, 23 23 
23 93.0 CH 92.3 CH 7.04 d J = 1.0 Hz 6.93 br s W1/2 = 4.4 Hz 20, 21, 23-OAc (C=O) 22 22 
28 24.4 CH3 24.4 CH3 0.77 s 0.76 s 3, 4, 5, 29 - - 
29 21.8 CH3 21.8 CH3 1.12 s 1.12 s 3, 4, 5, 28 - - 
30 76.0 CH 76.0 CH 5.56 d J = 4.5 Hz ** 5.55 d J = 4.4 Hz 1, 1", 2, 3, 8 2 2, 5 
1-OAc 
167.6 C 167.5 C - - - - - 
22.3 CH3 22.3 CH3 2.15 s 2.14 s 1, 1-OAc (C=O) - - 
7-OMe 52.2 CH3 52.2 CH3 3.69 s 3.69 s 7 - - 
23-OAc 
169.2 C 168.8 C - - - - - 
20.8 CH3 20.8 CH3 2.16 s 2.17 s 23, 23-OAc (C=O) - - 
3-acyl        
1' 175.8 C 175.7 C - - - - - 
2' 41.0 CH 41.1 CH 2.27* 2.28 m 1', 3', 4', 5' 3', 4a', 4b' - 
3' 16.7 CH3 16.7 CH3 1.13* 1.09** 1', 2', 4' 2' - 
4a' 
26.2 CH2 26.3 CH2 
1.63** 1.60 m 1', 2', 5' 2', 4b', 5' 4b', 5' 
4b' 1.41** 1.36 m 1', 2', 5' 2', 4a', 5' 4a', 5' 
5' 11.6 CH3 11.6 CH3 0.87** 0.85** 2', 4' 4a', 4b' 4a', 4b' 
30-acyl        
1" 176.2 C 176.5 C - - - - - 
2" 34.2 CH 34.1 CH 2.47* 2.46m 1", 3", 4" 3", 4" - 
3" 19.1 CH3 19.1 CH3 1.15** 1.14* - 2" - 
4" 18.9 CH3 19.1 CH3 1.06** 1.06* - 2" - 
*Refer to overlapped proton resonances 
**Superimposed with impurity 
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3.4.4.5 Structural elucidation of compound RH.5a: 23S-O-acetylxylorumphiin N 
 
 
 
 
 
 
Figure 3.49 Structure of compound RH.5a 
The HRMS [Spectrum 3.8e.1] gave a [M+Na]
+
 ion at m/z 753.3080, which indicated the 
molecular formula of C38H50O14 for the compound.  A double bond equivalence of fourteen 
was calculated.  The FTIR spectrum [Spectrum 3.8e.2] showed absorption bands at 3430, 
1781, 1732 and 1641 cm
-1
 corresponding to the OH stretching, C=O stretching of a 5-
membered lactone ring, C=O stretching of a saturated ester and C=O stretching of an α,-
unsaturated ester, respectively. 
The 
13
C NMR [Spectrum 3.8e.4], DEPT [Spectrum 3.8e.5] and HSQCDEPT [Spectrum 
3.8e.6] spectra displayed thirty-eight carbon resonances, which included ten methyl, four 
methylene, eleven methine and thirteen quaternary carbons. 
A comparison of all of the NMR spectra for compound RH.4a with those of compound 
RH.5a indicated that the chemical shifts were the same, except for the HMBC spectrum in 
which the H-3 resonance (δ 5.12, d, J = 9.2 Hz) showed a correlation with the carbon 
resonance at δ 176.1 (C-1') in compound RH.4a but at δ 176.3 (C-1') for compound RH.5a. 
The 
1
H NMR spectrum [Spectrum 3.8e.3] of compound RH.5a showed a methyl group 
proton resonance at δ 1.09 (d, J = 7.0 Hz), which was assigned to 3H-3' in the 3-acyl group 
due to observed correlations in the HMBC spectrum [Spectrum 3.8e.7] with the C-1' (δ 
176.3), C-2' (δ 34.2) and C-4' (δ 19.0).  The COSY spectrum [Spectrum 3.8e.8] showed 
correlations between the H-2' (δ 2.46, m) and 3H-3' (δ 1.09, d, J = 7.0 Hz) and 3H-4' (δ 1.06, 
d, J = 6.9 Hz).  These NMR data confirmed the isobutyryloxy group on C-3. 
The methylene proton resonances at δ 1.62 (m) and 1.37 (m) were assigned to 2H-4" in the 
30-acyl group due to observed correlations in the HMBC spectrum with the C-1" (δ 176.2), 
C-2" (δ 41.1), C-3" (δ 16.6) and C-5" (δ 11.6).  The COSY spectrum showed correlations 
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between the H-2" (δ 2.30, m) and 3H-3" (δ 1.12, d, J = 7.1 Hz) and 2H-4' (δ 1.62, m and δ 1.37, 
m).  These NMR data confirmed the 2-methylbutyryloxy group on C-30. 
The structures of the two epimers at C-23 (RH.5a and RH.5b) were generated and 
minimized with the hybrid functional B3LYP and 6-31G as the basis set by Professor 
Roberto R. Gil.  Singular value decomposition (SVD) fitting of the RDC data of RH.5a and 
RH.5b to the above computer generated structures was performed using MSpin.
143
  As a 
result, the configuration at C-23 was determined as S for RH.5a and R for RH.5b. 
Compound RH.5a was identified as 23S-O-acetylxylorumphiin N. 
Table 3.14 
1
H and 
13
C NMR assignments for compounds RH.5a and RH.4a [
1
H NMR 500 MHz, 
13
C 
NMR 125 MHz, CDCl3, J = Hz] 
No. δC RH.5a δC RH.4a δH RH.5a δH RH.4a HMBC (H→C) HMBC (H→C) COSY NOESY 
1 107.7 C 107.7 C - - - - - - 
2 53.3 CH 53.4 CH 2.91 dd J = 9.2, 4.2 Hz 2.90 dd J = 9.2, 4.2 Hz 1, 4, 10, 30 1, 3, 4, 10, 30 3, 30 3 
3 73.9 CH 73.6 CH 5.12 d J = 9.2 Hz 5.12 d J = 9.2 Hz 1', 2, 4, 5, 29, 30 1', 2, 4, 5, 29, 30 2 2 
4 38.0 C 38.0 C - - - - - - 
5 40.9 CH 40.8 CH 2.58 dd J = 10.1, 1.6 Hz 2.59 dd J = 10.3, 2.0 Hz 3, 4, 6, 7, 9, 10, 29 4, 6, 7, 9, 10, 19, 29 6a, 6b 30 
6a 
32.5 CH2 32.5 CH2 
2.34 m 2.35 m 4, 7 4, 5, 7 5, 6b - 
6b 2.15 m 2.15 m 4, 7, 10 4, 5, 7, 10 5, 6a - 
7 173.7 C 173.7 C - - - - - - 
8 81.5 C 81.6 C - - - - - - 
9 51.5 CH 51.5 CH 2.12 m 2.12 m 5, 8, 11, 14, 19, 30 5, 8, 10, 11, 14, 19, 30 11a, 11b 18, 19 
10 43.1 C 43.1 C - - - - - - 
11a 
15.3 CH2 15.3 CH2 
2.39 m 2.39 m 13 13 9, 11b, 12b - 
11b 1.84 m 1.85 m 8 8 9, 11a, 12a, 12b - 
12a 
25.1 CH2 25.1 CH2 
2.46 m 2.50 m 18 - 11b, 12b - 
12b 1.35 m 1.36 m 9, 13, 14 9, 11, 13, 14, 18 11a, 11b, 12a - 
13 39.2 C 39.2 C - - - - - - 
14 159.8 C 159.6 C - - - - - - 
15 117.4 CH 117.4 CH 5.98** 5.98 s 8, 13, 16, 18 8, 13, 14, 16 - - 
16 162.7 C 162.5 C - - - - - - 
17 78.9 CH 78.9 CH 5.03** 5.04 s 12, 16, 18, 20, 21, 22 13, 14, 18, 20, 21, 22 - - 
18 19.9 CH3 19.9 CH3 1.27 s 1.27 s 12, 13, 14, 17 12, 13, 14, 17 - 9 
19 20.7 CH3 20.7 CH3 1.06 s 1.06 s 1, 5, 9, 10 1, 5, 9, 10 - 9, 29 
20 134.1 C 134.2 C - - - - - - 
21 168.0 C 168.0 C - - - - - - 
22 147.8 CH 147.8 CH 7.39 br s W1/2 = 3.8 Hz 7.40 s 17, 20, 21, 23 17, 20, 21, 23 23 - 
23 92.3 CH 92.3 CH 6.93 br s W1/2 = 4.5 Hz 6.93 s 20, 23-OAc (C=O) 20, 21, 23-OAc (C=O) 22 - 
28 24.8 CH3 24.8 CH3 0.77 s 0.78 s 3, 4, 5, 29 3, 4, 5, 29 - 29 
29 22.2 CH3 22.1 CH3 1.24 s 1.23 s 3, 4, 5, 28 3, 4, 5, 28 - 19, 28 
30 76.5 CH 76.5 CH 5.51 d J = 4.2 Hz 5.52 d J = 4.2 Hz 1", 3, 8 1, 1", 2, 3, 8, 9 2 5 
1-OH - - 4.30 s 3.58** 1, 2, 10 1, 2, 10 - - 
7-OMe 52.2 CH3 52.2 CH3 3.69 s 3.69 s 7 7 - - 
23-OAc 
168.8 C 168.8 C - - - - - - 
20.8 CH3 20.9 CH3 2.17 s 2.17 s 23, 23-OAc (C=O) 23, 23-OAc (C=O) - - 
3-acyl         
1' 176.3 C 176.1 C - - - - - - 
2' 34.2 CH 41.1 CH 2.46 m 2.29 m 1', 3', 4' 1', 3', 4', 5' 3', 4' - 
3' 19.1 CH3 16.6 CH3 1.09 d J = 7.0 Hz 1.12 d J = 7.1 Hz 1', 2', 4' 1', 2', 4' 2' - 
4' 19.0 CH3 26.3 CH2 1.06 d J = 6.9 Hz 1.63 m, 1.38 m 1', 2', 3' 1', 2', 3', 5' 2' - 
5' - 11.7 CH3 - 0.87 t J = 7.5 Hz - 2', 4' - - 
30-acyl         
1" 176.2 C 176.2 C - - - - - - 
2" 41.1 CH 34.2 CH 2.30 m 2.43 m 1", 3", 4", 5" 1", 3", 4" 3", 4a", 4b" - 
3" 16.6 CH3 19.1 CH3 1.12 d J = 7.1 Hz 1.09 d J = 7.1 Hz 1", 2", 4" 1", 2", 4" 2" - 
4a" 
26.3 CH2 19.0 CH3 
1.62 m 
1.07 d J = 7.0 Hz 
1", 2", 3", 5" 1", 2", 3" 2", 4b", 5" 4b", 5" 
4b" 1.37 m 1", 2", 3", 5" - 2", 4a", 5" 4a", 5" 
5" 11.6 CH3 - 0.86 t J = 7.4 Hz - 2", 4" - 4a", 4b" 4a", 4b" 
**Superimposed with impurity 
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3.4.4.6 Structural elucidation of compound RH.5b: 23R-O-acetylxylorumphiin N 
 
 
 
 
 
 
 
Figure 3.50 Structure of compound RH.5b 
The HRMS [Spectrum 3.8f.1] gave a [M+Na]
+
 ion at m/z 753.3095, which indicated the 
molecular formula of C38H50O14 for the compound.  A double bond equivalence of fourteen 
was calculated.  The FTIR spectrum [Spectrum 3.8f.2] showed absorption bands at 3439, 
1779 and 1733 cm
-1
 corresponding to the OH and two C=O stretches. 
The 
13
C NMR [Spectrum 3.8f.3], DEPT [Spectrum 3.8f.4] and HSQCDEPT [Spectrum 
3.8f.5] spectra displayed thirty-eight carbon resonances, which included ten methyl, four 
methylene, eleven methine and thirteen quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound RH.5a with that of compound RH.5b 
indicated that the chemical shifts were the same, except for the C-23 resonance which occurred 
at δ 92.3 in compound RH.5a but at δ 93.0 for compound RH.5b.  The 1H NMR spectrum 
also showed a significant difference for the H-23 resonance where compound RH.5a 
exhibited a resonance at δ 6.93 (br s, W1/2 = 4.5 Hz) whereas compound RH.5b exhibited a 
resonance at δ 7.03 (s), indicating that the configuration at H-23 in compound RH.5b was 
different from compound RH.5a.  Compound RH.5b was identified as 23R-O-
acetylxylorumphiin N. 
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Table 3.15 
1
H and 
13
C NMR assignments for compound RH.5b [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RH.5a [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.5b δC RH.5a δH RH.5b δH RH.5a HMBC (H→C) COSY NOESY 
1 107.7 C 107.7 C - - - - - 
2 53.3 CH 53.3 CH 2.90 dd J = 9.2, 4.2 Hz 2.91 dd J = 9.2, 4.2 Hz 1, 3, 4, 10, 30 3, 30 3, 30 
3 73.9 CH 73.9 CH 5.12 d J = 9.2 Hz 5.12 d J = 9.2 Hz 1', 2, 4, 5, 29, 30 2 2, 30 
4 38.0 C 38.0 C - - - - - 
5 40.8 CH 40.9 CH 2.58 dd J = 10.0, 1.7 Hz 2.58 dd J = 10.1, 1.6 Hz 3, 4, 6, 7, 9, 10, 19, 29 6a, 6b 30 
6a 
32.5 CH2 32.5 CH2 
2.34 m 2.34 m 4, 5, 7 5, 6b - 
6b 2.14 m 2.15 m 4, 5, 7, 10 5, 6a - 
7 173.7 C 173.7 C - - - - - 
8 81.4 C 81.5 C - - - - - 
9 51.4 CH 51.5 CH 2.10 m 2.12 m 5, 8, 10, 11, 19, 30 11a, 11b 18, 19 
10 43.1 C 43.1 C - - - - - 
11a 
15.2 CH2 15.3 CH2 
2.38 m 2.39 m 13 9, 11b - 
11b 1.83 m 1.84 m 8, 9 9, 11a, 12b - 
12a 
25.1 CH2 25.1 CH2 
2.47 m 2.46 m - 12b - 
12b 1.32 m 1.35 m 9, 13, 18 11b, 12a - 
13 39.3 C 39.2 C - - - - - 
14 159.8 C 159.8 C - - - - - 
15 117.4 CH 117.4 CH 5.97 s 5.98** 8, 13, 14, 16 - - 
16 162.7 C 162.7 C - - - - - 
17 79.2 CH 78.9 CH 5.06 s 5.03** 13, 14, 18, 20, 21, 22 22 - 
18 19.9 CH3 19.9 CH3 1.24 s 1.27 s 13, 14, 17 - 9 
19 20.7 CH3 20.7 CH3 1.06 s 1.06 s 1, 5, 9, 10 - 9 
20 134.1 C 134.1 C - - - - - 
21 168.4 C 168.0 C - - - - - 
22 148.4 CH 147.8 CH 7.42 s 7.39 br s W1/2 = 3.8 Hz 17, 20, 21, 23 17, 23 23 
23 93.0 CH 92.3 CH 7.03 s 6.93 br s W1/2 = 4.5 Hz 20, 21, 23-OAc (C=O) 22 22 
28 24.8 CH3 24.8 CH3 0.77 s 0.77 s 3, 4, 5, 29 - 29 
29 22.2 CH3 22.2 CH3 1.23 s 1.24 s 3, 4, 5, 28 - 28 
30 76.5 CH 76.5 CH 5.50 d J = 4.2 Hz 5.51 d J = 4.2 Hz 1, 1", 2, 3, 8, 9 2 2, 3, 5 
1-OH - - 4.28 s 4.30 s 1, 2, 10 - - 
7-OMe 52.2 CH3 52.2 CH3 3.69 s 3.69 s 7 - - 
23-OAc 
169.2 C 168.8 C - - - - - 
20.8 CH3 20.8 CH3 2.15 s 2.17 s 23, 23-OAc (C=O) - - 
3-acyl        
1' 176.3 C 176.3 C - - - - - 
2' 34.2 CH 34.2 CH 2.47 m 2.46 m 1', 3', 4' 3', 4' - 
3' 19.1 CH3 19.1 CH3 1.08 d J = 6.9 Hz 1.09 d J = 7.0 Hz 1', 2', 4' 2' - 
4' 19.0 CH3 19.0 CH3 1.08 d J = 6.9 Hz 1.06 d J = 6.9 Hz 1', 2', 3' 2' - 
30-acyl        
1" 176.3 C 176.2 C - - - - - 
2" 41.2 CH 41.1 CH 2.29 m 2.30 m 1", 3", 4", 5" 3", 4a", 4b" - 
3" 16.6 CH3 16.6 CH3 1.12 d J = 7.1 Hz 1.12 d J = 7.1 Hz 1", 2", 4" 2" - 
4a" 
26.3 CH2 26.3 CH2 
1.62 m 1.62 m 1", 2", 3", 5" 2", 4b", 5" - 
4b" 1.38 m 1.37 m 1", 2", 3", 5" 2", 4a", 5" - 
5" 11.7 CH3 11.6 CH3 0.87 t J = 7.4 Hz 0.86 t J = 7.4 Hz 2", 4" 4a", 4b" - 
**Superimposed with impurity 
 
 
 
 
 
 
 
 
 
83 
 
3.4.5 Structural elucidation of compound RH.6: xylorumphiin O 
Compound RH.6 was isolated as a colourless solid from the methanol extract of the heartwood 
of X. rumphii and was identified as the new C-23 epimeric xylorumphiin O. 
 
 
 
 
 
 
 
Figure 3.51 Structure of compound RH.6 
The HRMS [Spectrum 3.9.1] gave a [M+Na]
+
 ion at m/z 725.3143, which indicated the 
molecular formula of C37H50O13 for the compound.  A double bond equivalence of thirteen 
was calculated.  The FTIR spectrum [Spectrum 3.9.2] showed absorption bands at 3405 and 
1733 cm
-1
 corresponding to the OH and C=O stretches. 
Compound RH.6 gives a cluttered spectrum [Spectrum 3.9.2-3.9.8] because of the presence 
of a hemiacetal group which opens and closes in solution making it impossible to purify.  
Acetylation enabled separation of the R and S forms.  Column chromatographic separation of 
the acetylated fraction of impure RH.6 led to the isolation of one acetylated derivative of RH.6 
(compound RH.6a). 
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3.4.5.1 Structural elucidation of compound RH.6a: 23S-O-acetylxylorumphiin O 
 
 
 
 
 
 
 
Figure 3.52 Structure of compound RH.6a 
The HRMS [Spectrum 3.9a.1] gave a [M+Na]
+
 ion at m/z 767.3250, which indicated the 
molecular formula of C39H52O14 for the compound.  A double bond equivalence of fourteen 
was calculated.  The FTIR spectrum [Spectrum 3.9a.2] showed absorption bands at 3408, 
1782 and 1732 cm
-1
 corresponding to the OH stretching, C=O stretching of a 5-membered 
lactone ring and C=O stretching of a saturated ester, respectively. 
The 
13
C NMR [Spectrum 3.9a.4], DEPT [Spectrum 3.9a.5] and HSQCDEPT [Spectrum 
3.9a.6] spectra displayed thirty-nine carbon resonances, which included thirteen quaternary, 
eleven methine, five methylene and ten methyl carbon resonances. 
A comparison of the 
1
H NMR, 
13
C NMR and DEPT spectra for compound RB.1 with those 
of compound RH.6a indicated that the chemical shifts were the same, except for the ring E 
which was a -substituted furan ring in compound RB.1 but was a substituted of 5-
membered lactone ring for compound RH.6a. 
The 
1
H NMR spectrum [Spectrum 3.9a.3] of compound RH.6a showed the characteristic 
proton resonances of protons of a α-substituted 5-membered lactone ring at δ 7.39 (br s, W1/2 
= 3.3 Hz), 6.93 (br s, W1/2 = 3.3 Hz) and 2.17 (s) which were assigned as H-22, H-23 and 
acetate methyl group protons, respectively.  In the HMBC spectrum [Spectrum 3.9a.7], the 
H-22 resonance showed correlations with the acetate carbonyl carbon (δ 168.8), C-17 (δ 78.9), 
C-20 (δ 134.1), C-21 (δ 168.0) and C-23 (δ 92.3) carbon resonances.  The H-23 resonance 
also showed connectivities over 
3
J with resonances at δ 168.8 (acetate carbonyl carbon), 168.0 
(C-21) and 134.1 (C-20).  The acetate methyl group protons resonance showed correlations 
with the acetate carbonyl carbon (δ 168.8) and C-23 (δ 92.3).  These HMBC correlations 
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confirmed the assignment of the H-22, H-23 and acetate methyl group protons resonances, 
indicating that compound RH.6a has a ring E lactone.   
The structures of the two epimers at C-23 (RH.5a and RH.5b) were generated and 
minimized with the hybrid functional B3LYP and 6-31G as the basis set. Singular value 
decomposition (SVD) fitting of the RDC data of compounds RH.5a and RH.5b to the above 
computer generated structures was performed using MSpin.
143
  As a result, the configuration 
at C-23 was determined as S for compound RH.5a and R for compound RH.5b.  In 
consequence, it is now possible to state that all of the other compounds with H-23 resonating 
at 6.93 ppm have S configurations (compound RH.6a).  Compound RH.6a was identified as 
23S-O-acetylxylorumphiin Q. 
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Table 3.16 
1
H and 
13
C NMR assignments for compound RH.6a [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RB.1 [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.6a δC RB.1 δH RH.6a δH RB.1 HMBC (H→C) COSY NOESY 
1 107.8 C 107.7 C - - - - - 
2 53.4 CH 53.6 CH 2.88 m 2.88 dd J = 9.2, 4.2 Hz 1, 3, 4, 10, 30 3, 30 3, 30 
3 73.8 CH 73.7 CH 5.14 d J = 9.3 Hz 5.13 d J = 9.2 Hz 1', 2, 4, 5, 29, 30 2 2, 29 
4 38.0 C 38.0 C - - - - - 
5 40.8 CH 40.8 CH 2.58 dd J = 10.2, 1.5 Hz 2.63 dd J = 10.2, 1.5 Hz 4, 6, 7, 9, 10, 19, 29 6a, 6b 6a, 6b, 30 
6a 
32.5 CH2 32.3 CH2 
2.34 m 2.35 m 4, 5, 7 5, 6b 5, 6b 
6b 2.14 m 2.15 m 4, 5, 7, 10 5, 6a 5, 6a 
7 173.7 C 174.0 C - - - - - 
8 81.5 C 81.8 C - - - - - 
9 51.5 CH 51.8 CH 2.12 t J = 10.5 Hz 2.15 m 5, 8, 9, 10, 11, 14, 19, 30 11a, 11b 18, 19 
10 43.1 C 43.1 C - - - - - 
11a 
15.3 CH2 15.3 CH2 
2.39 m 2.35 m 9, 10, 12, 13 9, 11b, 12a, 12b - 
11b 1.84 m 1.80 m 8, 9, 12 9, 11a, 12a, 12b - 
12a 
25.1 CH2 25.1 CH2 
2.46 m 2.17 m 11, 13, 17, 18 11a, 11b, 12b - 
12b 1.35 m 1.40 m 9, 11, 13, 14, 17, 18 11a, 11b, 12a - 
13 39.2 C 39.1 C - - - - - 
14 159.8 C 159.7 C - - - - - 
15 117.4 CH 118.0 CH 5.98 s 6.00 s 8, 13, 14, 16, 18, 30 - - 
16 162.7 C 163.7 C - - - - - 
17 78.9 CH 81.4 CH 5.05 s 5.03 s 13, 14, 18, 20, 21, 22 22, 23 - 
18 19.9 CH3 19.9 CH3 1.27 s 1.21 s 12, 13, 14, 17 - 9 
19 20.7 CH3 20.7 CH3 1.06 s 1.06 s 1, 5, 9, 10 - 9 
20 134.1 C 120.2 C - - - - - 
21 168.0 C 141.4 CH - 7.49 dd J = 1.6, 0.6 Hz - - - 
22 147.8 CH 110.2 CH 7.39 br s W1/2 = 3.3 Hz 6.43 dd J = 1.6, 0.6 Hz 17, 20, 21, 23 17, 23 23 
23 92.3 CH 143.1 CH 6.93 br s W1/2 = 3.6 Hz 7.41 t J = 1.6 Hz 20, 21, 23-OAc (C=O) 17, 22 22 
28 24.8 CH3 24.8 CH3 0.77 s 0.77 s 3, 4, 5, 29 - - 
29 22.2 CH3 22.1 CH3 1.24 s 1.24 s 3, 4, 5, 28 - 3 
30 76.5 CH 76.4 CH 5.53 d J = 4.0 Hz  5.57 d J = 4.2 Hz 1, 1", 2, 3, 8, 9 2 2, 5 
1-OH - - 4.19** 3.51 s 1, 2, 10 - - 
7-OMe 52.2 CH3 52.2 CH3 3.69 s 3.69 s 7 - - 
23-OAc 
168.8 C - - - - - - 
20.8 CH3 - 2.17 s - 23, 23-OAc (C=O) - - 
3-acyl        
1' 176.3 C 175.8 C - - - - - 
2' 41.1 CH 41.2 CH 2.29 m 2.27 m 1', 3', 4', 5' 3', 4a', 4b' - 
3' 16.6 CH3 16.4 CH3 1.13 d J = 7.0 Hz 1.13 d J = 7.0 Hz 1', 2', 4' 2' - 
4a' 
26.2 CH2 26.3 CH2 
1.63 m 1.65 m 1', 2', 3', 5' 2', 4b', 5' - 
4b' 1.40 m 1.38 m 1', 2', 3', 5' 2', 4a', 5' - 
5' 11.6 CH3 11.7 CH3 0.87 m 0.89 t J = 7.4 Hz 2', 4' 4a', 4b' - 
30-acyl        
1" 175.9 C 176.2 C - - - - - 
2" 40.9 CH 40.9 CH 2.22 m 2.23 m  1", 3", 4", 5" 3", 4a", 4b" - 
3" 15.8 CH3 15.9 CH3 1.06* 1.05 d J = 6.8 Hz 1", 4" 2" - 
4a" 
26.5 CH2 26.6 CH2 
1.63 m 1.65 m 1", 2", 3", 5" 2", 4b", 5" - 
4b" 1.40 m 1.33 m 2", 3", 5" 2", 4a", 5" - 
5" 11.8 CH3 11.9 CH3 0.87* 0.90 t J = 7.4 Hz 2", 4" 4a", 4b" - 
*Refer to overlapped proton resonances 
**Superimposed with impurity 
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3.4.6 Structural elucidation of compound RH.7: xylorumphiin P 
Compound RH.7 was isolated as a colourless solid from the methanol extract of the heartwood 
of X. rumphii and was identified as the new C-21 epimeric xylorumphiin P. 
 
 
 
 
 
 
 
Figure 3.53 Structure of compound RH.7 
Compound RH.7 gives a cluttered 
1
H NMR
 
spectrum [Spectrum 3.10.1] because of 
structures that have a hemiacetal group which opens and closes in solution making it 
impossible to purify.  Acetylation enabled separation of R and S forms.  Column 
chromatographic separation of the acetylated fraction of impure RH.7 led to the isolation of 
two acetylated derivatives of RH.7 (compound RH.7a and RH.7b). 
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3.4.6.1 Structural elucidation of compound RH.7a: 21S-O-acetylxylorumphiin P 
 
 
 
 
 
 
 
Figure 3.54 Structure of compound RH.7a 
The HRMS [Spectrum 3.10a.1] gave a [M+Na]
+
 ion at m/z 739.2935 (calculated for 
C37H48NaO14 739.2936).  A double bond equivalence of fourteen was calculated.  The FTIR 
spectrum [Spectrum 3.10a.2] showed broad absorption bands at 3430 and 1638 cm
-1
 
corresponding to the OH stretching and C=O stretching of esters. 
The 
13
C NMR [Spectrum 3.10a.4], DEPT [Spectrum 3.10a.5] and HSQCDEPT [Spectrum 
3.10a.6] spectra displayed thirty-seven carbon resonances, which included ten methyl, three 
methylene, eleven methine and thirteen quaternary carbons. 
A comparison of the 
13
C NMR and DEPT spectra for compound RH.2 with those of 
compound RH.7a indicated that the chemical shifts were the same, except for the C-14, C-
15, C-20, C-21, C-22 and C-23 resonances, which occurred at δ 46.7 (CH, C-14), 29.2 (CH2, 
C-15), 121.1 (C, C-20), 141.7 (CH, C-21), 110.2 (CH, C-22), and 143.2 (CH3, C-23) in 
compound RH.2 but at δ 159.3 (C, C-14), 117.6 (CH, C-15), 160.2 (C, C-20), 93.1 (CH, C-
21), 123.9 (CH, C-22) and 168.5 (C, C-23) for compound RH.7a 
The 
1
H NMR spectrum for compound RH.7a [Spectrum 3.10a.3] showed an olefinic proton 
resonance at δ 5.98 (s) was assigned to H-15 due to observed correlations in the HMBC 
spectrum [Spectrum 3.10a.7] with the C-8 (δ 81.4), C-13 (δ 39.4) and C-16 (δ 161.9) carbon 
resonances, indicating that H-15 was an olefinic proton at the α-position of an α,β-
unsaturated ring D lactone. 
The characteristic resonances of protons of a β-substituted 5-membered lactone ring occurred 
at δ 6.97, 6.44 (s) and 2.24 (s) and were assigned as H-21, H-22 and acetate methyl group 
protons, respectively.  In the HMBC spectrum, the H-21 resonance showed correlations with 
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the acetate carbonyl carbon (δ 168.7), C-22 (δ 123.9) and C-23 (δ 168.5).  The H-22 
resonance also showed correlations with carbon resonances at  168.5 (C-23), 93.1 (C-21) 
and 80.0 (C-17).  The acetate methyl group protons resonance showed correlations with the 
acetate carbonyl carbon (δ 168.7) and C-21 (δ 93.1).  These HMBC correlations confirmed 
the assignment of the H-21, H-22 and acetate methyl group protons resonances, indicating 
that compound RH.7a has a ring E lactone. 
The configuration at C-21 of compound RH.7a was determined using a combination of 
selective quantitative NOE interactions and molecular modelling by Professor Roberto R. 
Gil, our collaboration at Department of Chemistry, Carnegie Mellon University, Pittsburgh, 
USA.  A set of selective 
1
D NOE experiments were used to obtain the desired NOE 
interactions.
145-147
  The two possible epimeric structures at C-21 (RH.7a(R), RH.7a(S)) were 
generated in the Macromodel Suite using the MMFF force field, followed by a 
conformational search within an energy threshold of 5 kcal/mol.  A set of 88 structures was 
obtained for structure RH.7a(R) and 157 structures for RH.7a(S).  Redundant conformations 
were further filtered within a threshold of 3 kcal/mol.  Surprisingly, each configuration 
yielded only one preferred conformation, which should show unique NOE interactions for 
each epimer.  These two possible structures were further energy minimized using the 
semiempirical method AM1.  As a consequence of this computational analysis, for the C-21 
R isomer, the distance between H-21 and the methylene protons H-12a,b is ~3.9Å, while for 
the C-21 S isomer is 2.33 Å and 2.65 Å as shown in Figure 3.55.  In both isomers, H-22 is 
close to methyl C-18.  Based on this, the quantitive results of the NOE interaction between 
H-22 and H-12a,b were enough to determine the configuration at C-21 
 
Figure 3.55 Distances from H-21 to H-12 are from AM1 minimization. (for clarity only a 
fragment of the structure is shown) 
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The H-17, H-21 and H-22 proton resonances were selectively excited for the 
1
D NOE 
experiments.  Selective excitation of H-17 [Spectrum 3.10a.10] showed a strong NOE with 
H-12β ( 2.26).  The spectra from the selective excitation of H-22 [Spectrum 3.10a.11] gave 
NOE interaction with H-18 ( 1.30), while the experiment with selective excitation of H-21 
[Spectrum 3.10a.12] gives an NOE interaction with one of the methylene protons at C-12 ( 
1.44), which was identified as H-12α.  This is a key interaction to confirm the C-21S 
configuration of compound RH.7a (See Figure 3.55).  The interaction between H-22 and H-
18 is indicative of the preferred conformation of the lactone moiety, this conformation has 
the carbonyl C-23 pointing to the back, which correlates with the conformational search. 
The distances from the qNOE experiments have been calculated.  Distances were obtained 
from computer generated structures using molecular mechanics (MM) and from quantitative 
1
D selective NOE experiments (qNOE).  qNOE distances were calculated using two 
references: H-2 to H-3 and H-17 to H-12β. (see Table 3.17). 
Table 3.17 Calculated vs Experimental Distances (Å) 
Atoms 
Distances reference: 
H-2 to H-3 
Distances reference: 
H-17 to H-12β 
MM distances 
(C-21 R isomer) 
MM distances 
(C-21 S isomer) 
H-2 to H-3 2.27 2.17 2.27 2.27 
H-17 to H-12β 2.56 2.44 2.50 2.44 
H-17 to H-21 3.20 3.05 2.55 3.01 
H-17 to H-22 3.73 3.55 3.92 3.83 
H-17 to H-15 3.86 3.68 3.77 3.77 
H-21 to H-12α 2.42 2.30 4.12 2.17 
H-21 to H-12β 3.25 3.10 3.98 2.55 
H-21 to H-22 4.19 3.99 3.99 4.04 
Cornilescu quality factors (Q), χ2 and N/χ2 were calculated using references H-2 to H-3 and 
H-17 to H-12β for both diastereomers.  The error was assumed to be of 0.5Å for all 
measurements.  The results for references H-2 to H-3 and H-17 to H-12β are presented in 
Table 3.18 and 3.19, respectively.  Regardless of the distance reference used, we have 
observed a lowest Q factor for C-21 S, confirming the configuration of compound RH.7a.  
Also a low χ2 and a high N/χ2 was obtained.  Compound RH.7a was identified as 21S-O-
acetylxylorumphiin P. 
Table 3.18 Quality factors for both diastereomers using references H-2 to H-3 
 Q χ2 N/χ2 
C-21 R configuration 0.215 15.694 0.510 
C-21 S configuration 0.087 2.583 3.098 
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Table 3.19 Quality factors for both diasteromers using references H-17 to H-12β 
 Q χ2 N/χ2 
C-21 R configuration 0.241 17.857 0.448 
C-21 S configuration 0.074 1.676 4.773 
 
Table 3.20 
1
H and 
13
C NMR assignments for compound RH.7a [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], compound RH.2 [
13
C NMR 125 MHz, CDCl3] and xylorumphiin E 
[
13
C NMR 100 MHz, CDCl3]
9
 
No. δC RH.7a δC RH.2 δC
9 δH RH.7a HMBC (H→C) COSY NOESY 
1 107.6 C 106.8 C 106.7 C - - - - 
2 53.3 CH 57.2 CH 57.1 CH 2.92** 1, 3, 4, 10, 30 3, 30 3, 30 
3 73.8 CH 73.9 CH 73.4 CH 5.05 d J = 9.2 Hz 1', 4, 5, 29, 30 2 2, 29 
4 37.9 C 38.3 C 38.1 C - - - - 
5 40.7 CH 40.8 CH 40.5 CH 2.64 m 4, 6, 7, 9, 10, 19, 29 6a, 6b 6a, 6b, 28, 30 
6a 
32.3 CH2 32.7 CH2 32.5 CH2 
2.38 m 4, 5, 7 5, 6b 5 
6b 2.18 m 4, 5, 7, 10 5, 6a 5 
7 174.0 C 174.2 C 173.9 C - - - - 
8 81.4 C 82.4 C 82.4 C - - - - 
9 51.1 CH 63.5 CH 64.4 CH 2.14 m 5, 8, 10, 14, 19, 30 11a, 11b 18, 19 
10 43.2 C 43.9 C 43.7 C - - - - 
11a 
15.4 CH2 19.8 CH2 19.6 CH2 
2.46 m 13 9, 11b, 12a - 
11b 1.92 m 8, 12 9, 11a, 12a, 12b - 
12β 
24.9 CH2 36.0 CH2 35.9 CH2 
2.26 m 9, 13 11a, 11b, 12b - 
12α 1.44 m 11, 18 11b, 12a 21 
13 39.4 C 36.5 C 36.3 C - - - - 
14 159.3 C 46.7 CH 46.6 CH - - - - 
15 117.6 CH 29.2 CH2 29.0 CH2 5.98 s 8, 13, 16 - - 
16 161.9 C 170.4 C 169.9 C - - - - 
17 80.0 CH 77.3 CH 77.1 CH 4.84 s 13, 14, 18, 20, 22 22 2” 
18 20.7 CH3 22.4 CH3 21.0 CH3 1.30 s 12, 13, 14, 17 - 9 
19 20.8 CH3 21.3 CH3 22.2 CH3 1.08 s 1, 5, 9, 10 - 9 
20 160.2 C 121.1 C 121.0 C - - - - 
21 93.1 CH 141.7 CH 141.5 CH 6.97** 21-OAc (C=O), 22, 23 22 12b 
22 123.9 CH 110.2 CH 110.0 CH 6.44 s 17, 21, 23 17, 21 - 
23 168.5 C 143.2 CH 142.9 CH - - - - 
28 24.9 CH3 24.9 CH3 24.6 CH3 0.80** 3, 4, 5, 29 - 5, 29 
29 22.1 CH3 22.6 CH3 22.1 CH3 1.24 s 3, 4, 5, 28 - 3, 28 
30 76.5 CH 76.0 CH 75.9 CH 5.38 d J = 4.2 Hz 1, 1", 3, 8 2 2, 5 
7-OMe 52.3 CH3 52.0 CH3 51.9 CH3 3.71 s 7 - - 
21-OAc 
168.7 C - - - - - - 
20.6 CH3 - - 2.24 s 21, 21-OAc (C=O) - 17 
3-acyl        
1' 176.2 C 177.7 C 177.0 C - - - - 
2' 34.2 CH 34.2 CH 33.3 CH 2.46 m 1', 4' 3', 4' - 
3' 19.3 CH3 18.5 CH3 18.3 CH3 1.15 d J = 7.1 Hz 1', 2', 4' 2' - 
4' 19.1 CH3 20.2 CH3 20.0 CH3 1.09 d J = 6.9 Hz 1', 2', 3' 2' - 
30-acyl        
1" 176.9 C 175.2 C 174.9 C - - - - 
2" 34.2 CH 33.5 CH 33.9 CH 2.42 m 1", 3", 4" 3", 4" - 
3" 19.0 CH3 17.7 CH3 17.5 CH3 1.07** 1", 2", 4" 2" - 
4" 19.1 CH3 19.3 CH3 19.1 CH3 1.05 d J = 7.1 Hz 1", 2", 3" 2" - 
*Refer to overlapped proton resonances 
**Superimposed with impurity 
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3.4.6.2 Structural elucidation of compound RH.7b: 1,21S-di-O-acetylxylorumphiin P 
 
 
 
 
 
 
 
Figure 3.56 Structure of compound RH.7b 
The FTIR spectrum [Spectrum 3.10b.2] showed absorption bands at 1800, 1773 and 1735 
cm
-1
 corresponding to the C=O stretches.  Insufficient sample left for MS. 
Compound RH.7b was isolated in small quantities (less than 1 mg) but gave a good 
1
H NMR 
spectrum [Spectrum 3.10b.1] that was found to be related to the previously identified 
compounds RH.7 and RH.7a. 
A long 
13
C NMR experiment (35,000 scans) [Spectrum 3.10b.2] did not show all of 
resonances but the DEPT spectrum (22,000 scans) [Spectrum 3.10b.3] showed all possible 
methyl, methylene and methine carbon resonances.  2D NMR experiments (HSQCDEPT, 
HMBC, COSY and NOESY) were also interpretable.  
The DEPT and HSQCDEPT [Spectrum 3.10b.4] spectra displayed twenty-five carbon 
resonances, which included eleven methyl, three methylene and eleven methine carbons.  A 
comparison of the 
1
H NMR spectrum for compound RH.7a with that of compound RH.7b 
indicated that the chemical shifts were different for H-2 and acetate methyl group proton at 
C-1, which occurred at δ 2.92 (superimposed with impurity) in compound RH.7a but at δ 
4.11 (dd, J = 9.2, 4.2 Hz, H-2) for compound RH.7b and no acetate methyl group proton at 
C-1 resonance in compound RH.7a but at δ 2.15 (s, 1-OAc) for compound RH.7b, indicating 
that compound RH.7b has an acetoxy group at C-1.  Compound RH.7b was identified as 
1,21S-di-O-acetylxylorumphiin P. 
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Table 3.21 
1
H and 
13
C NMR assignments for compound RH.7b [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RH.7a [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.7b* δC RH.7a δH RH.7b δH RH.7a HMBC (H→C) COSY NOESY 
1 108.4 C 107.6 C - - - - - 
2 47.8 CH 53.3 CH 4.11 dd J = 9.2, 4.2 Hz 2.92** - 3, 30 3, 30 
3 72.9 CH 73.8 CH 5.04 d J = 9.2 Hz 5.05 d J = 9.2 Hz - 2 2, 29 
4 37.7 C 37.9 C - - - - - 
5 40.4 CH 40.7 CH 2.63 m 2.64 m - 6a 6a, 6b, 30 
6a 
32.2 CH2 32.3 CH2 
2.37 m 2.38 m - 5, 6b 5, 6b 
6b 2.19 m 2.18 m - 6a 5, 6a 
7 173.5 C 174.0 C - - - - - 
8 82.4 C 81.4 C - - - - - 
9 50.1 CH 51.1 CH 2.08 m 2.14 m - 11b 18, 19 
10 45.3 C 43.2 C - - - - - 
11a 
15.2 CH2 15.4 CH2 
2.46 m 2.46 m - 11b, 12a 11b 
11b 1.94 m 1.92 m - 9, 11a 11a 
12a 
24.9 CH2 24.9 CH2 
2.28 m 2.26 m - 11a, 12b 12b 
12b 1.45 m 1.44 m - 12a 12a, 21 
13 39.5 C 39.4 C - - - - - 
14 158.1 C 159.3 C - - - - - 
15 118.1 CH 117.6 CH 6.07 s 5.98 s 8, 16 - - 
16 161.6 C 161.9 C - - - - - 
17 79.9 CH 80.0 CH 4.83 s 4.84 s 16, 18 - 21 
18 20.7 CH3 20.7 CH3 1.30 s 1.30 s 12, 13, 14, 17 - 9 
19 21.4 CH3 20.8 CH3 1.08 s 1.08 s 1, 5, 9, 10 - 9 
20 160.2 C 160.2 C - - - - - 
21 93.1 CH 93.1 CH 6.97 s 6.97** 21-OAc (C=O), 23 - 12b, 17 
22 124.0 CH 123.9 CH 6.45 s 6.44 s 23 - - 
23 168.5 C 168.5 C - - - - - 
28 24.5 CH3 24.9 CH3 0.79 s 0.80** 3, 4, 5, 29 - 29 
29 21.8 CH3 22.1 CH3 1.12 s 1.24 s 3, 4, 5, 28 - 3, 28 
30 76.1 CH 76.5 CH 5.42 d J = 4.2 Hz 5.38 d J = 4.2 Hz - 2 2, 5 
1-OAc 
167.3 C - - - - - - 
22.3 CH3 - 2.15 s - 1-OAc (C=O) - - 
7-OMe 52.3 CH3 52.3 CH3 3.71 s 3.71 s 7 - - 
21-OAc 
168.7 C 168.7 C - - - - - 
20.6 CH3 20.6 CH3 2.24 s 2.24 s 21-OAc (C=O) - - 
3-acyl        
1' 175.6 C 176.2 C - - - - - 
2' 34.1 CH 34.2 CH 2.46 m 2.46 m - 3', 4' - 
3' 19.3 CH3 19.3 CH3 1.13** 1.15 d J = 7.1 Hz 1', 2' 2' - 
4' 19.1 CH3 19.1 CH3 1.10** 1.09 d J = 6.9 Hz 1', 2' 2' - 
30-acyl        
1" 176.8 C 176.9 C - - - - - 
2" 34.1 CH 34.2 CH 2.46 m 2.42 m - 3", 4" - 
3" 19.0 CH3 19.0 CH3 1.07** 1.07** 1", 2" 2" - 
4" 19.1 CH3 19.1 CH3 1.05** 1.05 d J = 7.1 Hz 1", 2" 2" - 
*The 
13
C NMR chemical shift are assigned from 
13
C NMR, DEPT, HSQCDEPT, HMBC and comparative 
analysis to these of compound RH 9a 
**Superimposed with impurity 
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3.4.7 Structural elucidation of compound RH.8: xylorumphiin Q 
Compound RH.8 was isolated as a colourless solid from the methanol extract of the heartwood 
of X. rumphii and was identified as the new C-21 epimeric xylorumphiin Q. 
 
 
 
 
 
 
 
Figure 3.57 Structure of compound RH.8 
The HRMS [Spectrum 3.11.1] gave a [M+Na]
+
 ion at m/z 711.2985, which indicated the 
molecular formula of C36H48O13 for the compound.  A double bond equivalence of thirteen 
was calculated.  The FTIR spectrum [Spectrum 3.11.2] showed absorption bands at 3410, 
1763 and 1731 cm
-1
 corresponding to the OH stretching, C=O stretching of a 5-membered 
lactone ring and C=O stretching of a saturated ester, respectively. 
Compound RH.8 gave cluttered spectra [Spectrum 3.11.3-3.11.9] because structures that 
have a hemiacetal group which opens and closes in solution are impossible to purify.  
Acetylation enabled separation of R and S forms.  Column chromatographic separation of the 
acetylated fraction of impure RH.8 led to the isolation of one acetylated derivative of RH.8 
(compound RH.8a). 
 
 
 
 
 
 
 
95 
 
3.4.6.1 Structural elucidation of compound RH.8a: 21S-acetoxyxylorumphiin Q 
 
 
 
 
 
 
Figure 3.58 Structure of compound RH.8a 
The HRMS [Spectrum 3.11a.1] gave a [M+Na]
+
 ion at m/z 753.3086, which indicated the 
molecular formula of C38H50O14 for the compound.  A double bond equivalence of fourteen 
was calculated.  The FTIR spectrum [Spectrum 3.11a.2] showed absorption bands at 3389, 
1790, 1728 and 1645 cm
-1
 corresponding to the OH stretching, C=O stretching of a 5-
membered lactone ring, C=O stretching of a saturated ester and C=O stretching of an α,-
unsaturated ester, respectively. 
The 
13
C NMR [Spectrum 3.11a.4], DEPT [Spectrum 3.11a.5] and HSQCDEPT [Spectrum 
3.11a.6] spectra displayed thirty-eight carbon resonances, which included ten methyl, four 
methylene, eleven methine and thirteen quaternary carbons. 
A comparison of the 
13
C NMR spectrum for compound RH.4a with that of compound RH.8a 
indicated that the chemical shifts were the same, except for the C-20, C-21, C-22 and C-23 
resonances which occurred at δ 134.2, 168.0, 147.8 and 92.3 in compound RH.4a but at δ 
160.2, 93.1, 123.9 and 168.5 for compound RH.8a.  The 
1
H NMR spectrum also showed a 
significant difference for the H-21, H-22 and H-23 resonances where compound RH.4a 
exhibited resonances at δ 7.40 (s, H-22) and 6.93 (s, H-23) and no H-21 whereas compound 
RH.8a exhibited resonances at δ 6.97 (s, H-21) and 6.44 (s, H-22) and no H-23, indicating 
that compound RH.8a is different from compound RH.4a on the ring E lactone. 
An olefinic proton resonance at δ 7.40 (s, H-22) in compound RH.4a was assigned to the 
proton on the -position of an α,-unsaturated ring E lactone but the olefinic proton 
resonance at δ 6.44 (s, H-22) for compound RH.8a was assigned to the proton on the α-
position of an α,-unsaturated ring E lactone. 
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An oxymethine proton resonance at 4.86 (s) of compound RH.8a was assigned to H-17 due 
to observed correlations in the HMBC spectrum [Spectrum 3.10a.7] with the C-13 (δ 39.4), 
C-14 (δ 159.4), C-18 (δ 20.7), C-20 (δ 160.2), C-21 (δ 93.1) and C-22 (δ 123.9) carbon 
resonances.  These HMBC correlations confirmed the assignment of the dioxymethine H-21 
(hemiacetal proton) resonance.  A comparison of the 
13
C NMR spectrum for compound 
RH.7a with that of compound RH.8a indicated that the chemical shifts of C-20, C-21, C-22 
and C-23 were the same, indicating the same ring E lactone.  Compound RH.8a was identified 
as 21S-O-acetylxylorumphiin Q.  
Table 3.22 
1
H and 
13
C NMR assignments for compound RH.8a [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz], compound RH.4a [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] and compound RH.7a [
13
C NMR 125 MHz, CDCl3] 
No. δC RH.8a δC RH.4a δC RH.7a δH RH.8a δH RH.4a HMBC (H→C) COSY NOESY 
1 107.6 C 107.7 C 107.6 C - - - - - 
2 53.3 CH 53.4 CH 53.3 CH 2.90 dd J = 9.2, 4.1 Hz 2.90 dd J = 9.2, 4.2 Hz 1, 3, 4, 10, 30 3, 30 3, 30 
3 73.7 CH 73.6 CH 73.8 CH 5.10 d J = 9.2 Hz 5.12 d J = 9.2 Hz 1', 2, 4, 5, 29, 30 2 2, 29 
4 38.0 C 38.0 C 37.9 C - - - - - 
5 40.7 CH 40.8 CH 40.7 CH 2.61 m 2.59 dd J = 10.3, 2.0 Hz 4, 6, 7, 9, 10, 19, 29 6a 28, 30 
6a 
32.3 CH2 32.5 CH2 32.3 CH2 
2.37 m 2.35 m 4, 5, 7 5 - 
6b 2.17 m 2.15 m 4, 5, 7, 10 6a - 
7 174.0 C 173.7 C 174.0 C - - - - - 
8 81.4 C 81.6 C 81.4 C - - - - - 
9 51.1 CH 51.5 CH 51.1 CH 2.09 m 2.12 m 5, 8, 10, 14, 19, 30 11a, 11b 18, 19 
10 43.2 C 43.1 C 43.2 C - - - - - 
11a 
15.4 CH2 15.3 CH2 15.4 CH2 
2.44 m 2.39 m - 9, 11b - 
11b 1.93 m 1.85 m - 9, 11a, 12b - 
12a 
24.8 CH2 25.1 CH2 24.9 CH2 
2.25 m 2.50 m - 12b 12b 
12b 1.44 m 1.36 m 9, 14, 18 11b, 12a 12a, 21 
13 39.4 C 39.2 C 39.4 C - - - - - 
14 159.4 C 159.6 C 159.3 C - - - - - 
15 117.6 CH 117.4 CH 117.6 CH 5.98 s 5.98 s 8, 13, 14, 16, 18 - - 
16 161.9 C 162.5 C 161.9 C - - - - - 
17 80.0 CH 78.9 CH 80.0 CH 4.86 s 5.04 s 13, 14, 18, 20, 21, 22 22 2" 
18 20.7 CH3 19.9 CH3 20.7 CH3 1.30 s 1.27 s 12, 13, 14, 17 - 9 
19 20.8 CH3 20.7 CH3 20.8 CH3 1.07 s 1.06 s 1, 5, 9, 10 - 9 
20 160.2 C 134.2 C 160.2 C - - - - - 
21 93.1 CH 168.0 C 93.1 CH 6.97 s - 20, 21-OAc (C=O), 22, 23 22 12b 
22 123.9 CH 147.8 CH 123.9 CH 6.44 s 7.40 s 17, 20, 21, 23 17, 21 - 
23 168.5 C 92.3 CH 168.5 C - 6.93 s - - - 
28 24.9 CH3 24.8 CH3 24.9 CH3 0.79** 0.78 s 3, 4, 5, 29 - 5 
29 22.1 CH3 22.1 CH3 22.1 CH3 1.24 s 1.23 s 3, 4, 5, 28 - 3 
30 76.6 CH 76.5 CH 76.5 CH 5.39 d J = 4.1 Hz 5.52 d J = 4.2 Hz 1, 1", 3, 8 2 2, 5 
1-OH - - - 3.56 s 3.58** 1, 2, 10 - - 
7-OMe 52.3 CH3 52.2 CH3 52.3 CH3 3.71 s 3.69 s 7 - - 
21-OAc 
168.7 C 168.8 C 168.7 C - - - - - 
20.6 CH3 20.9 CH3 20.6 CH3 2.24 s 2.17 s 21, 21-OAc (C=O) - 17 
3-acyl         
1' 175.9 C 176.1 C 176.2 C - - - - - 
2' 41.2 CH 41.1 CH 34.2 CH 2.28 m 2.29 m 1', 3', 4', 5' 3', 4a', 4b' - 
3' 16.3 CH3 16.6 CH3 19.3 CH3 1.11 d J = 7.0 Hz 1.12 d J = 7.1 Hz 1', 2', 4' 2' - 
4a' 
26.5 CH2 26.3 CH2 19.1 CH3 
1.61 m 1.63 m 1', 2', 3', 5' 2', 4b', 5' - 
4b' 1.38 m 1.38 m 1', 2', 3', 5' 2', 4a', 5' - 
5' 11.8 CH3 11.7 CH3 - 0.88 t J = 7.4 Hz 0.87 t J = 7.5 Hz 2', 4' 4a', 4b' - 
30-acyl         
1" 176.8 C 176.2 C 176.9 C - - - - - 
2" 34.2 CH 34.2 CH 34.2 CH 2.42 m 2.43 m 1", 3", 4" 3", 4" - 
3" 19.1 CH3 19.1 CH3 19.0 CH3 1.08** 1.09 d J = 7.1 Hz 1", 2", 4" 2" - 
4" 19.1 CH3 19.0 CH3 19.1 CH3 1.05 d J = 7.2 Hz 1.07 d J = 7.0 Hz 1", 2", 3" 2" - 
**Superimposed with impurity 
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3.4.8 Structural elucidation of compound RH.9: xylorumphiin R 
Compound RH.9 was isolated as a colourless solid from the methanol extract of the heartwood 
of X. rumphii and was identified as the new C-21 epimeric xylorumphiin R. 
 
 
 
 
 
 
 
Figure 3.59 Structure of compound RH.9 
The HRMS [Spectrum 3.12.1] gave a [M+Na]
+
 ion at m/z 725.3146, which indicated the 
molecular formula of C37H50O13.  A double bond equivalence of thirteen was calculated.  The 
FTIR spectrum [Spectrum 3.12.2] showed absorption bands at 3438 and 1733 cm
-1
 
corresponding to the OH stretching and C=O stretching of ester. 
Compound RH.9 gives cluttered spectra [Spectrum 3.12.2-3.12.8] because it has a 
hemiacetal group which opens and closes in solution making it impossible to purify.  As 
similar results were expected as for previous compounds, this mixture was not acetylated. 
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3.4.9 Structural elucidation of compound RH.10: xylorumphiin S 
Compound RH.10 was isolated as a colourless solid from the methanol extract of the 
heartwood of X. rumphii and was identified as the new C-21 epimeric xylorumphiin S. 
 
 
 
 
 
 
 
Figure 3.60 Structure of compound RH.10 
The mass spectrum did not show the expected molecular ion at m/z 660.28.  However, its 
acetylated derivative (compound RH.10a) gave the expected molecular ion [M+Na]
+
 at m/z 
725.2784. [Spectrum 3.13a.1] 
Compound RH.10 gave cluttered spectra because of the presence of the hemiacetal ring, 
which opens and closes in solution making it impossible to purify.  Acetylation enabled 
separation of R and S forms.  Column chromatographic separation of the acetylated fraction 
of impure RH.10 led to the isolation of one acetylated derivative of RH.10 (compound 
RH.10a). 
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3.4.9.1 Structural elucidation of compound RH.10a: 3β,21S-di-O-acetylxylorumphiin S 
 
 
 
 
 
Figure 3.61 Structure of compound RH.10a 
The HRMS [Spectrum 3.13a.1] gave a [M+Na]
+
 ion at m/z 725.2784 (calculated for 
C36H46NaO14).  A double bond equivalence of fourteen was calculated.  The FTIR spectrum 
[Spectrum 3.13a.2] showed absorption bands at 3419, 1781 and 1733 cm
-1
 corresponding to 
the OH stretching and C=O stretching of esters. 
The 
13
C NMR [Spectrum 3.13a.4], DEPT [Spectrum 3.13a.5] and HSQCDEPT [Spectrum 
3.13a.6] spectra displayed thirty-six carbon resonances, which included nine methyl, four 
methylene, ten methine and thirteen quaternary carbons. 
A comparison of the 
13
C NMR and DEPT spectra for compound RH.7a with those of 
compound RH.10a indicated that the chemical shifts were the same, except for the C-1', C-2', 
C-3', C-4', C-2", C-3", C-4" and C-5" resonances, which occurred at δ 176.2 (C, C-1'), 34.2 
(CH, C-2'), 19.3 (CH3, C-3'), 19.1 (CH3, C-4'), 34.2 (CH, C-2"), 19.0 (CH3, C-3"), 19.1 (CH3, 
C-4a") and C-5" was missing in compound RH.7a but at δ 170.2 (C, C-1'), 21.1 (CH3, C-2'), 
C-3' and C-4' were missing, 40.8 (CH, C-2"), 16.4 (CH3, C-3"), 26.7 (CH2, C-4") and 11.8 
(CH3, C-5") for compound RH.10a, indicating that compound RH.10a had different acyl 
groups from compound RH.7a on C-3 and C-30. 
The methyl proton resonance at δ 1.99 (s, Me-2') was assigned to an acetyl group.  In the 
HMBC spectrum, the Me-2' proton resonance showed correlations with carbon resonances at 
δ 170.2 (C-1') and 74.0 (C-3).  An oxymethine proton resonance at δ 5.08 (d, J = 2.4 Hz) was 
assigned to H-3 due to observed correlations in the HMBC spectrum with the C-1' (δ 170.2), 
C-5 (δ 40.7), C-29 (δ 22.0) and C-30 (δ 76.4) carbon resonances, indicating that the acetyl 
group was at C-3. 
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The proton resonances at δ 2.26 (m, H-2"), 1.58 (m, H-4a"), 1.37 (m, H-4b"), 1.02 (d, J = 7.0 
Hz, H-3") and 0.89 (t, J = 7.4 Hz, H-5") were assigned to protons of a 2'-methylbutyryloxy 
group.  In the HMBC spectrum, the H-2" proton resonance showed correlations with carbon 
resonances at δ 176.6 (C-1"), 26.7 (C-4"), 16.4 (C-3") and 11.8 (C-5").  An oxymethine 
proton resonance at δ 5.40 (d, J = 4.4 Hz) was assigned to H-30 due to observed correlations 
in the HMBC spectrum with the C-1" (δ 176.6), C-3 (δ 74.0) and C-8 (δ 81.3) carbon 
resonances, indicating that the acyl group was at C-30.  Compound RH.10a was identified as 
3β,21S-di-O-acetylxylorumphiin S. 
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Table 3.23 
1
H and 
13
C NMR assignments for compound RH.10a [
1
H NMR 500 MHz, 
13
C NMR 125 
MHz, CDCl3, J = Hz] and compound RH.7a [
1
H NMR 500 MHz, 
13
C NMR 125 MHz, 
CDCl3, J = Hz] 
No. δC RH.10a δC RH.7a δH RH.10a δH RH.7a HMBC (H→C) COSY NOESY 
1 107.6 C 107.6 C - - - - - 
2 53.3 CH 53.3 CH 2.90 dd J = 9.2, 4.4 Hz 2.92* 1, 3, 4 10, 30 3, 30 3, 29 
3 74.0 CH 73.8 CH 5.08 d J = 9.2 Hz 5.05 d J = 9.2 Hz 1', 5, 29, 30 2 2 
4 37.6 C 37.9 C - - - - - 
5 40.7 CH 40.7 CH 2.60 m 2.64 m 3, 4, 6, 7, 9, 10, 29 6a, 6b 30 
6a 
32.2 CH2 32.3 CH2 
2.37 m 2.38 m 4, 5, 7 5, 6b - 
6b 2.16 m 2.18 m 4, 5, 7, 10 5, 6a - 
7 174.1 C 174.0 C - - - - - 
8 81.3 C 81.4 C - - - - - 
9 51.1 CH 51.1 CH 2.09 m 2.14 m 5, 8, 10, 30 11a, 11b 18, 19 
10 43.2 C 43.2 C - - - - - 
11a 
15.3 CH2 15.4 CH2 
2.45 m 2.46 m 13 9, 11b, 12a - 
11b 1.92 m 1.92 m 8, 9 9, 11a, 12a, 12b - 
12a 
24.9 CH2 24.9 CH2 
2.23 m 2.26 m 13 11a, 11b, 12b - 
12b 1.44 m 1.44 m 9, 13, 14 11b, 12a 21 
13 39.4 C 39.4 C - - - - - 
14 159.3 C 159.3 C - - - - - 
15 117.7 CH 117.6 CH 5.99 s 5.98 s 8, 13, 16 - - 
16 162.0 C 161.9 C - - - - - 
17 80.0 CH 80.0 CH 4.83* 4.84 s 12, 13, 18, 20, 21, 22 22 21 
18 20.6 CH3 20.7 CH3 1.30 s 1.30 s 12, 13, 14, 17 - 9 
19 20.8 CH3 20.8 CH3 1.07 s 1.08 s 1, 5, 9, 10 - 9 
20 160.2 C 160.2 C - - - - - 
21 93.1 CH 93.1 CH 6.97 s 6.97* 21-OAc (C=O), 22, 23 22 12b, 17 
22 124.0 CH 123.9 CH 6.45 s 6.44 s 17, 20, 21, 23 17, 21 - 
23 168.5 C 168.5 C - - - - - 
28 24.7 CH3 24.9 CH3 0.79 s 0.80* 3, 4, 5, 29 - - 
29 22.0 CH3 22.1 CH3 1.23 s 1.24 s 3, 4, 5, 28 - 3 
30 76.4 CH 76.5 CH 5.40 d J = 4.4 Hz 5.38 d J = 4.2 Hz 1", 3, 8 2 5 
1-OH - - 3.72 s - 1, 2, 10 - - 
7-OMe 52.3 CH3 52.3 CH3 3.71 s 3.71 s 7 - - 
21-OAc 
168.7 C 168.7 C - - - - - 
20.6 CH3 20.6 CH3 2.25 s 2.24 s 21-OAc (C=O), 21 - - 
3-acyl        
1' 170.2 C 176.2 C - - - - - 
2' 21.1 CH3 34.2 CH 1.99 s 2.46 m 1', 3 - - 
3' - 19.3 CH3 - 1.15 d J = 7.1 Hz - - - 
4' - 19.1 CH3 - 1.09 d J = 6.9 Hz - - - 
30-acyl        
1" 176.6 C 176.9 C - - - - - 
2" 40.8 CH 34.2 CH 2.26 m 2.42 m 1", 3", 4", 5" 3", 4a", 4b" - 
3" 16.4 CH3 19.0 CH3 1.02 d J = 7.0 Hz 1.07* 1", 2", 4", 5" 2" - 
4a" 
26.7 CH2 19.1 CH3 
1.58 m 
1.05 d J = 7.1 Hz 
1", 2", 3", 5" 2", 4b", 5" - 
4b" 1.37 m 1", 2", 3", 5" 2", 4a", 5" - 
5" 11.8 CH3 - 0.89 t J = 7.4 Hz - 2", 3", 4" 4a", 4b" - 
*Superimposed with impurity 
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3.5 Conclusions 
Nine new compounds were isolated from the bark and the heartwood of X. rumphii and were 
identified as xylorumphiins K (RB.1), L (RH.1) and M-S (RH.4-10), together with eight 
known compounds; xylorumphiins E (RH.2), C (RH.3), xyloccensin E (RB.2), taraxer-14-
en-3-ol (RB.3), 22S-hydroxytirucalla-7,24-diene-3,23-dione (RB.4) and 25-hydroxy-
(20S,24S)-epoxydammaran-3-one (AT.5) and a mixtures of sitosterol (AT.8) and 
stigmasterol (AT.9).  The structure of limonoids RB.2, RH.1 and 3 were supported by X-ray 
analysis.  Protolimonoids RH.4-10 have a hemiacetal group which opens and closes in 
solution making them impossible to purify.  Acetylation enabled separation of the R and S 
forms.  Column chromatographic separation of the acetylated fraction of impure RH.4-10 led 
to the isolation of eleven acetylated derivatives.  The configuration at C-21 of protolimonoid 
RH.7a was determined using a combination of selective quantitative NOE interactions and 
molecular modelling.  Two possible C-21 epimeric structures were generated in the 
Macromodel Suite using the MMFF force field, followed by a conformational search within 
an energy threshold of 5 kcal/mol.  The two possible structures were further energy 
minimised using the semiempirical method AM1.  In both possible isomers RH.7a (S) and 
RH.7a (R), H-22 is close to the methyl C- 18.  The quantitave results of the NOE interaction 
between H-22 and H-12α,β enabled the configuration at C-21 to be determined as S.  The 
configuration at C-21 for protolimonoids RH.7-10a was determined in a similar manner.  The 
configuration at C-23 for protolimonoids RH.4-6b was unambiguously determined using 
Residual Dipolar Couplings (RDCs) measured in compressed poly(methylmethacrylate) 
(PMMA) gels swollen in CDCl3.
142
  It was found that the compounds that had H-23 
resonating at less than 7 ppm have the C-23 S configuration, while compounds with H-23 
resonating at more than 7 ppm have the C-23 R configuration.  Chemical constituents from 
the Xylocarpus genus are reported to exhibit several biological activities such as 
antidiarrhoeal,
43
 antimalarial,
77
 anti-inflammatory
9
 and insect antifeedant,
72
 and the aqueous 
extract of X. granatum is reported to show significant antifilarial activity.
148
  Eight 
compounds, RH.1-6, 4a and RB.2 were tested at one concentration, 1 x 10
-5
 M, against 
several leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate and 
breast cancer cell lines.  The compounds did not meet activity criteria in the one-dose NCI59 
cell test for further testing. 
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Figure 3.62 Compounds isolated from the bark and the heartwood of X. rumphii 
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CHAPTER FOUR: Bioactivity screening 
4.1 Bioactivity Screening  
4.1.1 NCI-59 human tumour cell line screen 
Seven compounds, RB.2 and RH.1-6, were sent to the NCI, Washington, USA for testing at 
one concentration, 1 x 10
-5
 M, against several leukemia, non-small cell lung, colon, CNS, 
melanoma, ovarian, renal, prostate and breast cancer cell lines. The compounds did not meet 
activity criteria in the one-dose NCI59 cell test for further testing [Figure 4.1-4.7]. 
The methodology of the in-vitro cancer screen can be found on the following website 
http://dtp.nci.nih.gov/branches/btb/ivclsp.html 
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Figure 4.1 NCI-59 human tumour cell line screen of compound RB.2 
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Figure 4.2 NCI-59 human tumour cell line screen of compound RH.1 
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Figure 4.3 NCI-59 human tumour cell line screen of compound RH.2 
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Figure 4.4 NCI-59 human tumour cell line screen of compound RH.3 
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Figure 4.5 NCI-59 human tumour cell line screen of the mixtures RH.4 and 5 
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Figure 4.6 NCI-59 human tumour cell line screen of compound RH.6 
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CHAPTER FIVE: General material and methods 
5.1 Spectroscopic and spectrometric analysis 
Various spectroscopic techniques including NMR, FTIR, mass spectrometric analysis, 
measurement of optical rotations, determination of melting points and X-ray analysis were 
used to identify the chemical constituents from Aglaia argentea and Xylocarpus rumphii. 
5.1.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear Magnetic Resonance spectroscopic experiments were performed on a 500 MHz 
Bruker AVANCE NMR spectrometer at the Chemistry Department, Faculty of Engineering 
and Physical Sciences, University of Surrey, Guildford, UK.  The spectra were recorded in 
deuterochloroform (CDCl3) and the chemical shifts were recorded in ppm (parts per million) 
relative to the solvent.  The deuterochloroform was referenced according to the central line at 
 7.260 in the 1H NMR spectrum and at  77.23 in the 13C NMR spectrum. 
5.1.2 Fourier Transform Infrared Spectroscopy (FTIR) 
The infrared spectra were recorded using a Perkin-Elmer (2000 FTIR) spectrometer.  The 
oily samples were dissolved in chloroform and analyzed using NaCl plates whereas the FTIR 
spectra of samples that were solids were determined using KBr plates at the Chemistry 
Department, Faculty of Engineering and Physical Sciences, University of Surrey, UK. 
5.1.3 Mass Spectrometry (MS) 
High resolution electro spray ionization mass spectra were recorded at Oxford University by 
Dr. Colin Sparrow on a Bruker MicroToF Mass spectrometer using an Agilent 1100 HPLC 
to introduce the samples. 
5.1.4 Optical Rotation 
Optical rotations were measured at room temperature in chloroform using a JASCO P-1020 
polarimeter at the Chemistry Department, Faculty of Engineering and Physical Sciences, 
University of Surrey, UK. 
5.1.5 X – ray analysis 
Single-crystal X-ray diffraction measurements for compounds RH.1 and RH.3 were 
collected using SMART 1-K CCD diffractometer with monochromated Mo-Kα radiation (λ 
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= 0.71073 Å) using ω-scan mode and SHELXTL for structure solution and refinement at the 
X-ray Crystallography Unit, School of Physics, Universiti Sain Malaysia, Penang, Malaysia. 
Crystallographic data for compounds RB.2 were collected at the EPSRC National 
Crystallography Service using a Bruker-AXS FR591 rotating anode diffractometer with Mo-
K radiation ( = 0.71073 A). Intensities were integrated from several series of exposures, 
each exposure covering a narrow angle in  or . Absorption corrections were applied, based 
on multiple and symmetry-equivalent measurements. The structure was solved by direct 
methods/Patterson synthesis and refined by least square on weighted F
2
 values for all 
reflections. All non-hydrogen atoms were assigned anisotropic displacement parameters and 
reefing without positional constraints. Hydrogen atoms were located in the electron density 
difference map, and refined with appropriate distance restraints. The positions of the methyl 
and hydroxyl hydrogen atoms were assigned by a rotating group refinement with fixed, 
idealized C-H or O-H distances. All other hydrogen atoms were constrained to ideal 
geometries. All hydrogen atoms were assigned isotropic displacement parameters equal to 
1.5 times (methyl and hydroxyl hydrogen atoms) or 1.2 times (all other hydrogen atoms) that 
of their parent atom. Refinement proceeded smoothly to give the residuals and complex 
neutral-atom scattering factors were used.  
5.2 Plant collection, extraction and isolation of the compounds 
5.2.1 Plant material  
Aglaia argentea was collected and identified by Dr. En Shamsul Khamis, Institute of 
Bioscience, University Putra Malaysia, Malaysia and the voucher specimen was deposited at 
University Putra Malaysia, Malaysia (Voucher number: SK2197/12). 
Xylocarpus rumphii was collected by Miss Watcharee Waratchareeyakul.  This plant 
specimen was prepared by Associate Professor Surat Laphookhieo, School of Science, Mae 
Fah Luang University, Chiang Rai, Thailand, identified by Professor James Maxwell, Chiang 
Mai University Herbarium, Chiang Mai, Thailand and the voucher specimen was deposited 
at Chiang Mai University Herbarium, Chiang Mai, Thailand. (Voucher number: laphookhieo 9) 
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5.2.2 Extraction 
Air-dried twigs Aglaia argentea (1.0 kg) were extracted with MeOH for 48 hours at room 
temperature by our research collaboration in Universiti Teknologi MARA, Malaysia.  The 
mixture was filtered and concentrated under reduced pressure to give the MeOH extract 
(10.4 g). 
Air-dried bark (4.0 kg) of Xylocarpus rumphii was extracted with MeOH for 7 days x 3 
times at room temperature.  The mixture was filtered and concentrated under reduced 
pressure to give the MeOH extract (174.3 g). 
Air-dried heartwood (5.0 kg) of Xylocarpus rumphii was extracted with CH2Cl2 for 7 days x 
3 times at room temperature.  The mixture was filtered and concentrated under reduced 
pressure to give the CH2Cl2 extract (28.9 g). 
5.2.3 Column chromatography 
For the isolation process the following techniques of column chromatography and thin layer 
chromatography (TLC) were used.  Different sized columns were used for column 
chromatography, ranging from 2-6 cm in diameter depending on the purification stage and 
the amount of the sample available.  Separations of the crude extracts were carried out using 
a large diameter column (5 cm) packed with silica gel (Merck Art. 9385) employed using 
mixtures of solvent based on the TLC analysis.  TLC was carried out on 0.2 mm silica gel, 
aluminium-backed plates (Merck Art. 5554).  The plates were developed using anisaldehyde 
spray reagent and heating. 
5.2.4 Size exclusion chromatography 
Sephadex LH-20 gel (sigma Aldrich) was packed into a column in a MeOH slurry.  The 
sample was dissolved in a mixture of MeOH and DCM and then loaded onto the column, 
which was flushed with a DCM/MeOH mixture until the desired component had eluted, the 
progress was monitored using thin layer chromatography. 
5.2.5 Acetylation of hydroxylated compounds 
Pyridine (1 ml) and acetic anhydride (1 ml) were added to the sample (~15 mg) in a round 
bottomed flask.  The reaction was left to stand for 24 hours.  Next, MeOH (5 ml) was added 
to the sample to remove the excess acetic anhydride and toluene (4 x 10 ml) was added 
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successively to remove the pyridine.  After each addition, the solvent was evaporated off on 
the rotary evaporator.  Thereafter, CHCl3 (3 x 10 ml) was added to remove the MeOH.  The 
mixture of products was purified using column chromatography. 
5.2.6 Investigation of the MeOH extract of the twigs of A. argentea 
The dark green viscous oil from the MeOH extract (10.4 g) was purified by column 
chromatography (CC) and eluted with a step gradient of hexane, diethyl ether, EtOAc and 
MeOH (collecting 75 ml fractions which were combined based on similarities on TLC) to 
afford thirteen fractions (A1-A13). 
MeOH extract of the twigs of A. argentea 
 CC 
       A1      A2      A3      A4      A5      A6      A7      A8      A9     A10    A11    A12   A13 
                                                                  Sephadex          Sephadex 
                AT.7             AT.6                    LH-20               LH-20        AT.3            AT.2    AT.1 
      AT.4 + AT.5      AT.5 
      CC                                              Acetylation 
                   AT.8 + AT.9      AT.4 + AT.5                                             AT.1a 
Figure 5.1 Flow chart of the compounds isolated from the twigs of A. argentea 
Fraction A6 (74.0 mg, white viscous oil) was subjected to size exclusion chromatography to 
remove fatty acids (50% DCM : MeOH), followed by silica gel column chromatography 
50% diethyl ether : hexane to give compounds AT.4 and 5. 
Fraction A8 (27.7 mg, white viscous oil) was subjected to size exclusion chromatography 
(50% DCM : MeOH) to removed fatty acids and gave compound AT.5 (5.0 mg). 
5.2.7 Investigation of the MeOH extract of the bark of X. rumphii 
The dark red solid from the MeOH extract (174.3 g) was partition with EtOAc to give the 
EtOAc extract (36.7 g).  The EtOAc extract was purified by column chromatography (CC) 
and eluted with gradient elution of hexane, EtOAc and MeOH (collecting 75 ml fractions 
which were combined based on similarities on TLC), to afforded eleven fractions (B1-B11). 
 
62.0 mg 97.9 mg 
6.0 mg      2.0 mg 
5.0 mg 
128.2 mg 405.0 mg 10.5 mg 
  3.5 mg 50.5 mg 
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EtOAc extract of the bark of X. rumphii 
 CC 
       B1        B2         B3        B4         B5        B6       B7        B8         B9        B10       B11  
                                                                            Sephadex           
                              RB.3     RB.4                          LH-20            RB.1                  RB.2 
AT.8 + AT.9                                             AT.5 
Figure 5.2 Flow chart of the compounds isolated from the bark of X. rumphii 
Fraction B6 (47.2 mg, white viscous oil) was subjected to size exclusion chromatography to 
removed fatty acids (50% DCM : MeOH) and gave compound AT.5 (26.3 mg). 
5.2.8 Investigation of the CH2Cl2 extract of the heartwood of X. rumphii 
The yellow gum from the CH2Cl2 extract (28.9 g) was purified by column chromatography 
(CC) and eluted with gradient elution of hexane, EtOAc and MeOH (collecting 75 ml 
fractions which were combined based on similarities on TLC), to afford five fractions (C1-
C5) 
CH2Cl2 extract of the heartwood of X. rumphii 
    CC 
       C1                            C2                            C3                             C4                            C5 
                                            CC                            CC                                   CC  
                            RH.1   26.3 mg     
                            RH.2     5.3 mg    RH.6        RH.4 + RH.5 
                            RH.3   17.8 mg  
            Acetylation        Acetylation    RH.9   RH.8         RH.7 
                                                      RH.6a       RH.4a   4.5 mg           
      RH.4b   7.6 mg          
      RH.4c   7.3 mg                  RH.8a   RH.7a  
      RH.4d   4.9 mg          RH.10 
      RH.5a   7.5 mg         RH.7b 
      RH.5b 24.3 mg 
            
               RH.10a 
 
Figure 5.3 Flow chart of the compounds isolated from the heartwood of X. rumphii 
 
53.4 mg 
26.3 mg 
10.3 mg 9.8 mg 7.9 mg 
30.5 mg 
35.1 mg 102.7 mg 
11.6 mg 
8.8 mg 
Acetylation Acetylation 
7.0 mg 
3.2 mg 3.6 mg 
0.3 mg 
4.0 mg 
Acetylation 
1.9 mg 
2.6 mg 
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Fraction C2, a pale yellow viscous oil (124.2 mg), was subjected to repeated column 
chromatography starting with hexane and increasing polarity with EtOAc to give compounds 
RH.1-3.  Compounds RH.1 and 3 were crystallized for X-ray studies with EtOAc and 
hexane. 
Fraction C3, a pale yellow viscous oil (511.1 mg), was subjected to repeated column 
chromatography with hexane, increasing polarity with EtOAc, to give the C-23 epimers 
RH.4-6.  Acetylation enabled separation of the R and S forms.  Column chromatographic 
separation of the acetylated fraction of mixtures RH.4 and 5 (102.7 mg) and compound 
RH.6 (35.1 mg) led to the isolation of six acetylated derivatives of mixtures RH.4 and 5 (4a-
d, 5a and 5b) and one acetylated derivative of compound RH.6 (6a). 
Fraction C4, a pale yellow viscous oil (368.6 mg), was subjected to repeated column 
chromatography with hexane, increasing polarity with EtOAc, to give the C-21 epimers 
RH.7-10.  Acetylation enabled separation of the R and S forms.  Column chromatographic 
separation of the acetylated fraction of compounds RH.7 (8.8 mg), 8 (7.0 mg)and 10 (4.0 
mg) led to the isolation of two acetylated derivatives of compound RH.7 (7a and 7b) and 
one acetylated derivative of compound RH 8 (compounds RH 8a). 
5.3 Physical data for the isolated compounds 
Physical data for compound AT.1 
Name: N-methyl-2Ɛ,4Ɛ-dihydroxypentano-5-lactam  
Yield: 10.5 mg 
Physical description: white solid 
Mass spectrum: [M-H2O]
+
 m/z 127.0, calculated 290.3160 (C6H11O3N) 
Infrared spectrum: 3375 cm
-1
 (OH stretch) and 1625 cm
-1
 (C=O stretch of lactam) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.2 
Physical data for compound AT.1a 
Name: N-methyl-2Ɛ,4Ɛ-diacetoxypentano-5-lactam 
Yield: 3.5 mg 
Physical description: white solid 
Infrared spectrum: 3417 cm
-1
 (OH stretch), 1738 and 1630 cm
-1
 (C=O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.3 
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Physical data for compound AT.2 
Name: (20S,24R)-epoxydammarane-3,25-diol 
Yield: 62.0 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 483.3795, calculated 483.3809 (C30H52NaO3) 
Infrared spectrum: 3446 cm
-1
 (OH stretch) and 1068 cm
-1
 (C-O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.4 
Physical data for compound AT.3 
Name: (20S,24S)-epoxydammarane-3,25-diol 
Yield: 97.9 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 483.3797, calculated 483.3809 (C30H52NaO3) 
Infrared spectrum: 3458 cm
-1
 (OH stretch) and 1060 cm
-1
 (C-O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.5 
Physical data for compound AT.4 
Name: 25-hydroxy-(20S,24R)-epoxydammaran-3-one 
Yield: 6.0 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 481.3650, calculated 481.3652 (C30H50NaO3) 
Infrared spectrum: 3468 cm
-1
 (OH stretch) and 1705 cm
-1
 (C=O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.6 
Physical data for compound AT.5 
Name: 25-hydroxy-(20S,24S)-epoxydammaran-3-one 
Yield: 7.0 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 481.3632, calculated 481.3652 (C30H50NaO3) 
Infrared spectrum: 3461 cm
-1
 (OH stretch) and 1706 cm
-1
 (C=O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.7 
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Physical data for compound AT.6 
Name: 3-acetoxy-(20S,24R)-epoxydammaran-25-ol 
Yield: 128.2 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 525.3907, calculated 525.3914 (C32H54NaO4) 
Infrared spectrum: 3567 cm
-1
 (OH stretch), 1731 cm
-1
 (C=O stretch) and 1248 cm
-1
 (C-O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.8 
Physical data for compound AT.7 
Name: 3-acetoxy-(20S,24S)-epoxydammaran-25-ol 
Yield: 405.0 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 525.3909, calculated 525.3914 (C32H54NaO4) 
Infrared spectrum: 3582 cm
-1
 (OH stretch), 1732 cm
-1
 (C=O stretch) and 1246 cm
-1
 (C-O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 2.9 
Physical data for mixtures AT.8 and 9 
Name: sitosterol and stigmasterol 
Yield: 50.5 mg 
Physical description: white solid 
Infrared spectrum: 3417 cm
-1
 (OH stretch) and 1260 cm
-1
 (C-O stretch) 
1
H NMR: presented in Spectrum 2.8.1 
Physical data for compound RB.1 
Name: xylorumphiin K 
Yield: 9.8 mg 
Physical description: white solid 
Mass spectrum: [M+H]
+
 m/z 671.34268, calculated 671.34259 (C37H51O11) 
Infrared spectrum: 3417 cm
-1
 (OH stretch) and 1732 cm
-1
 (C=O stretch)  
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.1 
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Physical data for compound RB.2 
Name: xyloccensin E 
Yield: 53.4 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 709.2438, calculated 709.2467 (C35H42NaO14) 
Infrared spectrum: 1739 cm
-1
 (C=O stretch) and 1259 cm
-1
 (C-O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.2 
Physical data for compound RB.3 
Name: taraxer-14-en-3-ol 
Yield: 10.3 mg 
Physical description: white solid 
Mass spectrum: M
+●
 m/z 426.3866, calculated 426.3862 (C30H50O) 
Infrared spectrum: 3444 cm
-1
 (OH stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.3 
Physical data for compound RB.4 
Name: 22S-hydroxytirucalla-7,24-diene-3,23-dione 
Yield: 7.9 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 477.3333, calculated 477.3339 (C30H46NaO3) 
Infrared spectrum: 3417 cm
-1
 (OH stretch) and 1711 cm
-1
 (C=O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.4 
Physical data for compound RH.1 
Name: xylorumphiin L 
Yield: 20.5 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 679.3082, calculated 679.3089 (C36H48NaO11) 
Infrared spectrum: 1765 and 1724 cm
-1
 (C=O stretches) 
[α]D
24
 = -58.90 (c = 0.00236 g/ml, CHCl3) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.5 
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Physical data for compound RH.2 
Name: xylorumphiin E 
Yield: 5.3 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 667.3084, calculated 667.3089 (C35H48NaO11) 
Infrared spectrum: 3385 cm
-1
 (OH stretch) and 1727 cm
-1
 (C=O stretch) 
[α]D
24
 = -51.24 (c = 0.01854 g/ml, CHCl3) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.6 
Physical data for compound RH.3 
Name: xylorumphiin C 
Yield: 17.8 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 679.3081, calculated 679.3089 (C36H48NaO11) 
Infrared spectrum: 3354 cm
-1
 (OH stretch) and 1725 and 1706 cm
-1
 (C=O stretches) 
[α]D
24
 = +40.04 (c = 0.00298 g/ml, CHCl3) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.7 
Physical data for mixtures RH.4 and 5 
Name: xylorumphiins M and N 
Yield: 102.7 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 711.2979, calculated 711.2967 (C36H48NaO13) 
Infrared spectrum: 3418 cm
-1
 (OH stretch) and 1769 and 1731 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in spectrum 3.8.1-3.8.7 
Physical data for compound RH.4a 
Name: 23S-O-acetylxylorumphiin M 
Yield: 4.5 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 753.3088, calculated 753.3093 (C38H50NaO14) 
Infrared spectrum: 3416 cm
-1
 (OH stretch) and 1782 and 1732 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.10 
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Physical data for compound RH.4b 
Name: 23R-O-acetylxylorumphiin M 
Yield: 7.6 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 753.3088, calculated 753.3093 (C38H50NaO14) 
Infrared spectrum: 3431 cm
-1
 (OH stretch) and 1776, 1730 and 1640 cm
-1
 (C=O stretches) 
[α]D
24
 = +46.44 (c = 0.00150 g/ml, CHCl3) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.11 
Physical data for compound RH.4c 
Name: 1,23S-di-O-acetylxylorumphiin M 
Yield: 7.3 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 795.3201, calculated 795.3198 (C40H52NaO15) 
Infrared spectrum: 1774 and 1735 cm
-1
 (C=O stretches) 
[α]D
24
 = +84.20 (c = 0.00188 g/ml, CHCl3) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.12 
Physical data for compound RH.4d 
Name: 1,23R-di-O-acetylxylorumphiin M  
Yield: 4.9 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 795.3176, calculated 795.3198 (C40H52NaO15) 
Infrared spectrum: 1777 and 1736 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.13 
Physical data for compound RH.5a 
Name: 23S-O-acetylxylorumphiin N 
Yield: 7.5 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 753.3080, calculated 753.3093 (C38H50NaO14) 
Infrared spectrum: 3430 cm
-1
 (OH stretch) and 1781, 1732 and 1641 cm
-1
 (C=O stretches) 
[α]D
24
 = +34.29 (c = 0.00280 g/ml, CHCl3) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.14 
 
122 
 
Physical data for compound RH.5b 
Name: 23R-O-acetylxylorumphiin N 
Yield: 24.3 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 753.3095, calculated 753.3093 (C38H50NaO14) 
Infrared spectrum: 3439 cm
-1
 (OH stretch), 1779 and 1733 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.15 
Physical data for compound RH.6 
Name: xylorumphiin O 
Yield: 35.1 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 725.3143, calculated 725.3144 (C37H50NaO13) 
Infrared spectrum: 3405 cm
-1
 (OH stretch) and 1733 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Spectrum 3.9.2-3.9.9 
Physical data for compound RH.6a 
Name: 23S-O-acetylxylorumphiin O 
Yield: 11.6 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 767.3250, calculated 767.3249 (C39H52NaO14) 
Infrared spectrum: 3408 cm
-1
 (OH stretch) and 1782 and 1732 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.16 
Physical data for compound RH.7 
Name: xylorumphiin P 
Yield: 8.8 mg 
Physical description: white solid 
1
H NMR spectrum: presented in Spectrum 3.10.1 
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Physical data for compound RH.7a 
Name: 21S-O-acetylxylorumphiin P 
Yield: 3.6 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 739.2935, calculated 739.2936 (C37H48NaO14) 
Infrared spectrum: 3430 cm
-1
 (OH stretch) and 1638 cm
-1
 (C=O stretch) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.20 
Physical data for compound RH.7b 
Name: 1,21S-di-O-acetylxylorumphiin P 
Yield: 0.3 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z , calculated 781.3047 (C39H50NaO15) 
Infrared spectrum: 1800, 1773 and 1735 cm
-1
 (C=O stretches)
 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.21 
Physical data for compound RH.8 
Name: xylorumphiin Q 
Yield: 7.0 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 711.2985, calculated 711.2987 (C36H48NaO13) 
Infrared spectrum: 3410 cm
-1
 (OH stretch) and 1763 and 1731 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Spectrum 3.11.3-3.11.9 
Physical data for compound RH.8a 
Name: 21S-O-acetylxylorumphiin Q 
Yield: 3.2 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 753.3086, calculated 753.3093 (C38H50NaO14) 
Infrared spectrum: 3389 cm
-1
 (OH stretch) and 1790, 1728 and 1645 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.22 
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Physical data for compound RH.9 
Name: xylorumphiin R 
Yield: 2.6 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 725.3146, calculated 725.3144 (C37H50NaO13) 
Infrared spectrum: 3438 cm
-1
 (OH stretch) and 1733 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in spectrum 3.12.2-3.12.8 
Physical data for compound RH.10 
Name: xylorumphiin S 
Yield: 4.0 mg 
Physical description: white solid 
Physical data for compound RH.10a 
Name: 21S-O-acetylxylorumphiin S 
Yield: 1.9 mg 
Physical description: white solid 
Mass spectrum: [M+Na]
+
 m/z 725.2784, calculated 725.2785 (C36H46NaO14) 
Infrared spectrum: 3419 cm
-1
 (OH stretch), 1781 and 1733 cm
-1
 (C=O stretches) 
1
H, 
13
C NMR and 2D NMR data: presented in Table 3.23 
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CHAPTER SIX: Virtual screening for cytochrome P450 11 inhibitors 
[This work is part of an ongoing project at the University of Innsbruck and was undertaken 
during a 3 months Erasmus
+
 placement] 
6.1 Introduction 
Drug design is the process of finding or creating a molecule which has some bioactivity.  
Modern drug design involves not only in vitro and in vivo techniques, but also computer 
aided in silico methods to optimize and model the target molecule.
149
  Pharmacophore 
modelling has become essential for the description of molecules and complex biological 
systems such as proteins and nucleic acids.  The concept of describing pharmacon drug 
interactions via pharmacophore models consisting of relevant chemical ligand features has 
become a well-accepted technique which can be considered as appropriate for use in virtual 
screening. 
The cytochrome P450 (CYP) genes that produce CYP enzymes are found in all kingdoms of 
life.  CYP enzymes form a superfamily which is divided into families and subfamilies based 
on their amino acid and nucleotide sequences.
149
  The CYPs with 40% similarity in their 
gene sequences are grouped into a family.  If the similarity extends over 55%, they fit into 
the same subfamily.  Similarities among genes in a family can allow prediction of where and 
when a specific gene is active (expressed).
150
  CYP families are labelled with Arabic 
numbers showing the order of discovery followed by a letter defining subfamilies.  For 
example, CYP11B1 is the official name of the gene: cytochrome P450, family 11, subfamily B 
and polypeptide 1. 
The aim of the present study was to identify inhibitors of CYP11 via virtual screening.  The 
CYP11 family is composed of three genes that are necessary for steroid biosynthesis in 
mitochondria. 
6.1.1 CYP11A 
CYP11A is a cholesterol side chain cleavage enzyme (also called CYP side chain cleavage, 
CYPscc, CYP11A1) and catalyses the conversion of cholesterol to pregnenolone in 
mitochondria (Figure 6.1), which is the first step in the biosynthesis of all steroid hormones, 
for example sex hormones, corticosterone, cortisol and aldosterone.
151-153
  If CYP11A is 
blocked, the production of all steroid hormones will be affected. 
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Figure 6.1 CYP11A converts cholesterol to pregnenolone 
6.1.2 CYP11B1 
The CYP11B1 gene provides instructions for making an enzyme called 11β-hydroxylase.  
This enzyme is found in the adrenal glands, which are located right above the kidneys.
154
  
The 11β-hydroxylase enzyme helps to convert 11-deoxycorticosterone to corticosterone155 
(Figure 6.2) and 11-deoxycortisol to cortisol
152,156
 (Figure 6.3).  Corticosteroids are the 
standard anti-inflammatory agents.
157
  They are widely used to treat a variety of 
inflammatory and auto immune diseases.
158,159
  They have been used to treat inflammatory 
bowel disease (IBD) since 1955.
160
  They have also been widely used to treat patients with 
asthma and other allergic diseases.
158
  The corticosteroids are a class of substances that 
includes steroid hormones naturally produced in the adrenal cortex of vertebrates.
161
  
Furthermore, cortisol, which helps maintain blood sugar levels, protects the body from 
physical stress and suppresses inflammation.
154,158
  If CYP11B1 is blocked, it will affect 
blood sugar levels, inflammation and the auto immune system. 
 
 
   
  
Figure 6.2 CYP11B1 converts 11-deoxycorticosterone to corticosterone 
 
 
 
 
 
Figure 6.3 CYP11B1 converts 11-deoxycortisol to cortisol 
 
CYP11A 
CYP11B1 
CYP11B1 
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6.1.3 CYP11B2 
The CYP11B2 gene provides instructions for making an enzyme named aldosterone synthase 
(also called 3β-hydroxysteroid dehydrogenase and corticosterone methyloxidase).  
Aldosterone synthase is also a member of the cytochrome P450 family of enzymes.  These 
enzymes are involved in the formation and breakdown of various molecules within cells, and 
help to convert 11-deoxycorticosterone to aldosterone (Figure 6.4).
152,155
  
 
 
 
 
Figure 6.4 CYP11B2 converts 11-deoxycorticosterone to aldosterone 
Aldosterone is a key cardiovascular hormone.
156
  Clinical and scientific evidence suggest 
that aldosterone is associated with a greater incidence of left ventricular hypertrophy, cardiac 
fibrosis, and remodelling which are independent of its effect on blood vessels.
90
  30% of 
severe heart failure cases are more likely to survive when given an aldosterone antagonist.
90
 
Aldosterone synthase (CYP11B2) is the key enzyme of mineralocorticoid biosynthesis.
162
  It 
is a mitochondrial cytochrome P450 enzyme that is located in the adrenal cortex and to a 
lesser extent in the heart, brain and vascular smooth muscle cells.
162
  The inhibition of 
CYP11B2 was proposed as an innovative strategy for the treatment of heart failure because 
elevated aldosterone levels are key effectors for the development and progression of 
congestive heart failure and myocardial fibrosis.
163
  The aim of this study is to find 
molecules that will block CYP11B2 for the treatment of heart failure and hypertension 
because of high aldosterone levels, but not block CYP11B1 which produces cortisol which is 
necessary for the body.  One should not block CYP11 for the normal healthy person. 
In addition, aldosterone controls sodium balance and intravascular volume, it also helps to 
keep blood pressure normal.
164
  The increased aldosterone action contributes to hypertension 
and cardiovascular damage in approximately 10% of patients.
156
  The studies show that up to 
15% of unselected patients with hypertension have a raised aldosterone to renin ratio (ARR) 
suggesting that altered regulation of aldosterone production may be a common factor in 
hypertension which affects more than 25% of the adult population worldwide.
165
  
CYP11B2 
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Hypertension is estimated to lead to over seven million deaths each year.
166
  Blocking of 
CYP11B2 is another option to treat hypertension. 
6.2 Pharmacophore modelling and pharmacophore-based virtual screening 
Ehrlich (1909) gives a concept of a pharmacophore as a chemical group responsible for toxic 
effects and binding.
167
  A pharmacophore model can be explained as the interaction between 
a drug and its receptors which can be used for predicting bioactivity.  They are also used for 
identification of new compounds with biological activity. 
Pharmacophore modeling has evolved into an important and successful method for drug 
discovery over the last few decades.  It has become essential for the description of molecules 
and complex biological systems.  Furthermore, the concept of describing pharmacon drug 
interactions via pharmacophore models consisting of relevant chemical ligand features has 
become a well-accepted technique which can be considered as appropriate for the use in 
virtual screening.
168
 
6.2.1 Pharmacophore model generation 
There are two different approaches for developing pharmacophore models: these are 
structure-based and ligand-based pharmacophore models. 
6.2.1.1 Structure-based pharmacophore models 
If interactions between a ligand and the pharmacological target are already known from an 
X-ray or NMR structure, pharmacophore models can be derived from structure-based 
pharmacophore modeling information. 
6.2.1.2 Ligand-based pharmacophore models 
If the above information is not available, the molecular and pharmacological properties and 
features of known active ligands for a particular target can be exploited to create 
pharmacophore models and identify new ligands with similar or improved ligand-based 
pharmacophore modeling properties. 
Nowadays, the most widely used programs for pharmacophore modelling are Catalyst 
implemented in Discovery Studio, LigandScout, Genetic Algorithm with Linear Assignment 
for Hypermolecular Alignment of Datasets (GALAHAD), the Genetic Algorithm Similarity 
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Program (GASP), and the Phase and the Pharmacophore module of MOE.  In this research, 
Discovery Studio and LigandScout were used. 
6.2.2 Pharmacophore features 
The generation of structure-based pharmacophore models for LigandScout was used.  
LigandScout is a commercial structure- and ligand-based pharmacophore modeling and 
virtual screening software suite, which allows the creation of pharmacophore models based 
on the X-ray crystal structure of the target.
169
  Different ligand-protein interaction types are 
represented by several objects which are listed below.  
While hydrogen bond features are defined by direction and distance constraints, hydrophobic 
interactions and ionizable areas have a distance constraint only.  Dedicated features are 
supplied for the characterization of the binding of ligands to magnesium, zinc and iron.  In 
addition to LigandScout's supported chemical features, the program increases selectivity of 
the generated pharmacophores with the excluded volume feature.  During pharmacophore 
generation, LigandScout analyzes the shape of the active site and places excluded volume 
spheres in positions that are sterically claimed by the macromolecular environment.  This 
process ensures that molecules retrieved via virtual screening match the steric requirements 
of the active site while simultanously drastically increasing selectivity. 
 
 Hydrogen Bond Donor   Hydrogen Bond Acceptor 
      Positive Ionizable Area        Negative Ionizable Area 
      Hydrophobic Interactions        Aromatic Ring 
 Iron Binding Location   Zinc Binding Location 
 Magnesium Binding Location       Excluded Volume 
Figure 6.5 Pharmacophore features in LigandScout 
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6.3 Design of datasets 
The quality of the calculated pharmacophore model is determined by the dataset used in the 
modelling.  Binding assays should be used for 3D modelling instead of functional assays 
because they show direct binding to the pharmacological target.  There are free access 
compound-activity databases such as ChEMBL and PubChem.  ChEMBL searches for 
binding data from over 47 international peer-reviewed journals and these are sorted by 
compound or by bioassay.
170
  ChEMBL is linked with PubChem, therefore a search in the 
ChEMBL will also report compounds from PubChem bioassay screening. 
The dataset consists of four parts, which are: 
1. The training set.  The training set is a template for generated models which are 
selected from the most active ligands. 
2. The test set.  The test set is a set of known active ligands used for tested 
pharmacophore models. 
3. The inactive dataset.  The inactive dataset is a dataset of known inactive compounds. 
4. The drug bank.  The drug bank is the dataset of commercial drugs.   
A pharmacophore model should get a high number of active compounds and a small number 
of inactive compounds and compounds from the drug bank. 
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6.4 Results and discussion 
6.4.1 CYP11A pharmacophore models 
Using the ChEMBL database, two positive hits, one compound and one bioactivity hit, were 
found relating to human CYP11A as shown in Figure 6.6 and Dataset A1.xls in the 
Microsoft Excel worksheet (see Appended CD).  One compound alone is not sufficient for 
generating a pharmacophore using the ligand-based pharmacophore model.  
 
Figure 6.6 Results of ChEMBL target search for CYP11A target 
Four genes for human CYP11A were found in the protein data bank database (PDB) as 
shown in Figure 6.7. These are 3N9Y, 3N9Z, 3NA1 and 3NA0 (Figure 6.8).  3N9Y is the 
crystal structure of human CYP11A in complex with cholesterol, 3N9Z is the crystal 
structure of human CYP11A in complex with 22-hydroxycholesterol, 3NA1 is the crystal 
structure of human CYP11A in complex with 20-hydroxycholesterol and 3NA0 is the crystal 
structure of human CYP11A in complex with 20,22-dihydroxycholesterol.  If the interaction 
between a ligand and pharmacological target is known, pharmacophore models can be 
derived using structure-based pharmacophore modelling information. 
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Figure 6.7 Four genes were found for CYP11A 
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Figure 6.8 3N9Y, 3N9Z, 3NA1 and 3NA0 crystal structures of human CYP11A  
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The resolutions of the crystal structures of human CYP11A from the PDB database were more than 2 Å which is acceptable (Figure 6.9). 
 
Figure 6.9 The resolution of the crystal structures of human CYP11A 
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We can check the resolution again using the WinCoot (Crystallographic Object Oriented 
Toolkit) program, which is a macromolecular model building program for model completion 
and validation, particularly suitable for protein modelling using X-ray data.   
The calculated blue space-fill represents the X-ray scattering electrons. It does not cover 
cholesterol properly, indicating that the 3N9Y crystal structure of human CYP11A doesn’t 
have a good resolution (Figure 6.10).  It means this crystal structure is not very good. 
   
 
Figure 6.10 3N9Y crystal structure in the Wincoot program 
 
The calculated blue space-fill 
covered some part of cholesterol 
No calculated blue space-fill 
covered 
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Four 3N9Y binding sites were shown in the PDB database which are HOH573:A, 
HOH538:A, GLN356:A and SER352:A (Figure 6.11).  We used these binding sites to 
generate the pharmacophore model. 
 
 
Figure 6.12 Four 3N9Y binding sites 
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The 3N9Y crystal structure of human CYP11A complexed with cholesterol was loaded into 
LigandScout (Figure 6.13).   
 
Figure 6.13 3N9Y in LigandScout 
In order to generate inhibitors for CYP11A using structure-based pharmacophore models, 
one needs to generate a molecule that binds at the same binding sides and have similar 
pharmacophores (Figure 6.14). 
 
Figure 6.14 Proposed CYP11A pharmacophore model 
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6.4.2 CYP11B1 pharmacophore models 
No genes were shown in the protein data bank (Figure 6.15), indicating that no known X-ray 
or NMR structure could be found. 
 
Figure 6.15 No gene was found in PDB database for CYP11B1 
More than six hundred compounds and more than seven hundred bioactivities were found as 
targets to human CYP11B1 in the ChEMBL database (Figure 6.16 and Dataset_B1.xls).  In 
this case, we are able to generate pharmacophore models using ligand-based pharmacophore 
models. 
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Figure 6.16 Results of ChEMBL targets search for CYP11B1 target 
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A training set was generated from highly active compounds (0.1-0.5 nM) from the 
Dataset_B1.xls as shown in Figure 6.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.17 Training set for CYP11B1 
 
IC
50
 = 0.1 nM 
IC
50
 = 0.3 nM 
IC
50
 = 0.5 nM 
IC
50
 = 0.5 nM 
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CYP11B1_4T_Ori_1.pmz is the pharmacophore model that was generated with the top four 
active compounds used as training compounds (Figure 6.18).  This pharmacophore was 
tested against 32 active compounds in the 0-10 μM range, 9 known compounds had the same 
pharmacophore and 12 known compounds were detected without the excluded volume 
feature.  This pharmacophore was tested against 185 active compounds in the 0-100 μM 
range, 38 known compounds had the same pharmacophore and 53 known compounds were 
detected without the excluded volume feature.  This pharmacophore was tested against 6316 
commercial drugs, 240 commercial drugs had the same pharmacophore and 779 commercial 
drugs were detected without the excluded volume feature, indicating that this pharmacophore 
is not selective enough. 
 
 
 
Figure 6.18 CYP11B1_4T_Ori_1 pharmacophore model 
 
240 (779) hits from  
6316 compounds in DrugBank 
38 (53) hits from  
185 active compounds in 0-100 µM  
1 (1) hits from  
19 inactive compounds 
9 (12) hits from  
32 active compounds in 0-10 µM  
without exclusion volumes 
with exclusion volumes 
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Thirty two pharmacophore models were generated [CYP11B1 pharmacophores.ppt, 
CYP11B1_2T_1.pmz, CYP11B1_2T_2.pmz, CYP11B1_2T_3.pmz, 
CYP11B1_2T_A1.pmz, CYP11B1_2T_A-1.pmz, CYP11B1_2T_A-1-1.pmz, 
CYP11B1_2T_A2.pmz, CYP11B1_2T_A2-1.pmz, CYP11B1_2T_A2-1-1.pmz, 
CYP11B1_2T_A2-1-2.pmz, CYP11B1_2T_A2-1-3.pmz, CYP11B1_2T_A2-1-4.pmz, 
CYP11B1_2T_B-1.pmz, CYP11B1_2T_B-1-1.pmz, CYP11B1_2T_B-1-2.pmz, 
CYP11B1_2T_B-1-3.pmz, CYP11B1_2T_B-1-4.pmz, CYP11B1_2T_B-1-5.pmz, 
CYP11B1_2T_C-1.pmz, CYP11B1_2T_C-1-1.pmz, CYP11B1_2T_C-1-2.pmz, 
CYP11B1_2T_D-1.pmz, CYP11B1_2T_D-1-1.pmz, CYP11B1_2T_D-1-2.pmz, 
CYP11B1_2T_D-1-3.pmz, CYP11B1_2T_D-1-4.pmz, CYP11B1_2T_D-1-5.pmz, 
CYP11B1_2T_D-1-6.pmz, CYP11B1_2T_D-1-7.pmz, CYP11B1_2T_D-1-8.pmz, 
CYP11B1_2T_Ori-1.pmz and CYP11B1_4T_Ori-1.pmz].  The top two generated 
pharmacophore models were compared with active compounds, inactive compounds and 
compounds in the DrugBank (Figure 6.19 and Figure 6.20). 
 
 
 
Figure 6.19 Proposed CYP11B1 inhibitors pharmacophore model (CYP11B1_2T_B-1-4.pmz) 
 
CYP11B1_2T_B-1-4 
184 (646) hits from  
6316 compounds in DrugBank 
61 (71) hits from  
185 active compounds in 0-100 µM  
12 (13) hits from  
32 active compounds in 0-10 µM  
1 (1) hits from  
19 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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Figure 6.20 Proposed CYP11B1 inhibitors pharmacophore model (CYP11B1_2T_D-1-8.pmz) 
 
 
 
 
 
 
 
 
 
CYP11B1_2T_D-1-8 
18 (94) hits from  
6316 compounds in DrugBank 
56 (65) hits from  
185 active compounds in 0-100 µM  
12 (13) hits from  
32 active compounds in 0-10 µM  
2 (2) hits from  
19 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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6.5.3 CYP11B2 pharmacophore models 
CYP11B2 pharmacophore models may be generated using the structure-based 
pharmacophore models and the ligand-based pharmacophore models. 
6.5.3.1 CYP11B2 structure-based pharmacophore models 
Two genes for human CYP11B2 were found in the PDB database as shown in Figure 6.21.  
These are 4DVQ and 4FDH (Figure 6.22).  4DVQ is the crystal structure of human 
CYP11B2 in complex with desoxycorticosterone and 4FDH is the crystal structure of human 
CYP11B2 in complex with 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-5-yl]benzonitrile 
or fadrozole. 
 
 
Figure 6.21 Two genes were found in PDB database for CYP11B2 
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Figure 6.22 4DVQ and 4FDH in PDB 
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The resolutions of the crystal structures of human CYP11B2 from the PDB database were 
more than 2.00 Å, which is acceptable (Figure 6.23).  These resolutions were proved again 
using the WinCoot program (Figure 6.24).  The calculated blue space-fill covers the ligands 
properly, indicating that the X-ray data has a good resolution.  
   
Figure 6.23 The resolution of the crystal structures of human CYP11A 
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Figure 6.24 4DVQ and 4FDH crystal structures in the WinCoot program 
 
Desoxycorticosterone 
4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-5-yl]benzonitrile 
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Three 4DVQ binding sites were showed in the PDB database which are GLU310:A, 
GLY379:A and PHE381:A as shown in Figure 6.25.   
 
 
Figure 6.25 Three 4DVQ binding sites 
All of these are the first steps in virtual screening which is the selection and preparation of a 
3D database.  The 4DVQ crystal structure of human CYP11B2 complexed with 
desoxycorticosterone was loaded into LigandScout (Figure 6.26).  In order to generate 
inhibitors for CYP11B2 using structure-based pharmacophore models, one needs to generate 
a molecule that binds with 4DVQ at the same binding sites and has similar pharmacophores 
as desoxycorticosterone. 
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Figure 6.26 Deoxycorticosterone models in LigandScout 
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One 4FDH binding site was shown in the PDB database which is ARG120:A as shown in 
Figure 6.27. 
 
 
Figure 6.27 4FDH binding site  
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The 4FDH crystal structure of human CYP11B2 complexed with Fadrozole was loaded into 
LigandScout (Figure 6.28).   
 
 
Figure 6.28 Fadrozole models in LigandScout 
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6.5.3.2 CYP11B2 ligand-based pharmacophore models 
Using the ChEMBL database, more than a thousand positive hits and six hundred sixty-two compounds and a thousand and fifty-six 
bioactivities, were found relating to human CYP11B2 as shown in Figure 6.29 and Dataset B2.xls. 
 
 
 
Figure 6.29 Results of ChEMBL target search for CYP11B2 target 
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CYP11B2_A-1.pmz is the pharmacophore model (Figure 6.31) that was generated with the 
top three active compounds used as training compounds, which are ChEMBL364956, 
ChEMBL451505 and ChEMBL681 (Figure 6.30). 
 
 
Figure 6.30 CYP11B2_A-1 was generated from three training compounds 
 
Figure 6.31 CYP11B2_A-1 pharmacophore model 
This pharmacophore model was tested against 151 active compounds in the 0-10 μM range, 
41 known compounds had the same pharmacophore and 92 known compounds were detected 
without the excluded volume feature.  This pharmacophore model was also tested against 
382 active compounds in the 0-100 μM range, 120 known compounds had the same 
444 (2125) hits from  
6316 compounds in DrugBank 
120 (239) hits from  
382 active compounds in 0-100 µM  
41 (92) hits from  
151 active compounds in 0-10 µM  
3 (3) hits from  
10 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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pharmacophore and 239 known compounds were detected without the excluded volume 
feature.  This pharmacophore model was tested against 6316 commercial drugs, 444 
commercial drugs had the same pharmacophore and 2125 commercial drugs were detected 
without the excluded volume feature (Figure 6.31), indicating that this pharmacophore is not 
selective enough. 
CYP11B2_B-1.pmz is the pharmacophore model (Figure 6.33) that was generated with the 
two training compounds, which are ChEMBL364956 and ChEMBL451505 (Figure 6.32). 
 
 
Figure 6.32 CYP11B2_B-1 was generated from two training compounds 
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Figure 6.33 CYP11B2_B-1 pharmacophore model 
This pharmacophore model was tested against 151 active compounds in the 0-10 μM range, 
29 known compounds had the same pharmacophore and 96 known compounds were detected 
without the excluded volume feature.  This pharmacophore model was also tested against 
382 active compounds in the 0-100 μM range, 114 known compounds had the same 
pharmacophore and 252 known compounds were detected without the excluded volume 
feature.  This pharmacophore model was tested against 6316 commercial drugs, 467 
commercial drugs had the same pharmacophore and 2559 commercial drugs were detected 
without the excluded volume feature (Figure 6.33), indicating that this pharmacophore is not 
selective enough. 
CYP11B2_C-1.pmz is the pharmacophore model (Figure 6.35) that was generated with the 
two training compounds, which are ChEMBL364956 and ChEMBL681 (Figure 6.34). 
 
467 (2559) hits from  
6316 compounds in DrugBank 
114 (252) hits from  
382 active compounds in 0-100 µM  
29 (96) hits from  
151 active compounds in 0-10 µM  
4 (4) hits from  
10 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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Figure 6.34 CYP11B2_C-1 was generated from two training compounds 
 
 
Figure 6.35 CYP11B2_C-1 pharmacophore model 
 
This pharmacophore model was tested against 151 active compounds in the 0-10 μM range, 
6 known compounds had the same pharmacophore and 8 known compounds were detected 
without the excluded volume feature.  This pharmacophore model was also tested against 
382 active compounds in the 0-100 μM range, 28 known compounds had the same 
pharmacophore and 42 known compounds were detected without the excluded volume 
feature.  This pharmacophore model was tested against 6316 commercial drugs, 1 
commercial drug had the same pharmacophore and 11 commercial drugs were detected 
1 (11) hits from  
6316 compounds in DrugBank 
28 (42) hits from  
382 active compounds in 0-100 µM  
6 (8) hits from  
151 active compounds in 0-10 µM  
0 (0) hits from  
10 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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without the excluded volume feature (Figure 6.35), indicating that ChEMBL364956 and 
ChEMBL681 are good training compounds. 
CYP11B2_D-1.pmz is the pharmacophore model (Figure 6.37) that was generated with the 
two training compounds, which are ChEMBL451505 and ChEMBL681 (Figure 6.36). 
 
 
Figure 6.36 CYP11B2_D-1 was generated from two training compounds 
 
Figure 6.37 CYP11B2_D-1 pharmacophore model 
This pharmacophore model was tested against 151 active compounds in the 0-10 μM range, 
25 known compounds had the same pharmacophore and 37 known compounds were detected 
107 (344) hits from  
6316 compounds in DrugBank 
77 (131) hits from  
382 active compounds in 0-100 µM  
25 (37) hits from  
151 active compounds in 0-10 µM  
0 (0) hits from  
10 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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without the excluded volume feature.  This pharmacophore model was also tested against 
382 active compounds in the 0-100 μM range, 77 known compounds had the same 
pharmacophore and 131 known compounds were detected without the excluded volume 
feature.  This pharmacophore model was tested against 6316 commercial drugs, 107 
commercial drugs had the same pharmacophore and 344 commercial drugs were detected 
without the excluded volume feature (Figure 6.37), indicating that ChEMBL451505 and 
ChEMBL681 are good training compounds. 
Seventeen more pharmacophore models were generated [CYP11B2_C-1-1.pmz, 
CYP11B2_C-1-2.pmz, CYP11B2_C-1-3.pmz, CYP11B2_C-1-4.pmz, CYP11B2_C-1-
5.pmz, CYP11B2_C-1-6.pmz, CYP11B2_C-1-7.pmz, CYP11B2_C-1-8.pmz, 
CYP11B2_C-1-9.pmz, CYP11B2_D-1-1.pmz, CYP11B2_D-1-2.pmz, CYP11B2_D-1-
3.pmz, CYP11B2_D-1-4.pmz, CYP11B2_D-1-5.pmz, CYP11B2_D-1-6.pmz, 
CYP11B2_D-1-7.pmz and CYP11B2_E-1.pmz].  The top two generated pharmacophore 
models were compared with active compounds, inactive compounds and compounds in the 
DrugBank (Figure 6.38 and Figure 6.39). 
 
 
 
Figure 6.38 Proposed CYP11B2 inhibitors pharmacophore model (CYP11B2_C-1-7.pmz) 
 
5 (58) hits from  
6316 compounds in DrugBank 
52 (119) hits from  
382 active compounds in 0-100 µM  
16 (26) hits from  
151 active compounds in 0-10 µM  
0 (0) hits from  
10 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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Figure 6.39 Proposed CYP11B2 inhibitor pharmacophore models (CYP11B2_D-1-8.pmz) 
6.6 Conclusions 
In this work the generation and theoretical validation of ligand-based pharmacophore models 
were performed.  The data set acquired from the ChEMBL database for active and inactive 
cytochrome P450 11 ligands was used to develop systematically predictive models using 
industry-standard software (Inte:Ligand LigandScout).  The best models attained were used 
for virtual screening of databases of commercial compound libraries. 
This work was undertaken on a 3 months Erasmus
+
 Placement, pharmacophore models have 
been generated and now this work will be continued in the group at University of Innsbruck 
by a subsequent student to find potential inhibitors.  The number of hits will be reduced by 
refining the model and hits will be screened in vitro to produce potential drug leads to treat 
hypertension and heart failure as a result of high aldosterone levels. 
 
 
 
155 (463) hits from  
6316 compounds in DrugBank 
141 (194) hits from  
382 active compounds in 0-100 µM  
51 (62) hits from  
151 active compounds in 0-10 µM  
1 (1) hits from  
10 inactive compounds 
without exclusion volumes 
with exclusion volumes 
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